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ABSTRACT 
This thesis describes an investigation into the principal metabolites of 
the catecholamines dopamine, noradrenaline and adrenaline, present in urine 
samples from normal subjects in various circumstances and from patients suffering 
from various pathological conditions. 
Methods have been developed for the quantitation of the phenolic acids, 
4-hydroxy-3-methoxymandelic acid (jvvMA) and 4-hydrory-3-methozyphenylacetic acid 
(HVA; 
and the phenolic amines, normetadrenaline (NNA) and metadrenaline 
(11A). 
Applying these techniques, normal ranges of the metabolites output over 
twenty-four hours were established for babies, young children and adults. In 
" addition, the rate of output of metabolites for normal adults and for healthy 
students under mental stress (University examinations) was determined on urines 
collected overnight, and that for healthy adults during hard prolonged exercise, 
Was determined on pre- and post-exercise urine collections. Metabolite patterns 
emerge which are characteristic of these normal groups. 
For example, when expressed relative to urinary creatinine the metabolite 
levels of babies are higher than those of young children. The metabolites of 
sleeping students show no significant variation in the short-term during a period 
of expected increased mental activity; there is some evidence, however, that 
their output of i"IA is higher compared with an older age group. Physical exercise 
causes marked increase in the urinary levels of metabolites in healthy adults but 
the relative levels of metabolites do not vary significantly over the period of 
the exercise. 
Analysis of catecholamine metabolites made on urines from patients with 
sub-arachnoid haemorrhage, hypertension and catecholamine secreting tumours, show 
marked variations of the metabolite patterns when compared with an appropriate 
normal control group. For example, sub-arachnoid haemorrhage is associated with 
high urinary levels of normetadrenaline such that high sustained levels correspond 
with the poorest prognosis. Our patients with essential hypertension appear in 
general to have elevated overnight urinary levels of 4-hydroxy-3-methozymandelic 
acid together with normal levels of normetadrenaline, in contrast to the high 
normetadrenaline levels and variable levels of 4-hydroxy-3-methoxy mandelic acid 
associated with catecholamine secreting tumours. 
On the assumption that raised urinary metabolite levels correspond with 
actual high plasma levels of the appropriate catecholamine, attempts are made 
to relate the aberrant patterns observed in metabolites in the urine in pathologics 
conditions with the pathogenesis of the actual disease. 
.ý 
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ABBREVIATIONS USED IN THESIS 
PA - phenylalanine 
TY- - tyrosine, (4-hydroxyphenylalanine) 
DOPA - 3,4-dihydroxyphenylalanine 
DA - dopamine, 2-(3,4-dihydroxyphenethylamine) 
NA - noradrenaline, 2-(3,4-dihydroxyphenyl)-2-hydroxyethylamine 
A- adrenaline, 2-(3,4-dihydroxphenyl)-2-hydroxy-N-methylethylamine 
3MT - 3-methoxytyramine, 2-(4-hydroxy-3-methoxyphenethylamine) 
NMA - normetadrenaline, 2-(4-hydroxy-3-methoxyphenyl)-2-hydroxyethylamine 
" MA - metadrenaline, 2-(4-hydroxy-3-methoxyphenyl)-2-hydroxy-N-methyl- 
"e thylamine 
HVA - homovanillic acid, 4-hydzoxy-3-methoxy-phenylacetic acid 
1ß1A - vanilmandelic acid, 4-hydroay-3-methoay-mandelic acid 
DOMA - 3,4, dihydroxymandelic acid 
MQG - 1-4(-hydroxy-3 methoxyphenyl)ethane-1,2-diol 
COriT - catechol-0-methyltransferase 
VIAO - monoamine oxidase 
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CHAPTER 1 
INTRODUCTION 
1.1 Historical Background 
In 1856 a substance which gave a green colour with iron(III) chloride 
was detected in the human adrenal gland by Vulpian, 
1 
but it was not until 
1901 that two workers 
2,3 independently isolated this material and determined 
its structure. The compound, which was shown to be the 'active principle' 
of the adrenal gland from its physiological properties, was named 
adrenaline. 
3 
It had also been shown by Oliver4 that when an extract of the adrenal 
glands was injected into the arm of a child it produced a marked pressor 
effect and constricted the radial artery. Later, Oliver and Schafer5 found 
that the active substance is present in the adrenal medulla, but not in the 
cortex. 
It was left to other workers6'7'$ to point out the similarity between 
the response to an injection of adrenal gland extract and the result of 
electrical stimulation of the sympathetic nerves to an organ and Elliott8 
suggested that adrenaline is released at the ends of the sympathetic nerves 
when they are stimulated. However, this was such a radical idea that when 
Elliott published his work9 it was omitted from his discussion although he 
noted that 'adrenaline disappears in the tissues it excites'. 
Noradrenaline which was first synthesised 
10 in 1904 was found*to be 
a more powerful pressor agent11 than adrenaline. Barger and Dale12 
reported that noradrenaline's physiological effects corresponded better 
with the action of the sympathetic nerves than did those of adrenaline, but 
they did not suggest it is noradrenaline and not adrenaline which is 
released at the sympathetic nerve endings, probably because at that time 
the existence of chemical transmitters in the autonomic system was 
unproven. 
8'9'13 It was not until 1921 that Loewi14 proved experimentally 
the existence of autonomic transmitters by stimulating the sympathetic 
nerves to a perfused frog's heart. - He showed that the perfusate acquired 
the property of accelerating the rate of contraction of a second frog's 
heart, in the same way as an infusion of adrenaline. 
I 
1- 
Scheme 1 Synthesis of the Catecholamines 
Dopamine, Noradrenaline and Adrenaline 
CH2CH000H 
NH2 
PA 
STEP 1 (PH) 
CH2CH000H 
HO NH2 
TY 
STEP 2 (TH) 
HO 
' 
CH2CH000H 
HO NH2 
DOPA 
STEP 3 (DC) 
HO CH2CH2M2 
Ho 
DA 
STEP 4 (DGH) 
HO CH(0H)CH2NH2 
HO 
iiTy 
NA 
STEP 5 (PNMT) 
HO CH(OH)CH2NHCH3 
xo 
A 
Key - Scheme I. ' 
Enzyme 
Step 1. Phenylalanine hydroxylase 
2 Tyrosine hydroxylase 
3 Dopa decarboxylase 
4 Dopamine- ß -hydroaylase 
5 Phenylethanolamine N-methyltransferase 
--4 
Similarly, results from the stimulation of the sympathetic nerves 
supplying the cat's liver liberated substances which had an 'adrenaline 
like' action when applied to other tissues, but the effects varied between 
different organs. This-led Cannon and his co-workers to suggest that there 
might be two sympathetic transmitters operating, a Sympathin E15 producing 
excitation in the target organ receptors and Sympathie 116 which would 
inhibit the receptors. 
The suggestion that Sympathin I could be adrenaline and Sympathin E 
could be noradrenaline17 was supported by further experimental work16-21 
In 1946 von Euler22 showed that extracts of adrenergic nerves and 
organs supplied by these nerves contained significant amounts of noradrenaline 
but only traces of adrenaline. Direct evicence that sympathetic nerves 
released noradrenaline was obtained by Peart23 tho that sf ter 
stimulation of the splanchnic nerves to the catlb liver, that the plasma 
separated from the blood obtained from the hepatic veins when applied to various 
pharmacological preparations, such as the isolated rat uterus and colon, caused 
them to relax. Comparing the activity of the extracts with that of adrenaline 
and noradrenaline on these preparations indicated that the main substance active 
in this plasma was. noradrenaline. This work showed finally that noradrenaline 
is the main sympathetic nerve transmitter. 
1.2 Formation of Adrenaline and Noradrenaline 
The isolation of dopamine (3,4-dihydroxyphenethylamine) from mammalian 
urine and its formation in vivo by decarboxylation :, ° DOPA (3,4- 
dihydroxyphenylalanine)24 led Blasch o25 to suggest that this could be one 
step in a series of reactions leading to the formation of noradrenaline and 
adrenaline from DOPA. Later work has confirmed this suggestion. Final 
proof that DOPA is the main precursor of adrenaline was obtained by Gurin 
26 14 and Delluva, who incubated C-phenylalanine with rats' adrenal glands 
and subsequently isolated from this tissue 
14C-adrenaline 
plus the 
suggested intermediates 25 (Scheme 1) Step 1. 
-2- 
Radioactive tracers were further used to establish the particular 
steps involved at each stage in the biosynthesis of adrenaline and 
noradrenaline. Udenfriend and 'dyngaarden27 showed that 
14C-tyrosine 
and 
14C-DOPA 
are converted to 
14C-adrenaline by the adrenal medulla and Dennis 
et a1,28 showed that 
14C-dopanine is converted to 
'4C-noradrenaline. 
The 
work of 1cGoodall and Kirshner 
29,30 
also confirmed the in vivo pathway 
14C-tyrosine 
- 
14C-DOPA 
- 
14C-dopamine 
- 
14C-noradrenaline. Thus, the 
original suggestions of Blashko in 1939 as to the biosyntheses of the 
25 
catecholamines have been proved correct by the use of radio-isotopes. 
However, the isolation of the enzymes responsible for each stage in the 
" transformation was more difficult and has taken longer to achieve. 
Udenfriend and co-workers in 1954,61 showed that tyrosine could be 
converted to DOPA in a model system that required the presence of ascorbic 
acid, iron(II) and oxygen. Levitt et a132 and Udenfriend33 finally showed 
that the enzyme responsible for converting tyrbsine to DOPA was tyrosine 
hydroxylase (Scheme 1) Step. 2. The rate of hydroxylation of L-tyrosine is 
slower than the subsequent enzymatic reactions and thus is the rate-limiting 
step in the formation of the catecholamines. The enzyme which requires the 
cofactor, 6-methyltetrahydropterin, for optimal activity is widely 
distributed in sympathetically innervated tissue and in the central nervous 
system (C. N. S. ); also, it has been purified from the adrenal medulla. 
35'36'37 
The enzyme, DOPA"decarboxylase (Scheme 1) Step 3 was, as mentioned 
above, the first of the enzymes involved in catecholamine formation to be 
discovered and isolated. It decarboxylates only DOPA and 5-hydroxy- 
tryptophane38 at significant rates and is widely distributed in mammalian 
tissues. It shows high activity in the kidney and has been purified from 
kidney and adrenal glands. 
39,40 
The fourth stage (Scheme 1) in the biosynthesis of the catecholamines, 
the ß -hydroxylation41 of dopamine to produce noradrenaline, is catalysed by 
dopamine -hydroxylase, an enzyme that has a broad substrate specificity 
-3- 
Ephedrine 
QCH(OH)CH(CH3)NHCH3 
(I) 
1-4 
Corbasil (3.4-dihydroxvephedrine) 
OH 
HO \/ H(OH)CH(CH3)NHCH3 
(II) 
catalysing the hydroxylation of many phenethylamines to produce their 
respective ß-phenylethanolamines. Dopamine-3-hydroaylase is. present in 
42 
high concentration in the chronaffin granules of the adrenal medulla, 
-44 
in the central nervous system, and most sympathetically innervated tissues. 
The enzyme contains copper5,46 and has been isolated in pure form from 
beef adrenal medulla. 
46 
The final conversion in the biosynthetic chain (Scheme 1) Step 5, is 
brought about by the enzyme phenylethanolamine N-methyltransferase. 
47'48 
This enzyme, which is soluble and specifically located in cells able to 
form adrenaline, methylates the amino function converting noradrenaline to 
adrenaline, principally in the adrenal medulla. It can also methylate 
adrenaline49,50 and various 0=iethyl derivatives 
(see later). The enzyme 
which requires S-adenosyl-L-methionine as methyl donor, but has no metal 
requirements, has been partially purified from beef adrenals. 
51 
1.3 Metabolism of Adrenaline and Noradrenaline 
In 1937, Blaschko and his colleagues52 showed that adrenaline could 
be'oxidised and inactivated by an enzyme found in mammalian liver; this 
enzyme, monoamine oxidase (MAO), could also inactivate noradrenaline. 
Further data was obtained by Gaddum and Kwiatkowski in 193853 who noticed 
that ephedrine (I) sensitised various nerve preparations to M. The effect was 
thought to arise from a blocking of the 14A0 in blood vessels and elsewhere 
by the ephedrine, resulting in the build-up of high levels of the neuro- 
hormones. However, when in 1955, von Euler and Zetterstrom54 investigated 
the part played by MAU in inactivating the catecholamines in man, they gave 
intravenous injections of adrenaline, noradrenaline and corbasil (II) 
(3,4-dihydroayephedrine) to normal subjects and found all three amines were 
inactivated to the same extent although corbasil is not subject to oxidation 
by MAO. From these results they suggested that circulating catecholamines 
were destroyed only to a minor degree by MAU and that some other enzyme 
system was largely responsible for their deactivation. 
-4- 
Scheme 2 Metabolism of Dopamine. Noradrenaline and 
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HO I 
CH 2CH 2 
Hi 
DA 
CH o cg3o 
cs2cooa 
37 2ý2H2 
AO ii AO 
3MT EVA 
Key - Scheme 2 
i Catechol-0-methyltransferase 
Dt H 
HO cs(o11)ca2NH2 Ii 
110 
NA 
.ý 
ýý ' ii ý ,ý 
r 
CR30 CH(aH)CH2NB2 
Ho 
I 
Nn 
' ii 
Ho (ox)cooa CH30 cx(OH)coo$ 
AO 
IC r 
lwýcl 
DOIU1 
x (OH)cH 2cH3 CH3OcH(ou)CHPc3 IýI 
H0 /i HO 
1 MA 
ii Monoamine oxidase 
- ---"- - --i Minor route 
Major route 
v 
Analysis of urine from a subject with pathologically high systemic 
levels of catecholamines (phaeochromocytoma) by Armstrong and his 
colleagues55 in 1957, showed the presence of large amounts'of 4-hydroxy-3- 
methoxy-inandelic acid (HIrniA) and they suggested. that MU could be a 
metabolite of the catecholamines. In the same year Axelrod, 
56 
after 
incubating rat liver slices with adrenaline in vitro showed that the 
3-0-methyl derivative, metadrenaline, was formed and that incubating met- 
adrenaline with an MAO system gave HMMA. Axelrod also showed that 
noradrenaline behaved in a similar manner. Thus, an alternative pathway 
to direct oxidation for catecholamines had been established for their 
metabolism (Scheme 2). 
Kirshner et a157 and La Brosse et a158 showed that 80-90% of an 
injected dose of 
3H-adrenaline 
can be recovered from urine as the sum of the 
metadrenalines and HI-AA. Confirmation was provided by Kopin, 
59 in 1960, who 
gave small doses of (±) 
3H-adrenaline 
intravenously to male subjects and 
, found that after collecting their urine for 54 hours, 950/-a' of the original 
-radioactivity was found in the urine, of which 97yß was in the form of 
metabolites and only a tiny fraction was excreted unchanged. 3-0-Methylated 
compounds constituted 8 of the original dose, suggesting that 3-0-methylation 
is the principal pathway for deactivation (Scheme 2). When both 3-0-14C- 
metadrenaline and 
3H-adrenaline 
were, given together to student volunteers, 
70/'- of the adrenaline was first 0-methylated to the metadrenaline and 2(7% 
was denminated by MAO to 3,4-dihydroxymandelic acid (DOMA). On the other 
hand 50A' of the radioactive metadrenaline was excreted unchanged or as the 
sulphate conjugate and the other 50% was deaminated and then oxidised to 
give HMMA. Noradrenaline metabolism was observed to follow a similar pattern. 
Thus the major route in the inactivation of injected catecholamines is that 
of 3-0- methylation followed by oxidative deamination and not direct oxidation 
as was first proposed. 
One of the enzymes responsible for the inactivation of the catechol- 
amines, catechol-0-methyltrarsferase 
(COMT), catalyses the 0-methylation of 
a large variety of catechols60 such as DOPA, dopamine, noradrenaline, 
adrenaline, and 3,4-dihydroxymandelic acid (DOMA). The enzyme shows very 
little stereospecificity for both (+) and 
(-) adrenaline are 0-methylated 
at the same rate, 
61 
but it shows regiospecificity in that 3-0-methylation 
predominates. 
62 
The enzyme is usually soluble and found in most animal 
tissues, 
61 
but a bound variant has been isolated from both brain63 and 
liver. 64 The soluble enzyme from rat liver which requires S-adenosyl-L- 
methionine as the methyl donor and a divalent cation, probably magnesium, 
has been purified, 
60,61 
The enzyme which plays the minor part in the deactivation of the 
catecholamines has been shown to be a Group I MAO which is not inhibited by 
carbonyl reagents65 and semicarbazide66,67 unlike Group II MAO which are 
inhibited by carbonyl reagents but are sensitive to semicarbazide. 
65-67 
68 69 
The oxidase was located in 1951 by Cotzias and Dole, and Hawkins, 
who independently showed that the enzyme was intimately bound in most organ 
tissues to the insoluble structures of mitochondrial membranes. 
1.4 The Regulation of Catecholamine Biosynthesis and Metabolism 
Catecholamines are normally released from storage organelles in amounts 
which depend on three factors; the storage capacity available, the rate of 
discharge and recharge of the stores, and the rate at which new organelles 
can be formed. The development of new storage organelles within the 
sympathetic system depends on the activity of the nerve growth factor, 
70 
its mode of action is, however, at present unknown. 
The control of catecholaniine synthesis appears to be mediated by 
inhibition of tyrosine hydroxylase by excess noradrenaline (i. e. end-product 
inhibition). Spector and his colleagues71 found that after blocking the 
breakdown of noradrenaline with a MAO inhibitor the levels of noradrenaline 
in the tissues of guinea pigs increased. If radioactive tyrosine was then 
given to the animals the formation of radioactive noradrenaline was reduced 
by comparison with a control group. However, when radioactive DOPA was 
given, the treated animals, by comparison with the control group, showed 
-6- 
neither an increase nor decrease in radioactive noradrenaline, suggesting 
that the excess noradrenaline produced as a result of the inhibition of the 
MAO inhibited the tyrosine hydroxylase. Subsequent work has supported this 
view72; however, the site of action of the noradrenaline has not yet been 
elucidated. This inhibitory action of noradrenaline on the tyrosine 
hydroxylase appears to be the key factor in the short term regulation of 
catecholamine formation. Long term regulation is effected by control over 
the formation of new enzyme73 an increase in the flow of nerve impulses 
acting on chromaffin or sympathetic tissue results in increased enzymatic 
activity,. 
74 This activity starts in the ganglionic cells and enzyme appears 
" to travel along the axon of the nerve to the effector organ. Apart from the 
rate-limiting enzyme tyrosine hydroxylase, all the other enzymes involved 
in the biosynthesis of the catecholamines, both soluble and particle bound, 
appear to be increased and controlled in this way. 
74 The mechanism by 
which neuronal activity in the pre-ganglionic sympathetic fibres induces, 
trans-synaptically, an increased enzymatic activity in the noradrenergic 
neurones is not clear. 
_ 
Coupland75, in 1953, observed that chromaffin cells which were not in 
contact with adrenal cortical tissue contained only_noradrenaline and he 
suggested that the development of phenylethanolamine N-methyltransferase 
for converting noradrenaline to adrenaline depended on the presence of 
cortical hormones. Later work by Wurtman and Axelrod76 showed that hypo- 
physectomy led to a severe reduction in the transferase level in rat adrenal 
medulla, which could be overcome by giving glucocorticosteroids. 
77 
Similarly the hypophysectomy reduced the level of dopamine- ß-hydroxylase 
in adrenal medulla. 
77 
Axelrod and co-workers73 had previously shown that 
after hypophysectomy tyrosine hydroxylase levels in the adrenal medulla 
fell; however, administration of corticotrophin ACTH prevented the fall. 
The reduction in activity of dopamine-ß-hydroxylase and tyrosine hydroxylase 
following hypophysectomy could not be prevented by glucocorticosteroids. 
7 
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Thus a hormonal effect produced by the pituitary gland indicates a further 
control mechanism for catecholamine biosynthesis. The primary action of 
these pituitary hormones could be to produce adrenergic structures which 
would lead to an increase in either amine or enzyme levels. Support for 
this idea has come from the in vivo and in vitro work of Eränko and 
Eränko, 78'79 who showed that giving hydrocortisone to newborn rats produces 
an increase in the number of small intensely fluorescing cells (S. I. F. cells) 
of sympathetic ganglia; the-catecholamine content of the cells is also 
increased. S. I. F. cells appear to be intermediate between chromaffin cells 
and nerve cells and could form the chemical link between the pre- and post- 
ganglionic neurones. 
78 
The metabolism of the catecholamines by COMT and MAO has been 
investigated by Parvez and Parvem, 
80 
who observed that glucocorticosteroids 
inhibit MAO and CONNT activities in vivo and in vitro. They gave adult rats 
Metapirone (III), a strong inhibitor of corticosteroid synthesis, and found 
that as the cortisol level fell both COMT and MAO activities increased in 
proportion. This led them to postulate that glucocorticosteroids act as a 
rate-limiting factor for catecholamine degradation. Other workers, 
76 
had 
given a synthetic glucocorticosteroid, dexamethasone (IV) and found that 
both MAO and COMT levels were lowered in rat adrenal tissue. 
A study of the sub-cellular action of these steroid hormones by Litwack 
and Singer 
1 in relation to their molecular inhibition of the MAO and COMT 
indicated that the exact connection between receptor sites for gluco- 
corticosteroids and their effect on the induction of new protein (enzyme) 
synthesis remains in doubt. It is possible that contral is exerted at the 
genetic level within the cell. 
82 
In short, the complexity of the formation of the catecholamines and 
their subsequent breakdown involves the idea of a spatial separation of the 
enzymes from each other and an active movement of precursors from one site 
to another which is controlled by uptake mechanisms within the cells. A 
nerve growth factor, 
70 
appears to play an important part during the early 
-8- 
development of the adrenergic system. 'End-product' inhibition appears to 
govern short term regulation of catecholamine synthesis, coupled with this 
are factors, probably hormonal, which act upon storage particles and other 
structural elements in regulating the synthesis and metabolism of the 
catecholamines. 
1.5 Release of Catecholamines from Sympathetic Nerves and Adrenal Medullary 
Tissue 
The synaptic vesicles contained in the terminal varicosities of sympathetic 
nerves contain NA and it is commonly assumed that the NA released from the 
nerves originates from these vesicle stores. There are two principal ways 
" in which the NA contained within the vesicles could reach the extracellular 
space. First, the NA could pass from the vesicle into the cell cytoplasm 
and from there pass through the cell membrane. However, in animals which 
have not been treated with a monoamine oxidase inhibitor, most of the NA 
passing from the vesicles into the cytoplasm will be oxidised by the MAO 
of the mitochondria in the nerve endings and will then leave the nerves as 
deaminated metabolites. This is found83 to occur when animals are treated 
with reserpine, a drug. which depletes the vesicles of their NA, and is in 
direct contrast to the action of a nerve impulse which evokes the release 
of NA at the nerve endings. The second method by which NA can be released 
is by discharging the vesicles directly into the extracellular space. It 
has now been established that catecholamines are secreted from the adrenal 
medulla by exocytosis, by the fact that other soluble constituents (adenosine 
phosphate and proteins) of the chromaffin granules are also liberated 
stoicheiometrically. A similar approach has been adopted in studying NA 
released from the sympathetic nerves. It has been found that electrical 
85 
stimulation of the splenic nerve evokes the release of two vesicle proteins, 
chromogranin and the enzyme dopamine- P -hydroxylase. Both are large protein 
molecules whose release from the nerve other than by a process of exocytosis, 
would be difficult to imagine. However, applying the model of the adrenal 
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medullary release of catecholamines to the sympathetic neurone presents 
difficulties, as any experiments with nerves must take into account the 
fact that NA after it has been released into the extracellular spaces can 
be taken up and bound both by nerve terminals and postsynaptic'tissues. 
86 
The release of NA from the terminal varicosities of a sympathetic 
nerve is initiated by the arrival of 'action potentials' which originate 
within the cell-body. It has been suggested that the link between. 
depolarization of the nerve and release of NA is probably due to an influx 
of calcium ions into the nerve terminals. However, nothing is known regard- 
ing the role of calcium within the nerve endings. The vesicles probably 
reach the cell membrane by the Brownian movement within the cytoplas 
87 
and 
once there the vesicle and cell membranes fuse, probably by means of the 
phospholipid molecules in the membranes. Lysolecithin has been shown to be 
present in quite large amounts both in the adrenal chromaffin granule 
membranes and in the purest preparations of noradrenergic vesicles so far 
isolated. 83 Once fusion has taken place a pathway is then open for the 
discharge of the NA into the eatracellular spaces.. 
1.6 Catechöla. mine Uptake Processes 
Burn in 193289 suggested that catecholamines might be taken up into 
tissue binding sites. However, it has only recently become clear that not 
one but several different processes exist for the uptake of the catecholamines 
into animal tissues. NA and related amines are known to be transported from 
the extracellular space across the axonal membranes of adrenergic nerves, a 
process usually termed 'Uptake1'; a further mechanism exists to promote 
the free catecholamines from the cytoplasm into the nerve storage vesicles. 
Additionally catecholamines are transported across the membranes of smooth 
muscle and various other postsynaptic cells by another process termed 
'Uptake 2'. 
No equivalent of the enzyme acetylcholinesterase exists at adrenergic 
synaptic junctions, but inhibitors of the MAO and COINIT enzyme systems do 
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not markedly prolong or potentiate the effects of NA after it has been 
released from sympathetic nerve terminals. The termination of the actions 
of released NA appears to be mediated not by enzymatic conversion but by a 
transfer of the amine back from its extracellular site of action into the 
nerve terminal. This recapture process is called 'Uptake, 
'. 
': The NA after entering the nerves is rapidly accumulated into the 
intracellular storage vesicles both in the adrenal medulla and adrenergic 
nerves. The catecholamines are stored in an apparently stoicheiometric 
complex with adenosine triphosphate (ATP). 
" Catecholamines are also taken up by the second transport system 
'Uptake2' into various extraneuronal peripheral tissues, such as vascular 
smooth muscle, cardiac muscle and certain glandular tissues. Arterial smooth 
muscle90 in particular has a'high affinity for concentrating and retaining 
NA. However, the actual mechanism is uncertain but a form of facilitated 
diffusion9l with some intracellular binding seems most likely. It has also 
been suggested92 that 'Uptake2' like 'Uptakel' may be a further method for 
inactivating physiologically active catecholamines. Gillespie93 states 
that it is now generally accepted that extraneuronal uptake will inactivate 
some of the nerve liberated NA and also bind circulating adrenaline and that 
its importance may be much greater than the fraction of transmitter handled 
might. indicate, since the transmitter which is being metabolised is that 
which has reached the effector cell membrane and is therefore remote from 
neuronal recapture. 
In short, we can see that the inactivation of circulating noradrenaline 
or nerve liberated NA involves uptake both by nerves and by effector cells, 
including smooth muscle. The amine which is transported into nerves is 
largely protected by being incorporated into storage vesicles, whilst that 
transported into the smooth muscle is partly metabolised by the MAO and 
C014T enzyme and partly leaked back into the extracellular space where- it 
may prolong the physiological response. If either 'Uptake, ' or 'Uptake2' 
is inhibited a compensatory increase occurs in the other mechanism, 
similarly inhibition of one of the two metabolic enzymes 
(MAO) (COIJT) is 
accompanied by an increase in the other. 
1.7 Plasma vs Urine Levels of Catecholamine Estimation 
A frequent assumption regarding the measurement of catecholamines 
is that the urinary excretion rate of catecholamines reflects their plasma 
concentration; this assumption implies that the catecholamines are passively 
handled by the kidneys. Although the assumption is commonly made, there is 
no solid evidence available on this point in man. Observations on the fate 
of isotopically labelled NA injected into the circulating blood have 
shown57-59 that only a small fraction of the original dose appears unaltered 
in the urine, and an even smaller fraction of NA secreted from the nerve 
terminals escapes metabolism and appears unchanged in the urine. 
94 
95 Overy et a1 however, demonstrated that in dogs which had been given trace 
quantities of radioactive NA, the free urinary NA was in fact derived from 
the total body production of the hormone rather than from local renal 
sympathetic activity. These workers suggested that their findings justified 
the measurement. of urinary NA as a method 
. 
of estimating the secretion of the 
sympathetic neurotransmitter produced from the whole body mass. They further 
showed that such measurements were not affected by urine pH, urine flow or 
by variation in the level of renal sympathetic activity. Similarly the 
urinary output of adrenaline might be expected to reflect that of the whole 
body mass which is essentially that of the adrenal medulla. 
However, since 97% of these catecholamines are metabolised in vivo59, 
and the small amount which escapes is extremely labile, measurement of 
neither NA nor adrenaline in the urine is likely to be a reliable guide to 
secretion rates. A better reflection of catecholamine secretion would be 
to measure plasma levels of these compounds. However, the levels are so low 
that special techniques which need both experienced personnel and 
sophisticated and expensive equipment are required to measure them. The 
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plasma catecholamines are also extremely labile, so that once a blood 
specimen has been obtained it must be centrifuged quickly and the plasma 
separated and, if not assayed immediately, it must be stored deep frozen 
at - 20C. Carruthers et a1 have shown that within 30 min of collecting 
° 96 
a blood sample approximately 40/'o of its catecholamine content is lost. As 
we have noted, because of the re-uptake and binding of active catechol- 
amines within the body a random plasma analysis does not give a measure of 
the actual rates at which the amines are being secreted. Daggett and 
Carruthers97 have recently shown that when blood is continuously sampled 
over 1h periods, then the integrated catecholamine levels are higher than 
" random estimations taken over the same period of time. Continuous blood 
sampling and measurement of catecholamines would probably give a much better 
picture of actual catecholamine secretion rates. However, this technique 
is not yet a routine procedure in the majority of hospitals. 
It would seem that, rather than measuring the small amount of highly 
labile catecholamines which escape inactivation, a better reflection of 
amine secretion rates might be given by measuring the output of the urinary 
catecholamine metabolites over a particular time period. The end product 
of dopamine metabolism is HVA and of NA and adrenaline HMMA. These two 
phenolic acids are the most abundant catecholamine metabolites found in 
human urine. However, whilst the level of HVA could be taken to reflect 
dopamine secretion, the level of I UM depends on the secretion rates of both 
" NA and adrenaline. Therefore, to compare the relative activities of the 
adrenal medulla and the sympathetic nervous system, urinary levels of both 
NMA and MA have to be individually measured. 
It seems reasonable to assume, although there is no direct evidence 
available to justify this, that the physiologically active catecholamines. 
after release, are rapidly metabolised and the metabolites produced are 
efficiently excreted by glomerular filtration through the kidneys regardless 
of their concentration in the blood, so that the rate of excretion of the 
13 
metabolites reflects the rate of their production. The work that follows 
has been done on this assumption to try to assess both the secretion of 
adrenaline and noradrenaline using simple techniques which can be performed in 
most clinical laboratories in both normal situations and those which are known 
to be associated with high secretion rates of the physiologically active 
catecholamines. 
I-i 
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CHAPTER 2 
THE MEASURMENT OF PHENOLIC ACIDS AND 
PHENOLIC AMINES FOUND IN URINE FROM 
NORMAL SUBJECTS 
Scheme Formation of adrenolutine from adrenaline 
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2.1 General Introduction 
The elucidation of the biosynthesis and metabolism of the catechol- 
amines in mammals and later studies on their storage, release and re-uptake 
(both in the sympathetic system and adrenal medulla) would not have been 
possible without sensitive and specific methods for measuring both the 
catecholamines and their major metabolites. Earlier methods employed 
biological techniques for measuring dopamine, 
98 
noradrenaline and adrenaline, 
99'1! 
in brain tissue, blood plasma and urine. However, such methods are time 
consuming and imprecise. More recently physico-chemical methods have been 
developed which are sensitive and more precise and can be used to carry out 
large numbers of determinations. In these methods the catecholamines are 
adsorbed on alumina, 
101 
or ion-exchange resins, 
102,103 they are then eluted 
from the adsorbent and assayed b fluorimetric methods. 
In general, two fluorimetric procedures have been developed for this 
purpose, namely the trihydroxyindole (THI)104 and the ethylenediamine (IDA) 
condensation methods. 
105 
The THI method consists in oxidising adrenaline 
in alkaline solution to adrenochrome which then rearranges to form a 
fluorescent N-methyl-3,5,6-trihydroxyindole (adrenolutine) Scheme 3. 
Noradrenaline undergoes a similar reaction. Ascorbic acid is added as a 
reducing agent to prevent the oxidation of the relatively unstable adreno- 
lutine. However, ascorbic acid itself can produce some fluorescence and 
lead to high blank values. To overcome this problem Weil-Nalherbe106 
replaced ascorbic acid by mercaptoethanol to reduce fluorescence in the 
blanks. 
The need for expensive fluorimeters as well as the technical diffi- 
culties involved in measuring the small amounts of dopamine, NA and 
adrenaline found in normal urine and the interference from drugs, which are 
often present in urines obtained from hospital patients, suggested the need 
to develop simple techniques capable of separating and quantitating the 
individual urinary levels of the catecholamine metabolites, compounds which 
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Vanillin (4-hydroxy-3-methozybenzaldehyde) 
CH3 CHO 
H 
(v) 
1-(4-hydroxv-3-methoxvphenvl)ethane-1,2-diol (HIqPG) 
CH30 CH(0H)CH2OH 
190 
(vi) 
are relatively stable and certainly more abundant in urine than the free 
catecholamines. 
2.2 Concurrent Measurement of 3-methoxv-4-hydroxy mandelic acid and 
Homovanillic acid in Urine 
Introduction 
Numerous methods have, in the past, been proposed for the determina- 
tion of Him in urine. In earlier techniques, 
55.107v108 the phenolic 
acids were first extracted with an organic solvent from acidified urine, 
separated by paper or thin layer chromatography, 
1090110 
and the spots, 
after development, were compared visually with known standards. Other 
workers measured H1MA either by a colorimetric technique based on a diazo- 
coupling reaction, 
111-117 
or by converting it to vanillin, (V) which was 
then estimated indirectly as a. cdloured complex118 or by direct spectro- 
photometric measurement at 360-nm. 
119-121 
Other methods which require more complex-instrumentation have been used 
to determine HMMA. These consist of low 
122-124 
and high voltage125 paper 
electrophoresis, radio isotope techniques, 
126 
column chromatography 
127 
and 
gas chromatography. 
128 
HVA has proved more difficult than EMMA to estimate quantitatively. 
The more specific techniques consist of repeated extraction of the HVA, 
followed by further purification by ion exchange chromatography, the final 
extract being converted to a derivative which is isolated and measured 
either colorimetrically, 
129 by t. l. c., 
130 fluorimetricallyl3l-133 or by gas 
134 
chromatography. graPhY" 
In the present work the method which has been developed estimates HNNA 
and HVA concurrently. The technique is simple and uses equipment which 
can be found in most hospital laboratories. 
2.3 Isolation, Separation and Estimation of Phenolic Acids 
a) Separation by high voltage electrophoresis 
Preliminary work on the separation of urinary phenolic acids was 
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attempted using high voltage electrophoresis 
(HVE), a technique which appeared 
t 
to combine ease of handling with rapid separation. Standard amounts of HiIIA and 
HVA were extracted. from aliquots of acidified distilled water (pH3), using 
ethyl acetate. The organic solvent was removed and then evaporated to dryness 
after which the residue was redissolved in two drops of methanol and applied 
quantitatively to a sheet of chromatography paper which was then dipped in a 
pyridine-acetate buffer (pH 3.85) solution, blotted dry and placed on the iiVE 
base plate. Each end of the paper was connected by soaked paper wicks to buffer- 
containing compartments and a voltage of 2,500 volts was applied across the 
chromatography paper for 30 min. 
The phenolic acids were located by diazo coupling with 4-nitrobenzene- 
diazonium ion. This method gave a good separation of the phenolic acids. 
The coloured bands from the azo dyes were cut out, eluted using a mixture 
of aqueous sodium carbonate-methanol and the dyes were estimated spectro- 
photometrically. Unfortunately, after elution of the grey azo complex of 
IWA, levels of HVA below 10)j, - could not be detected spectrophotometrically. 
The recovery of HMMA using this technique was not very good either, 
(60 - 65%). To try and overcome these problems the HIM and HVA spots 
after their separation by HVE were scanned using ä Chromoscan recording 
densitometer fitted with a red filter and integrator. This improved the 
limits of detection for HVA and resulted in recoveries of 73% and 79% for 
the HN]IA and HVA standards respectively. However, when this technique was 
applied to the separation and estimation of the HMMA and HVA from normal 
urine, the spots from HMMA and HVA overlapped those from other phenolic 
acids, mainly dietary compounds, present in normal urine. In an attempt 
to overcome this problem the chromatograms after HVE were rechromatographed 
at right angles using propan-2-ol/ammonia/water as the solvent system. 
However, after development the phenolic acids were poorly separated and the 
chromatograms had a high degree of background colour. 
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As well as these technical problems, instrumental difficulties also 
arose which made electrophoresis unreliable for routine use. Furthermore, 
recently the D. H. S. S. has issued instructions to withdraw from service all 
HVE instruments of the make used because they have been found to be 
electrically dangerous to operate. 
It was decided that a more reliable and safer method of separation 
was required which used simple equipment found in even the most poorly 
equipped hospital laboratory. As a result a method using organic extraction 
followed by two dimensional chromatography was developed. 
b) Extraction and separation by two dimensional paper chromatography 
The rapid extraction of phenolic acids both from aqueous solutions and 
urine samples at acid pH was found to be extremely efficient using the 
solvent ethyl acetate (see 2.4 a, b). After mixing and centrifuging the 
solutions, a clear demarcation line was present between the aqueous and 
organic phase which enabled a clean, uncontaminated aliquot of solvent, to 
be easily removed and transferred to a small conical test tube prior to 
evaporation. This was carried out carefully under reduced pressure at room 
temperature. The residue containing the phenolic acids was re-dissolved in 
methanol and applied quantitatively as ä small spot to-one corner of a sheet 
of chromatography paper which was then subjected to two dimensional paper 
chromatography (Chapter 9.3-4). It was essential to adopt a two dimensional 
technique because of the large quantity and number (between 30 - 40) of 
phenolic acids present in normal urine. A basic solvent system was employed 
for the first chromatographic separation, followed by an acidic solvent 
system, which was run at right angles to the first solvent system, for the 
second separation. Using this technique maximum separation of the phenolic 
acids, MIA and EVA, was achieved. After chromatography, the chromatogram 
was dipped'in sodium carbonate, dried and re-dipped in a solution of 
diazotised 4-nitroaniline. Phenolic acids produce a wide variety of colours 
with this reagent, thus enabling the spots of EMMA (purple) and HVA (grey) 
to be easily located on the chromatogram (see Chapter 9.4). 
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After identifying the HI'NA and HVA the spots were cut out from the paper 
and scanned using a Chromoscan densitometer, which recorded the integrated 
numbers as each spot was scanned. The amount of HN1MA and HVA present on 
each chromatogram was then estimated by comparison with standard amounts 
treated in the same way as the tests and the results expressed as mg H1*4A 
or HVA per 24 h (Chapter 9.5-6). 
2.4 Evaluation of Extraction. Separation and Estimation Procedures 
a) Recovery of HMMA and HVA from distilled water 
The recovery of HMNA, using the method above varied from 80 - 87% and of 
HVA from 80 - 85%. (Chapter 9.7a). 
b) Recovery of HMNiA and HVA from urine 
Determination of the efficiency of recovery of Hr1MA and HVA from urine 
requires first the removal from the urine of all the KMMA and HYA initially r 
present. This was done by oxidation with sodium periodate followed, after 
destruction of excess periodate, by the addition of known amounts of HMMA 
and HVA, after which the samples were treated as for normal urines. (9.7b) 
The recovery of HMNA and HVA after this procedure ranged from 81 - 86% 
and 74 - 79°i respectively, figures which, are in close agreement with those 
for the recovery from distilled water and which were deemed to be acceptable. 
c) Between batch reproducibility of method 
Duplicate samples taken from 8 24 h urine collections were analysed on 
consecutive days for EMMA and EVA to assess precision. The mean excretion 
per minute of H1NA was 1.9 ug, the standard deviation was 0.06 jig with a 
coefficient of variation of 3.2%. Similarly the mean EVA concentration was 
shown to be 4.7 yg with a standard deviation of 0.3}ig and a coefficient of 
variation of 6.7%. (See Appendix) 
2.5 Normal Urinary Levels of HMMA and HVA 
The urinary outputs of HMNA and HVA in 24 h from 123 normal subjects, 
comprising 80 males (ages 18 - 78 years) and 43 females 
(ages 19 - 75 years) 
were as follows, where the quantities are expressed as mean outputs± 1 
standard deviation. Results were not corrected for recovery which 
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Table 1 
Comp arison of 24 h mean outputs of MIA and HVA in urine from 123 normal 
subjects, compared with published normal values 
No. of 
Subjects -MA/mg Range HVA/mg Range Reference 
68 3.7 (0.6-6.8) - - 118 
u 20 3.7 ± 1.1 (1.8-7.1) - - 120 
6 3.3-10.7 (-) - - 128 
8 3.65 ± 0.9 (2.9-5.0) - - 126 
11 11'. 0 2.3 (-) - - 117 
15 3.9 0.7 (2.1-5.2) - - 119 
9 13.5 (9 -17.9) - - 113 
25 7.5 (2.0-13) - - 115 
20 4.0 1.5 (-) - - 116 
14 5.4 3. C (-) - - 114 
50 4.3 (0-5--10) - - 109 
14 4.3 (0.4-8.1) - - 137 
8 - - 4.45 0.62 - 136 
- - - 7.2 
± 2.1 - 130 
- - - 6.0 
± 1.1 - 129 
12 3.6 1.2 (1.7-6.3) 9.4 2.5 (4.3-12.8) 127 
20 5.7 1.3 - 4.2 1.5 - 134 
25 3.4 1.6" - 4.1 1.8 - 135 
7 4.8 0.7 - 4.2 0.8 - 133 
123 3.3 0.9 (1.6-7.5) 4.9 1.3 (2.4-8.8) * 
80 3.3 ± 0.9 (1.6-7.5) 4.9 ± 1.3 (2.4-8.8) 
males 
43 3.2 ± 0.9 (2.3-6.4) 4.9_ ± 1.3 (2.6-8.6) * 
females 
* Present study 
averaged 84% for HMMA and 77% for HVA. 
HMMA/mg HVA m 
All 3.3 0.9 4.9 1.3 
Male 3.3 0.9 4.9 1.3 
Females 3.2 0.9 4.9 1.3 
Students' 't' test indicated no statistically significant difference 
between the male and female groups (Appendix) - 
The values for the mean and standard deviations of the catecholamine 
metabolites have been calculated based on the assumption that their outputs 
conformed to a normal'Gaussian distribution pattern. Previous workers in 
this field (see Tables 1 and 9 for references) have all applied statistical 
treatments to their analytica3, results on the assumption of a normal 
distribution. 
However, when the frequency distribution of the values obtained for 
HI MiA, UVA, NMA and MA were plotted from our 123 normal group of adults the 
plots intimated a possible 'skew' distribution for the catecholamine 
metabolites. To confirm this possibility the data has been subjected 
to further computer analysis using specialised statistieal tests to evaluate 
the degree of skewness and transformation of the data has been attempted 
to try and normalise any 'skew' distributions (For statistical detail, 
see Appendix, e ) 
The finding of a skew distribution means that statistical methods 
applicable to normal Gaussian curves cannot be applied to our 1esults to 
determine means and standard deviations. Consequently empirical normal 
ranges have been put forward (Addendum, a) which are based on clinical 
interpretation of expected normality. 
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2.6 Discussion 
Relatively few workers have measured }{NNA and HVA concurrently 
employing a single technique. Roginsky and colleagues, 
135 
using a g. l. c. 
method for both analyses quoted a normal range 
of 3.4 ± 1.6 mg per 24 h 
for HMMA and 4.1 
± 1.8 mg per 24 h for HVA, obtained from 25 normal subjects. 
The values for MINA and HVA reported by other workers are tabulated 
in Table 1. From this table the value for IINU output per 24 h obtained 
using the present method is in close-agreement with those of Sunderman 
et al, 
118 O'Gorman 
126 
and Pisano et al, 
120 
who used colorimetric and 
spectrophotometric techniques and with those of Dekirmerjian and Maas, 
128 
Messiha et a1127 and Roginsky et a1135 who estimated HMNA using more 
sophisticated column-and gas-c4 omatographic methods. Similarly, the mean 
HVA value is comparable with those of Karoum et al134 and Roginsky et x1135 
who used g. l. c. analysis and Smith and Weil-Malherbe, 
136 
and Kahane and 
Vestergaard, 
133 
who used a modified fluorimetric technique, based on the 
original method of Sato, 
132 
but is much lower than those reported by Messiha 
et-al 
127 
who used the original method of Sato, 
132 
and Sankoff and Sourkes, 
130 
who used a t. l. c. method. 
In the past, estimation of EMMA in urine by direct colorimetric 
techniques113,115,117 without prior purification has tended to give high 
results for HNMA output per 24 h due to interference from drugs, such as 
salicylic acid, or from dietary phenols.. For example, Mahler and 
Humoller114 
using a direct colorimetric technique, obtained a mean value for HMMA of 
5.4 1 3.03 mg per 24 h. However, they stressed the need for strict dietary 
restrictions over a period of 48 - 72 h before the urine was collected. 
Methods for HMMA estimation which use a preliminary extraction stage, 
followed by the oxidation of the BIIMA to vanillin and subsequent spectro- 
photometric measurement119,120 appear to give lower results than colori- 
metric estimations. However, Sapira121 found that free HMPG 
1-(4-hydroay-3-methoxyphenyl)ethane-1,2-diol (VI), a natural constituent of 
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urine, which is extracted aC acid pH is also oxidised to vanillin and can 
contribute between 4- 56% of the total vanillin measured, which clearly 
would lead to falsely elevated results. More recent methods109,137 have 
used t. l. c. coupled with densitometric measurements of the spots to 
separate and estimate HIIMA. These methods have similar mean values but 
tend to give a wider normal range than the present method. A criticism of 
the t. l. c. method is that great care must be taken to retain activation of 
the plate during the spotting procedure in order to obtain good separation 
of the phenolic acids. High humidity or the presence of pyridine, hydro- 
chloric acid or ammonia vapours tends to deactivate the plates. Also the 
presence of drugs and dietary compounds in the urine extract can produce 
problems in a one-dimensional t, l. c. technique. 
Values very similar to the levels found in the present study have been 
obtained by Dekirmerjian and'Maas128 who used sophisticated and expensive 
g. l. c. methods; their. normal values, however, are based on a study of only 
six subjects. These were students who were living in a special metabolic 
ward and on a special diet which did not include oranges, bananas, tea, 
coffee, ice-cream or other substances which might conceivably elevate the 
urine levels of HIIMA. It is impracticable, however, to have special dietary 
control in hospital prior to collecting 24 h urine samples for routine 
analysis of EMMA. 
Two-dimensional chromatography produces good separation of the phenolic 
acids, thus allowing HMNA and HVA to be measured even when the subject is 
taking a normal diet and drugs such as aspirin. The only problem likely 
to be encountered using the proposed method is the appearance of a pink 
background on the chromatograms on development due to adventitious phenol 
in the chromatography area. The obvious remedy for this (exclusion of strong 
phenolic substances from the area in which the chromatography is performed) 
is a measure preferable to one which inconveniences patients or their 
treatment. 
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The method could also be used, by modifying the filters in the 
Chromoscar, to measure other phenolic acids present on the chromatograms. 
The significance of many of these is at present unknown. 
2.7 Measurement of Normetadrenaline and t; etadrenaline in Normal Adult Urine 
Introduction 
I4etadrenalines are known to be about ten tines more abundant in urine 
and to have a greater stability than their precursors, noradrenaline (NA) 
and adrenaline. Hence the estimations of normetadrenaline (NMA) and 
metadrenaline (MA) are easier to perform than those of NA and adrenaline 
and they may afford a better measure of the rates of turnover and secretion 
of NA and adrenaline. 
Previous"workers138-140 in this field, after a preliminary extraction 
of the metadrenalines from the urine used two-dimensional chromatography to 
separate them and they were either estimated semi-quantitatively138,139 or 
by elution followed by colorimetry140 at 550 
nm. Others141,142 used high 
voltage paper electrophoresis to separate the metadrenalines which were 
then coupled with diazotised 4-nitroaniline and the azo compounds were eluted 
and measured colorimetrically at 520 nm. 
PiýanolO in 1960, described a method for measuring the combined 
amounts of both metadrenalines which involves a preliminary extraction 
followed by oxidation of the metadrenalines with sodium periodate to vanillin 
which is extracted and measured spectrophotometrically at 360 nm. 
Fluorimetric techniques144-147 have also been developed for the 
estimation of NI4A and MA extracted from urine by ion exchange chromatography. 
A few g. l. c. procedures have been reported for the quantitation of urinary 
NNA and MA either as total metadrenalines by estimation of vanillin, from 
their oxidation by periodate, as its trimethylsilyl derivative148 or 
individually as trifluoracetyl derivatives. 
149 
However, no attempt has been 
made to determine normal urine values of NMA and MA by g. l. c. and few of the 
other sophisticated techniques150-152 have been used for the routine analysis 
of NMA and MA in normal urine. 
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A method has been developed in this study using simple equipment 
found in most hospital laboratories which is quick, easy to perform by 
relatively unskilled personnel and gives reproducible and quantitative 
results for both NMA and MA. 
2.8 Extraction of Metadrenalines from Standard Aqueous Solutions 
a) Solvent extraction 
Preliminary extraction of the metadrenalines was first attempted using 
a procedure similar to that of Yoshinaga et a1.142 These workers hydrolysed 
urine samples for one hour at pH 1.0; after cooling, the samples were 
adjusted to pH 10 with sodium hydroxide, saturated with sodium chloride and 
extracted with 5 volumes of ethyl acetate. A modification of this procedure 
(Chapter 9.8a) was tried in which acid hydrolysis was carried out for only 
20 mins at pH 0.9 instead of pH 1.0. Although the difference in pH is 
relatively small previous workers143 have noted losses were reduced when 
hydrolysis was carried out at pH 0.9. After hydrolysis the mixture was 
cooled, basified and saturated with sodium chloride prior to extraction using 
two separate aliquots of ethyl acetate, in an attempt to improve the yield. 
The organic extracts were pooled and evaporated to dryness and the residue 
re-dissolved. in methanol and applied quantitatively to a sheet of chromatography 
paper which was then developed by two dimensional chromatography over a period 
of two nights. The NMA and hk spots were visualised using diazotised 4-nitro- 
aniline and the purple colour eluted from the paper using a sodium carbonate/ 
methanol mixture (2: 1) followed by colorimetric estimation, against known 
standards chromatographed and eluted in the same way. The percentage recovery of 
the metadrenalines ranged between 15 - 20%. An attempt was made to improve 
the recovery and to reduce the time factor. The extraction and evaporation 
procedures were repeated exactly as before, except that the residue dissolved 
in methanol was now applied to a sheet of chromatography paper cut to the 
dimensions illustrated in Fig. l. Test residues were applied to the hatched 
areas at the bottom of the paper strip labelled test, whilst standard amounts 
of NxA and E, A were applied to a similar area on the corresponding strip, labelled 
C. ntt0l 
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Table 2 
Results showing the variation with pH of the 
Percentage of netadrenalines extracted 
from water or NaOH into ethyl acetate 
pH of Sample NMA Ilk 
solution Number recovered/% recovered/% 
1 20.6 20.6 
2 17.3 17.3 
7.0 
" 3 16.3 29.0 
4 14.7 16.0 
5 16.2 " 22.7 
6 22.0 30.0 
8.0 
7 14.7 19.3 
8 18.9 17.8 
9 21.2 24.2 
10 22.1 16.0 
9.0 
' 11 23.2 13.5 
12 24.6 16.8 
13 18.3 16.0 
14 19.6 17.2 
10.0 
15 18.3 19.6 
16 23.9 15.5 
Mean/%% 
NMA MA 
17.2 20.7 
18.0 22.5 
22.8 17.6 
20.0 17.0 
Fig 1 Layout of chrornatography paper for one-dirensional 
cixoxato raphy of NNA and MA 
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The chromatography paper was then developed overnight using a single solvent 
system (Chapter 9.9b). The control strip was dipped in sodium carbonate, 
and after drying was dipped in a solution of diazotised 4-nitroaniline to 
locate the purple bands of NMA and MA. The areas on the test strip 
corresponding to the standards were cut out and eluted with alcoholic ammonia, 
converted with periodate to vanillin and measured spectrophotometrically (Chap 9, 
9c). The reaction was quantitated using standard amounts of NMA and MA 
chromatographed in exactly the same way as the test. The mean NMA recovery 
for three extractions and estimations was 27/'Pf and for MA 33% which were an 
improvement on the previous figures but still unacceptable. 
i) Effect of pH on the solvent extraction efficiency 
It was felt that the poor recoveries of metadrenalines after ethyl 
acetate extraction could be due to their extraction at an incorrect pH. 
This factor was examined in morel detail. Sixteen (20 cm3) of acidified 
(pH 0.9) distilled water containing known amounts of NNA (10 }ig) and IA (10 pg) 
were, after being boiled and then cooled, adjusted to pH 7.0 (Samples 1 -4), 
pH 8.0 (Samples 5- 8), pH 9.0 (Samples 9- 12) and pH 10 (Samples 13 - 16) 
with sodium hydroxide, after which they were extracted with ethyl acetate as 
above, separated by one-dimensional paper chromatography and the NMA and MA 
content estimated spectrophotometrically (See Chapter 99b- c). 
The results (Table 2) indicate that organic extraction at pH 9.0 is the 
best, although the overall recovery of both NMA and MA is very poor over the 
whole pH range. This is in conflict with the results of Yoshinaga It al142 who 
quote an overall recovery of 80 -. 90% using ethyl acetate at pH 10. 
3-Methylbutan-l-ol extraction was also tried but difficulty was 
experienced due to the formation of emulsions. Organic extraction was 
finally abandoned and alternative extraction methods were examined. 
b) Ion-exchange resins 
Good recoveries of metadrenalines from ion-exchange resins 
have been reported by Bertoni et a1153 (90%) and Coward and Smith154 
(65 
- 100°% who used the strong suiphonated polystyrene cation exchange 
- 2.5- 
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Fig 2 Standard Graph for estimation of NMA and MA after conversion 
to Vanillin 
)ig NMA and MA standards 
Table 3 
Percentage recovery of NMA and MA extracted from 
water by Dowex AG50-XSNa+ resin and eluted with-alcoholic ammonia 
Time used for NMA MA Mean/ 
elution/min recovered/% recovered/% NMA MA 
49 64 
1 44 55 '46 62 
45 " 67 
47 64 
3 51 - 69 50 67 
52 68 
49 70 
5 52 62 49 67 
' 46 66 
45 69 
10 38 69 42 67 
43 63 
44 58 
15 36 56 39 62 
37 72 
I 
resins Dowex AG 5O - X2H+ and Dowex AG 50W-X8H+ respectively. 
Sugiura155 used a weaker cation exchange resin, namely Amberlite CG-50, but 
his recoveries (50%) were lower. It was decided to investigate the use of 
r Dowea AG-50W-X8N An aliquot of a 24 h urine collection was first acidified and 
heated to liberate the free metadrenalines from their sulphate conjugates by 
hydrolysis. This solution was then cooled and brought to neutrality using 
sodium hydroxide. 
An aqueous slurry of the Dowex cation exchange resin (prepared as in 
Chapter 9, la) was added and the mixture stirred for 15 wins to allow adsorption 
of the free metadrenalines to occur. The resin was allowed to settle and the 
supernatant decanted. The resin was then treated with successive washes of 
water (10 cm3), 50% (5 cm3) and 85% (10 cm3) ethanol to remove non-basic 
substances before it was finally stirred (5 mins) with 4M alcoholic ammonia 
to elute the phenolic amines. The mixture was filtered through a sintered glass 
filter funnel and the eluate measured and divided into equal portions labelled 
'test' and 'control' both of which were evaporated under reduced pressure to 
dryness before being re-dissolved in methanol and applied respectively to the 
'test' and 'control' strips of a one dimensional paper chromatogram 
(Chapter 9.9b) which was developed overnight to separate the individual 
metadrenalines. Location and extraction was performed as in (Chapter 9.9c) 
and the results were quantitated using a standard calibration graph (Fig. 2). 
'" i)- Recovery of metadrenalines from ion-exchange resin 
The extraction of pure INMA and MA standards from Dowex cation exchange 
resin over timed periods ranging from 1- 15 mins using 4M alcoholic ammonia 
(see Chapter 9.9a) suggests that a mixing time of 3 mins produced the best 
figures. The percentage recoveries were also reproducible with the recovery 
of MA being better than that of NMA (Table 3). However, the mean recovery 
level of 50 and 67% for NMA and MA respectively suggested that a high 
proportion of the standards was being lost during the extraction procedure. 
To track down the loss of metadrenalines each step of the extraction was 
checked. Thus a standard aqueous solution (10 cm3) of NMA (10, pg), after 
- 26- 
Table 4 
Effect of varying the concentration of alcoholic ammonia 
on recovery of metadrenaline; from Dowex AG50-X8Na+ 
Concentration 
of alcoholic % NMA MA 
ammonia recovered/% Mean/% recovered/% Mean/% 
1M 46 45 53 55 
44 57 
2M 46 44 58 56 
42 54 
4M 37 41 60 61 
45 62 
am 49 46 54 57 
43 59 
Table 
Recovery of N14A and MA from distilled water using Dowex AG5O-X8Ya+ 
and elution with 21,1 aqueous ammonia 
hi'IA MA 
Standard recovered/% Mean/% recovered/p Mean/% 
1 86.7 83 
2 90 87.2 86 82.3 
3 85.0 78 
Table 6 
Separation of NMA and KA by paper chromatography and 
recovery by elution with 4M alcoholic ammonia 
Amount of Amount Amount 
NfiNA and MIA Recovered Mean Recovered Mean 
added/yg 101A/pg Recovered/% NA/pg Recovered/% 
1.5 1.75 1.55 
1.60 110 1.52 102 
1.62 1.54 
2.5 2.66 2.57 
2.66 105 2.62 102 
2.53 2.48 
5.0 4.85 4.76 
4.92 97.8 4.80 96 
4.90 4.89 
7.5 6.55 7.20 
6.70 88,3 7.10 95.5 
6.62 7.18 
Table 7 
Reproducibility of estimation of NMA and Mk in 24 h urine samples 
Metadrenaline levels Metadrenaline levels 
in a normal urine in an abnormal urine 
Day /)ig per 24 h /pg per 24 h 
NMP MA NMA MA 
1 430 370 1,302 505 
2 400 381 1,259 519 
3 395 399 1,200 459 
4 408 387 1,316 493 
5 409 393 1,200 526 
6 422 390 1,135 501 
Mean 410 387 1,235 500 
S. D. +13 ±10 169 ±24 
Coeff. of 
variation/% 3.2 2.6 5.6 4.8 
treatment with the ion-exchange resin, was examined for non-absorbed NINA by 
oxidation with periodate and estimation of vanillin. Similarly, each of the 
successive resin washes consisting of distilled water, 50% and 85% ethanol, 
after decantation, were made up to 10 cm, divided, and after adding ten drops 
of 414 alcoholic ammonia and 0.1 cm3 of periodate were scanned for the presence 
of vanillin. No vanillin was detected in any case. Vanillin, as expected, 
was found after oxidation of the NNA, eluted (3 min) by the 4M alcoholic 
ammonia (10 cm3), but the recovery (31%) was lower than in previous findings. 
To try and overcome this problem the concentration of the alcoholic ammonia 
used to extract the metadrenalines was varied (Chapter 9,8 b ii) and the 
supernatants removed and worked up as in (Chapter 9,8 b i). The results 
(Table 4) show that all the solutions give comparable results with the mean 
recovery for Nr, A below 50Z and below 60$ for M. 
The possibility that theethanolic ammonia in contact with the 
polystyrene resin beads causes the resin to distort, thus trapping some of 
the metadrenalines within the lattice framework was considered. To test this 
idea, the extraction procedure (Chapter 9,8 b i) for NMA and MBA was repeated, 
as described, but elution of the metadrenalines from the resin was carried out 
using 2M aqueous ammonia (10 cm3) for 5 wins, the mixture was filtered and 
the eluate'evaporated under reduced pressure to less than 10 cm3. The volume 
3 
of each sample was readjusted to 10 cm with distilled water before being 
divided into half. One half-was oxidised and the other used as blank in the 
spectrophotometric estimation of vanillin. A standard solution of NM (10 pg) 
in distilled water (20 cm3) was evaporated, readjusted to 10 cm3, divided and 
treated as the tests. The results (Table 5) show a good overall recovery and 
reproducibility for the extraction of metadrenalines using aqueous ammonia. 
This method of elution was therefore used for the research reported in this 
Thesis. 
2.9 Recovery of NI4A and MA standards from one dimensional paper 
chromatograms, after elution and periodate oxidation 
-27- 
Table 8 
Recovery of 10 up amounts of NIlUk and MA added to 6 norma 
urine samples 
Recovery of 
Sample Number metadrenaline/pg Recovery/% 
NN0A NA NMA MA 
1 8.3 7.6 83 76 
2 7.6 8.0 76 80 
3 7.2 7.0 72 70 
4 8.5 7.1 85 71 
5 7.7 7.1 77 71 
6 7.4 6.8 74 68 
Nean 7.8 7.3 78 73 
Table 9 
Comparison of 24 h rear outputs of NMA and MA in urine from 123 
normal subjects. compared with published normal values 
Number of 
Subjects N, 'KA/ pg IIAý 'Potal/}ig Reference 
30 6001300 143 
less than 
800 141 
18 6701200 148 
600 150 750 140 
6 176 205 380 142 
19 160 80 240 144 
47 288 137 425 146 
192 110 302 157 
6 245172 164126 409 145 
420 88 "508 156 
123 males 
and 394195 352+94 746 
females 
80 males 404195 369+89 773 
43 females 3 77±94 320195 697 
* This study 
Triplicate amounts of each standard 
(1.5,2.5,5.0 and 7.5 jg) were 
chromatographed, located, eluted, oxidised and quantitated spectrophotorretricall., 
using the adopted technique (Chapter 9,9 a- c). The results (Table 6) show 
good recoveries for NMA and MA over the levels studied. 
2.10 Reproducibility of the Adopted Method 
A normal 24 h urine sample and a 24 h urine sample obtained from a 
patient suffering from a phaeochromocytoma were analysed on six consecutive 
days to determine the day to day reproducibility of the method. The results 
(Table 7) show that the method has a good degree of reproducibility both at 
normal and high levels of metadrenaline excretion. 
2.11 Recovery of XA and NA from Normal Urine 
Duplicate samples equivalent to a '30 min volume of urine' were taken 
from each of 6,24 h samples. To one of each pair of duplicates was added 
10 jig amounts of NMA and MA. The MIA and MA in each of the urine samples was 
extracted and estimated using the proven method (Chapter 9,9 a- c). 
The recovery of the added NVA and MA was determined for each by subtracting 
the values for the urines without added amines from the value obtained for the 
corresponding duplicate to which amine had been added. The results (Table 8) 
indicate an overall recovery of 78) for NkA and 73% for MA, with a range of 
72 - 85% and 68 - 80% respectively. 
2.12 Normgl Urinary Levels of NM and MA 
Twenty-four hour urine samples from 123 physically fit normal subjects 
were analysed for N11A and MA, comprising 80 males (ages 18 - 78 years) and 
43 females (ages 19 - 75 years). Table 9 records the NMA and MA values 
(mean ±1 standard deviation) obtained in this study and those from other 
investigations (see Appendix appertaining to distribution studies). 
A comparison of the results shows that output of NNA from the 80 males 
and 43 females are in close agreement; statistical analysis shows no significan 
difference of }? 1A output between males and females. However, the MA values 
of the males are higher than those of the females, and the difference is 
-28- 
significant at the 1% level. The values for MA are similar to those obtained 
by Kattok et a1156but higher than those of most other workers. The LA levels 
determined in this study are higher than have previously been reported, 
possibly due to a better recovery of N. A using the extraction procedure described 
above. Host workers in the past have quoted normal ranges determined using 
only a few normal subjects and none have studied more than 50 subjects. 
This could account for some of the variability between the quoted normal 
ranges for NY1A and MA. 
2.13 Discussion 
The amines }NA and. NA are normally excreted in man as the sulphate 
conjugates, plus a small percentage as the more stable glucuronide. 
59,158 
Therefore, a preliminary hydrolysis stage usually with acid is required to 
liberate the free amines. Most workers in the past139' 
142,144 have carried 
out this hydrolysis at pH 1.0; however, Pisano143 found that losses were 
reduced when the hydrolysis was done at pH 0.9 and this procedure has been 
adopted in this work. 
- 29 - 
Earlier workers 
133,140,142 
extracted the metadrenalines from alkaline 
urine using organic solvents but this technique has been shown here to give 
very poor recoveries so this method was not used in this study. 
The use of weak cation exchange resins such as Anberlite CG-50, to 
isolate the metadrenalines from urine has been reported. 
143.144 
Smith and Wei1-Tialherbe144 found that the isolation depended on a low urine 
salt concentration which required elaborate desalting techniques before 
adsorption of the rnetadrenalines could be carried out successfully. The 
observation145 that free metadrenalines are quantitatively held by strong 
polysulphonated ion exchange resins and that 9Dp recovery of the metadren- 
alines from urine can be obtained using Dowex AG 50W - X2H+, 
153 
led to the 
trial of a Dowex polysulphorated resin in this study, namely Dowex AC-50W- 
XSH+ converted to the Na+ form. -However, preliminary work using this strong 
cation resin was disappointing due to the low recoveries found after elution 
of the metadrenalines with 4M alcoholic ammoni-a, a result which was at 
variance with the findings of Coward and Smith154 who obtained recoveries 
(65 
- 100f) using 5r1 alcoholic ammonia. The good recoveries of MA and MA 
found in the present study using 2M aqueoiis'ammonia contradict the findings of 
other workers154,155 who found low recoveries when elution from Dowex 50-X8H+ 
was carried out using aqueous ammonia. The reason for the differences could 
be due to the form in which the resin is used. Alcoholic ammonia appears 
to be a better eluant when the Dowex resin is in the H+ form, whilst 
aqueous ammonia is a better eluant for Dowex resin in its Na+ form. The 
work of Coward and Smithl54 would support this idea. They obtained a recovery 
of 931'o' for NMA using Dowex 50-X2 (Na+ form) when eluted with 5M aqueous 
ammonia. To obtain consistent results with ion-exchange resins each batch 
was carefully prepared and standardised for recovery before being used for 
analysis. 
The elution time used to release the amines from the resin was fixed 
at 5 min, but the results suggest that a3 min elution time would be 
- 30 - 
p-Svioato2 (h -r: ethyl-2-(4-hydroxyphen_y1)ethanolanine_) 
CH(o3)CH2aUCH3 
Ho 
(vii) 
a-rcethvlDOPA(2-9mino-2-methyl-3-(3,4-dihvdroxyDhenyl) procanoic acid 
HO 
HO 
CH3 
CH2-C --COON 
NH2 
(viii) 
sufficient. The levels of MvIA and MA recovered fell with an increase in 
extraction time possibly due to some re-adsorption onto the resin, 
emphasising the importance of keeping the elution time constant for 
reproducible results. 
tlany of the problems involving column techniques are due to the 
differences between column flow rates, producing poor reproducibility and 
in some instances low recoveries, due to marked variation in elution 
pattern, which correspond to marked changes in room temperature or resin 
quality. Wilk et x1147 overcame such problems by using tritiated NMA to 
determine the exact point at which the netadrenalines were eluted from the 
Amberlite CG-50 resin. Their technique, however, is too time consuming for 
the routine analysis of the metadrenalines. By stirring the resin with 
the metadrenaline solution at a constant speed and eluting for a fixed 
period of time most of these problems have been overcome in the present 
study. The other aspects of the extraction and estimation (chromatography, 
elution from the paper chromatogram and quantitation using periodate 
oxidation and spectrophotometry) were found to be almost quantitative for 
both MqA and NMA. 
In the original method of Pisano143 both NMA and MA were extracted and 
converted to vanillin which was then estimated spectrophotometrically at"a 
wavelength of 360 nm rather than at the max for vanillin (347 nm). The 
longer wavelength was used to minimise interference from other compounds 
which were also oxidised by the periodate, notably g-sympatol (VII) which 
is oxidised to 4-hydroxybenzaldehyde which adsorbs between 330 - 350 na. 
Similarly certain drugs and their metabolites [such as a-methyl DOPA (VIII)7 
which can be found in the urine, are oxidised and will also give a falsely 
159,160 
elevated value for total metadrenalines. The method which has been 
used here has overcome these problems, since the chromatography stage 
enables the individual metadrenalines to be located, separately extracted 
and quantitated, after oxidation, as vanillin at 350 nm without any inter- 
ference from extraneous materials. The method has been shown to be very 
-31- 
reproducible, even at high metadrenaline levels, and gives good recoveries 
for I. NA and M. An interesting point is the finding of a significant 
difference in PA output between the male and female groups. 
The value of screening hypertensive subjects, whose hypertension may 
be due to the presence of a phaeochromocytoma tumour, by estimating, total 
metadrenalines, has been emphasised by Gitlo+r et a1161 and by Sandler 
162 
who state that urinary netadrenaline estiration is the best single test for 
the diagnosis of a phaeochromocytoma. Total metadrenaline estimation. 
however, suffers from the faults previously mentioned, in that it gives no 
indication, especially in the case of a phaeochromocytoma, as to which of 
the catecholamines, noradrenaline or adrenaline, is being secreted by the 
tumour, information which it is useful to have prior to any surgical 
procedure. The method reported here, however, provides this information. 
It can also be used to monitor levels of catecholamine metabolites, even 
when the subject is being treated with drugs such as a-methyl DOPA. 
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CHAPTER 
i'' ESTIMATION OF URINARY HI+IMA, HVA 
MIA, Ai]) ICk LEVELS IN BABIES 
AND YOUNG CHILDREN 
3.1 Introduction 
The discovery 
55 
of a raised level of I DNA in the urine of a subject 
with a catecholamine-secreting tumour, 
led to the development of many methods 
for estimating HJMA as an aid in the diagnosis of 
this type of tumour 
(phaeochromocytoma) and the related neural crest tumour 
(neuroblastoma) which 
occurs in babies and young children. In addition, the observation 
by McMillan163 
in 1956 that a malignant chromaffin tumour contained a 
high percentage of 
dopamine, was followed by the finding 
164 - 166 of an increased level of 
dopamine in the urine of children suffering from neuroblastomas. 
The estimation of Urinary dopamine is technically 
difficult. However, 
the output of its final metabolite HVA which would 
be expected to reflect any 
marked increase in secretion rates, has 
been carried out. 
Gitlow et al167 in a study of normal children suggested that the total 
output of metadrenalines (NNA +MA) varied less in children below the age of 
one than did their HNNA and HVA levels. As total metadrenaline output gives 
no guide to the individual secretion rates of NA and adrenaline, in the 
present work separate measurements of NriA and kA have been carried out. 
These might help to distinguish between normal children under conditions of 
stress sufficient to elevate their adrenaline secretion and thus increase 
their total metadrenaline output, from children with neuroblastomas. 
The study first of all required the collection of accurate 24 h urine 
samples. These were collected from a group of eleven normal babies aged 1- 12 
months designated (Group A) who were admitted for minor surgical procedures 
(repair of squint or cleft palate defect) to the metabolic ward of the 
Birmingham Children's Hospital. The urines were collected under trained 
nursing supervision using the method described in Chapter 9,2 . 
The second group, termed Group B, consisted of fourteen fit and healthy 
children, aged 2- 11 years who collected 24 h urine samples under close 
supervision of adults. 
The output of HM A, HVA, NPE and MA were then measured in an attempt 
to establish the normal daily output and ranges for each group. The results 
have been compared with various parameters such as age, urine volume per 24 h 
- 33- 
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Fig 3 Output of urinary metabolites per 24 h comcared with 
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and body surface area, in order to find the most reliable diagnostic index 
for assessing babies and young children who are thought to be suffering from 
a catecholamine secreting tumour. 
A further aim of this work has been to seek any relationships which 
might exist between the various pairs of metabolites and to establish 
whether the ratio of their levels is of diagnostic value (e. g. in 
neuroblastoma). 
3.2. Results 
The results in Table 10 indicate that the differences in the mean 
daily outputs of EMMA, EVA, NMA and MA from the young babies (Group A) and 
the children (Group B) are statistically significant (p =(0.001). 
Similarly, the differences in the mean outputs of urine per 24 h between 
the babies (Group A) and young children (Group B) are statistically 
significant (p =(0.001). Likewise the differences in the mean body surface 
area and the differences in the mean outputs of creatinine per 24 h were also 
shown to have 'p' values less than 0.001. 
When the values for the daily outputs of HMMA, HVA, NMA and MA are 
plotted against age (Fig. 3a- d) we see that each metabolite shows a 
good correlation. The results (Fig. 4, a- d) show that there is also a 
good correlation between the output of all four metabolites when compared 
with the urine volume per 24 h. 
Because of the difficulties inherent in collecting 24. h urines 
accurately from young babies and children, creatinine (ix) levels were 
determined on all the urine samples and the results expressed as jig metabolite 
per mg of creatinine. 
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Fig. 5, a-d indicates the output of HI-14A, H VA, NM and III expressed 
as pg metabolite per mg creatinine compared with output of creatinine mg per 
24 h. The finding of relatively high negative correlation coefficients for 
M Ilk (-0.82), HVA (-0.76), NhA (-0.83), with a poorer degree of correlation for 
ILIA (-0.63) suggests that as the output of creatinine per 24 h increases the 
output of the catecholamine metabolites expressed as pg metabolite per mg 
creatinine falls in proportion. 
Similarly, the outputs of HIS"IA, HVA, ICU and Nk per 24 h volume all 
correlate well with body surface area (Fig. 6, a- d) with positive 
correlation coefficients ranging from (0.79 - 0.86). The results in Table II 
indicate that the difference between the mean daily outputs of Hii1MA, HVA, NMA 
and hA from the babies (Group A) and the young children (Group B), when 
expressed as }xg metabolite per cm3 urine is small except for MA which shows 
some significant degree of difference exists between the two groups. However, 
when the difference between the mean outputs for the four metabolites, HMIr1A, 
HVA, N14A and MA, calculated as jug metabolite per mg creatinine, 
is compared 
between babies (Group A) and young children (Group B), the results show very 
significant statistical differences (p ( 0.001) between the two groups. 
The difference between the mean output of MA for the two groups, however, 
suggests a lower degree of statistical significance (0.1) pý0.05). 
Similarly, comparing the differences between the mean outputs of HhMA, HVA, 
INDIA and MA, expressed as pg metabolite per m2 of body surface area between 
babies (Group A) and young children (Group B), we find some degree of 
significance for HiNA, but no statistically significant difference for HVA 
between the two groups. The differences between the metadrenaline mean 
outputs for the two groups do show quite significant differences (0.0)F> 0.01) 
for NMA and a much higher degree for MA (p =<0.001). 
The outputs of HMMA, HVA, NMA and MA per cm3 of urine, when plotted 
against age (Fig. 7a- d) show no significant degree of correlation for 
HMIIA, HVA and NMA, although for MA there is some correlation (0.46). On the 
other hand, the outputs of these metabolites when plotted as )lg per mg of 
creatinine against age (Fig 8a- d), give a good negative correlation. 
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Further when the output of these metabolites expressed as yg per m2 of body 
surface area are plotted against age (Fig 9a- d) there is a slight correlation 
for the output of HMMA, HVA and Mk (correlation coefficient 0.49,0.26 and 0.40 
respectively), but a good degree of correlation (0.70) for NA output. 
The relationships between the output of different pairs of metabolites 
expressed as mg per 24 h urine volume are shown (Fig 10 a- d). The 
correlation coefficients between HMNA/HVA, YhA/HVA, NIA/HVA, and NA/HJ A are 
0.89,0.90,0.80 and 0.90, suggesting good correlation between the 
catecholamine pairs. 
A similar study (Fig 11 a- d) comparing the same metabolite pairs, 
but expressed on the basis of pg metabolite per mg of creatinine gives 
correlation coefficients ranging from 0.92 - 0.79. 
3.4 Discussion 
The relative merits of expressing the urinary output of catecholamine 
metabolites either as yg per mg creatinine or per 24 h urine volume, especially 
in young babies and children, has been an unresolved problem for a number of 
years. Because of the difficulty in obtaining accurate collections of urine 
from babies and young children, relatively few workers have studied the 24 h 
urinary excretion of catecholamine metabolites in normal children. 
McKendrick and Edwards168 measured the output of urinary HMMA in a group of 
132 normal children and obtained a mean value, for ten children below the 
age of one, of 0.47 mg per 24 h, which is lower than that found in the present 
study; however, their range of 1.2 - 3.2 mg per 24 h for HNNA output in a 
group of children aged 1- 12 years is more in line with our findings for 
children of a similar age. 
The increase in the mean values of urinary HMMA,. HVA, NMA and MA 
found for the older children over the babies shows that the output of these 
metabolites increases with age, an observation which is supported by the 
plots of metabolite output against age (Fig 3a- d). Karki, in 1956,169 
shcwed that the output of urinary NA and adrenaline in a group of normal 
_36_ 
r 
children whose ages ranged from 1.5 - 16 years, increased with age. 
His work was confirmed by Voorhess170 who measured NA, adrenaline, dopamine 
and E41, -LA output per 24 h urine volume in normal children of various ages. 
Our findings indicate that the output of the metabolites of dopamine, NA and 
adrenaline also increase with age. 
There is a relatively steady increase in the mean urine output per 
24 h in babies and young children with age which is due presumably to increasing 
body size and with it a concomittant increase in fluid intake and urine output. 
This results in the outputs of all the metabolites per 24 h when plotted 
against urine volume showing good correlations. 
The validity of expressing results for children based on the output of 
creatinine especially in young infants and babies has been questioned by 
Applegarth and Ross, 
171 
who found that the output of«. -amino nitrogen 
expressed relative to creatinine suggested that the creatinine output in 
the first few years of life is much lower than the creatinine output in later 
life, a finding which makes the normal value of excretion of a metabolite 
expressed relative to creatinine extraordinarily and falsely age dependant. 
Weetman et al172found a significant'diurnal variation in the outputs 
of HMMA and total metadrenalines expressed as ug metabolite per mg of 
creatinine which confirmed the finding of others168,172 but was at 
variance with those of other groups. 
167P 174 
A possible explanation for this difference between the two groups of 
workers could be that the urine specimens in the first study172 were collected 
as timed overnight and daytime collections, whilst other groups167,174 
collected mid-morning samples where the creatinine levels would not be 
expected to vary as widely compared to the overnight/daytime creatinine levels. 
In the present study, it is also apparent that there is a much larger 
increase in the mean output of creatinine per 24 h between the Group A 
babies and Group B children, due probably to the rapidly increasing muscle 
mass and increased activity of the children compared to the babies. When the 
output of the catecholamine metabolites are plotted as pg per mg of creatinine 
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against creatinine output per 24 h, quite good negative correlations are 
found for i 'MA, Hi/A and NMA. NSA output, however, does not correlate well 
with creatinine output. A possible reason for the good negative correlations 
for HMMA, HVA and NFIA output per mg of creatinine against creatinine output 
(Fig. 5a- d) is that the output of the sympathetic nervous system increases 
less with age than does the muscle mass and consequently as creatinine output 
increases so the relative outputs of H NA, HVA and NMA to creatinine decrease. 
The secretion of adrenaline from the adrenal medulla and the subsequent urinary 
output of 1A would not be expected to be closely related to body muscle mass 
as the secretion of adrenaline is dependant to a large extent on external 
stimuli acting on the organism. This could explain the poorer degree of 
correlation found for the output of NIA when compared with creatinine output. 
An interesting point, however, was the good correlation obtained 
between the outputs of all four catecholamine metabolites, expressed as 
output per 24 h compared with body surface area, a finding which suggests 
that an increasing body surface area results in an increase in urine volume; 
the output of MA also appears to be closely correlated with body size and urine 
volume, unlike the previous finding, when relating MA to creatinine output. 
9 However, whilst there is an apparent increase in catecholamine metabolite 
output with age (Fig-3), an interesting point emerges when the average 
concentration of metabolites per cm3 of urine over 24 h are compared between 
the two groups. Here we find no significant difference exists between the 
mean outputs of IRMA, HVA and MA per cm3. There-is, however, a significant 
difference between the two groups when the mean outputs of MA per cm3 are 
compared. These findings become more apparent when all the catecholamine 
metabolite results, expressed as concentration per cm3 of urine are plotted 
against age; only the output of NiA increases with age, 
This could suggest that the output per cm3 of urine for HIVIMA, HVA and 
NMA is independant of age and that the production of NA and dopamine is 
closely related to the increasing size of the sympathetic nervous system. 
The increase per cm3 of urine found for MA output with increasing age might 
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be a measure of the actual stress effects which would be expected to vary and 
probably show a positive increase with age, or it could be that in babies and 
young children the production of adrenaline is very low due to a delay in the 
maturation of the enzyme system which converts NA to adrenaline in the 
adrenal gland. Previous workers175 have shown that the total catecholamine 
content of foetal adrenal glands is relatively low, reflecting the limited 
amount of adrenal chromaffin tissue, and that NA is the predominant amine in 
chromaffin tissue in foetal life, being present in greater absolute and 
relative amounts in extramedullary rather than medullary tissue. 
Various groups of workers have measured urinary HMMA and HVA output 
as ug per mg creatinine in young babies and children. Von Studnitz found 
ranges of 1.2 - 9.5 pg HM14A and 3.9 - 39.9 pg EVA per mg of creatinine in 
twelve normal children aged 0.5 - 12 years using an electrophoretic technique. 
Gjessing177 and Gitlow et al167 used paper chromatography to separate HTiiMA 
and HVA which were estimated by visually comparing the spots with known amounts 
of standards. They reported ranges of 6- 12 mg creatinine'EMMA, 10 - 14 
P949 creatinine EVA and 1.4 - 15 mg creatinine HMMA and 12 - 35 jemg 
creatinine EVA respectively, for children below the age of one year. 
Our ranges tend. to be higher for HMMA, due perhaps to our more accurate method 
of scanning the developed spots which could detect amounts which would be 
missed by visual technique. Our EVA results show a closer agreement. 
Similarly, the outputs of HMMA and HVA in the children, aged 2- 12 years, 
in Group B have higher ranges when compared to other workers' findings for 
HMMA, but are similar with regard to HYA output. Individual outputs of NMA 
and ILIA }. ig per mg creatinine have not been determined by other workers,. to our 
knowledge. The linear relationships obtained when the output of the 
metabolites HMMA, HYA and NINA per mg creatinine were plotted against age 
were similar to those previously obtained by Gitlow et al167 for HMMA, HVA 
and total enetadrenalines, who stressed the extreme variability of MIA and 
HVA excretion below the age of one. They also pointed out that the output of 
total metadrenalines against age, however, appeared to maintain linearity 
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below the age of one and suggested that the future assay of these amines 
might serve as a useful tool in differentiating normal children from those 
with neural crest lesions. 
When the 24 h excretion of the four metabolites by the subjects in 
this study was related to body surface area the mean output of HHNA expressed 
as pg metabolite per m2 for the older children (Group B) was found to show 
a slightly significant increase when compared with the mean value found in 
the babies (Group A) but no difference between the mean HVA output was 
observed between the two groups. The difference between the mean outputs 
pg metabolite per m2 of N? ', A and MA for the babies (Group A) and the older 
children (Group B), however, showed a statistically significant increase 
for Group B over Group A. 
However, when these outputs were plotted against age for all the 
children we found a poor degree of correlation for the outputs of MAMA, HYA 
and IM, but the output of Mpg per m2 of body surface area compared to age 
gave a good correlation. These findings are at variance with those found by 
Voorhess170 who found little difference in adrenaline and HMMA output 
per, m2 of body'surface area between her groups of children consisting of 
nineteen babies (birth to 1 year) and twenty-eight children (aged 1- 15 years). 
Dopamine and noradrenaline outputs per m2 were found, however, to be greater 
during the first year of life, a finding which she attributed to the rapid 
growth and maturation of the sympathetic nervous system with its increased 
production of NA. ' Our results for the outputs of HIM, HVA and NMA do not 
support these findings, but tend to suggest that the output of catecholamines 
with age is directly proportional to increasing body size and urine volume. 
The catecholamine which one would expect to show the largest rise because 
of the maturation of the enzyme system plus the increase in external stress 
factors with age, would be adrenaline. However, Voorhess170 found no 
difference in adrenaline output between her groups, unlike the findings in 
the present study which showed a significant increase in I4A output per m2 
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of body surface area when compared with age. 
Scheme 2, Chapter 1, shows the metabolic pathways for the 
catecholamines. If we assume under normal conditions that the sympathetic 
nervous system produces most of the dopamine and NA and the adrenal medulla 
secretes adrenaline we might expect to find good correlations between 
selected pairs of metabolites. The good correlation between HMMP and HVA 
outputs per 24 h (Fig 10a) indicates a relationship between these metabolites 
as does the good correlation between NAIA and HYA outputs 
(Fig 10b), 
suggesting that the rates of dopamine and NA production are closely related. 
The output of JA compared to HVA, whilst showing some degree of correlation 
(Fig 10c), had the lowest degree of correlation. The correlation between 
HMMA and MA, its precursor (Fig 10d) also had a high degree of correlation. 
When the same pairs of metabolites are expressed as Pg metabolite per mg 
of creatinine, there is a good correlation between HMMA and HVA and Ni4A and 
HVA, (Fig lla and b) but a lower degree of correlation between MA output 
and HVA or HI'IMA (Fig llc and d). A likely explanation for this is that the 
outputs of HMNA, HVA and NMA appear to be closely related to muscle mass 
with attendant creatinine production, whilst the output of MA does not appear 
to be as closely linked to body muscle mass and hence creatinine output. 
From these studies, it would appear that measuring and relating 
outputs of MIA, HVA, NMA and MA per 24 h urine volume could enable us to 
assess the sympathetic and medullary activity of the body. 
When the outputs of HMMA, HVA and NIIA are expressed as pg per mg of 
creatinine they appear to be directly related to muscle mass. The values 
should therefore reflect any increase in sympathetic nerve activity resulting 
in the production of dopamine and NA. However, because the output of the 
stress hormone, adrenaline, from the adrenal medulla is closely related to 
external stimuli, the output of urinary MA is linked to a lesser degree with 
muscle mass and subsequent creatinine output than the other three metabolites. 
The finding of correlation coefficients which range from (0.77 - 0.88) 
when the outputs of HPMA, HVA, NMA and I1A per 24 h are compared to age and 
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urine volume and a lower range (-0,46 to -0.76) when the output of the four 
metabolites expressed as pg per mg of creatinine are compared against age and 
creatinine output, might suggest, especially regarding MA output, that in 
babies and young children the output of catecholamine metabolites expressed 
as pg or mg per day might be a better guide than ig metabolite per mg creatinine. 
Our findings would tend to support the recent work of Weetman et a1172 
who suggested that urine samples used for screening for neuroblastomas in 
children below the age of five should be obtained from a 24 h collection of 
urine rather than from a random sample, and also support the work of 
Applegarth and Ross171 with regard to the variability of creatinine output 
in young children. 
CHAPTER 4 
A STUDY OF THE OVERNIGHT URINE OUTPUTS FO: t }i 24A, HVA, i+I1A A14D 
MA FOUND IN A GROUP OF S1CON1) YEAR STUDENTS AT 'T'HE UNIVERSITY 
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4.1 Introduction 
A chance observation that the overnight output of }14A and NA in 
urine, expressed as jig metabolite per min, increased in a normal - 
subject from a basal level to a much higher level in advance of a known 
stress situation, namely an hour's lecture, presented to a large 
audience, led to the suggestion that normal people faced with a future 
stress situation might respond by increasing their catecholamine secretion. 
To test this suggestion a group of twenty normal healthy students 
at the University of York, consisting of fourteen males and six females, 
volunteered to collect a total of four overnight urine specimens starting 
eight weeks before an important examination. These urines were designated 
Group I (Control). Other overnight urine collections were made respectively 
at four weeks, Group 2, and two days, Group 3, before the examination. 
The final urine samples, Group 4, were collected five weeks after the 
examination at the start of a new term. The urines were accurately timed 
collections and were collected overnight in order to try to eliminate the 
effect of individual variations in physical activity and day-time 'stress 
factörs' in the students in the hope that any increase in their overnight 
output of catecholamine metabolites might reflect 'on-going' stress factors. 
4.2 Results 
Table 12 shows the mean overnight outputs for HMMA, HVA, NMA and MA 
obtained from the twenty students who participated at each stage of the 
investigation. When the mean outputs of the catecholamine metabolites 
for Groups 2,3 and 4 are compared against the Control Group 1, we find 
only a slight increase in the HMIiA, HVA and NNlA mean outputs. The output 
of 1A, however, shows a steady. increase in mean values from Group 1 
through to Group 4. A statistical comparison between the Groups indicates 
that no significant difference exists between the Control Group and the 
other three Groups with regard to the outputs of H11(A and NNA. 
A slight degree of significance relating to the output of }WA was 
indicated between Group 2 and the Control Group, but not between 
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Groups 3 and 4 and the Control Group. Comparing the mean NA outputs of 
Groups 2,3 and 4 against the Control Group indicated that a statistically 
significant increase in the output of ALk had occurred over the period of 
the trial. However, there were no dramatic increases in catecholarnine metabolite 
outputs as the examination approached as had been expected. 
4.3 Discussion 
Early this century Cannon178 pioneered the study of the adreno- 
medullary response to stress. He attributed the physiological responses he 
obtained from experimental animals treated with a crude extract of adrenal 
gland tissue to a substance he called 'adrenin'. The adrenal medulla 
contains two active hormones, adrenaline and NA. Adrenaline is synthesised 
and stored in the chromaffin cells and is released into the circulation to 
act on distant organs when the body is subjected to a sudden physiological 
emergency, such as cold, fear, fatigue, shock, etc. In this sense, it 
mobilises what he termed the 'fight and flight' mechanism, a co-operative 
effort consisting of the adrenal medulla and the sympathetic nervous system. 
One of the easiest emotions to elicit is that of anxiety, for example, 
in situations such as parachute jumping. 
179 
climbing wet and slippery 
rocksl80 or even when visiting the dentist. 
181 Stress of this nature tends, 
on the whole, to be quick and short-lived, although the response as measured 
by adrenaline output is often quite dramatic. In general, the body after 
a sudden short-lived stress soon returns to a normal state. Since stress 
situations as described above produce a demonstrable increase in adrenaline 
output previous work has in the main tended to concentrate on these short- 
lived stress situations, plasma or urine levels of catecholamines being 
measured immediately before and after the stress. Long-term responses to 
stress which may take place over weeks, months or years are obviously more 
difficult to measure. However, long-term stress factors, particularly 
environmental, must exist, as without them animals and man would not have 
adapted and attained their present evolutionary states. Certain groups of 
-44- 
people, such as pilots, because of their occupations, nignt be expected to 
be subjected to a greater degree of stress than other more sedentary workers, 
and, in fact, it has been shown182 that catecholamine levels are often 
double resting catecholamine values, during the time a pilot is at the 
controls. Carruthers183 has suggested that airline pilots, because of the 
stress factor associated with their jobs should be biochemically screened 
for the early detection of heart disease. It has also been shown 
184 
that 
air traffic controllers at the busy O'Hare Airport, Chicago, who were studied 
daily, during two five-day work periods, using a battery of chemical tests 
including urinary NA and adrenaline, were shown to have greater stress 
levels than those obtained from pilots subjected to long or difficult 
flying operations -a 10-hour test in a flight-simulator, or prolonged 
decompression tests. It was also shown that these flight controllers, 
although asleep during the afternoon period of the study, excreted more 
adrenaline than was excreted at this same time of day by other groups of 
men who were awake and active and performing work which would not be 
regarded as stressful. It could be that long-continued or intermittent 
contact with a known stressor tends to raise thresholds and perhaps individ- 
uals may then become unresponsive to that particular stress and in fact 
adapt. 
Lucas (1976)185 points out that some students entering college for the 
first time and having to meet the challenge and stimulus of a new environ- 
ment can develop stress symptoms, often in relation to study or examinations 
or both. Others presumably can adapt and cope reasonably well with their 
new environment. Krishnan 
186 has shown that students at Leicester 
University who attended a Health Centre with symptoms referable to'forth- 
coming examinations, could be helped by being given a drug (Oxprenolol) 
which relieves anxiety and tension by interfering with the action of the 
catecholamines. As a result they became more confident and performed better 
in their examinations than anticipated by their tutors, findings which 
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support the work of Brewer, 
187 
who studied a group of psychology students 
sitting an examination. The students were classed as having 'high test 
anxiety' or 'low test anxiety'. These students were given propranolol, 
of -adrenergic blocker or a placebo, before the examination. The results 
showed that propranolol does not impair examination performance, and in 
fact it did improve performance in those students who had severe anxiety 
symptoms. 
Our study group consisted of students who had already attended the 
University for one year and were starting their second year of study. Our 
findings of only a slightly significant statistical difference between the 
outputs of MA, the metabolite of adrenaline, at various stages before and 
after their Part 1 Examination and no difference in the outputs of HNItA, 
HVA and NIA could suggest that the second year students have already adapted 
quite well to the University life with its attendant pressures and therefore 
did not respond significantly to the 'thoughts' of a forthcoming examination. 
However, when the students' overnight values acre compared with the overnight 
values found in a normal, but much older (average age 43 years) group of 
adults (Chapter 6, Table 15) there appears to be quite marked differences 
between the two groups regarding the mean outputs of HMIIA, HVA and NMA, in 
particular the mean overall output of MA found for the students was over 
70% higher than that of the adult group. 
An explanation of these findings could be that for the young, active, 
intellectual University students our results are in, fact 'normal' for this 
group, suggesting that perhaps overnight production of catecholamines falls 
with increasing age, due to a decrease in physical and mental activity. 
Alternatively, these findings could imply that young adults after entering 
a University are being subjected daily to hard, mentally stimulating 
experiences which could, over an extended period of time, lead to an 
increased production of catecholamines. This idea, of an ongoing stress 
might account for the enhanced level of MA found in Group 4 at the start of 
a new term. 
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The concept of students functioning at a higher level of catechola: nine 
activity would also explain : shy the prospect and actual sitting of an 
important examination did not produce the biochemical stress response 
that was anticipated. The students appear to be already working under a 
high degree of applied pressure and were able to cope quite readily with the 
extra stress imposed by an examination without the need for a further 
increase in catecholamine production. 
It would be interesting to repeat the trial with groups of 1st, 2nd 
and 3rd year students, or the same group of 1st year students followed 
throughout their University life, compared to a normal group of non- 
University subjects matched for age and sex. In this way it might be pos- 
sible to detect changes in catecholamine metabolite output patterns over a 
longer period of time to determine if the methods are in fact sensitive 
enough to provide a chemical means of measuring the physiological adaptive 
responses to an ongoing stress. 
f 
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CI DER 
A STUDY OF THE INFLUENCE OF A 54-NILE RACE ON URINARY 
CATECHOLANMI14E Mx''i'ABOLITb; LEVELS 
5.1 Introduction 
The North Yorkshire Moors' Search and Rescue Team annually organise 
a race called the Five Crosses Walk. It starts and finishes at Goathland, 
a village at the centre of the North Yorkshire Moors. The competitors cover 
a distance of 54 miles non-stop. This race is open to anyone, male or female, 
over the age of 16 years and the winner in 1975 for the second year in 
succession was a Sheffield man, who covered the distance in 9.5 h. 
It was felt that a comparison of the competitors' urinary catecholamine 
levels before and after the walk might yield information on the effect, in 
healthy subjects, of the acute physical and possible mental stress associated 
with the exercise. 
Every walker who volunteered to participate in this study was given a 
typewritten sheet of instructions which set out in detail the procedure to 
follow for the accurate collection of the urine samples. 
A sample of urine was obtained from 23 volunteers, aged between 20 - 70 
years, immediately prior to the start of the race at noon, on Saturday, 
12th July, 1975. 
The volunteers, after producing their first sample, were each given 
a numbered adhesive label which corresponded to their pre-race sample number 
and asked to produce a urine sample at the completion of the race and to 
attach their number to the bottle. A box of empty plastic bottles was left 
at the finishing point for this purpose. As the majority of competitors took 
between 16 - 20 hours to complete the race, these post-race urine bottles 
were collected from the finishing point at mid-day, Sunday, 13th July. 
Fourteen post-race urine samples were obtained from the original 23 volunteers - 
these urines were returned to the laboratory and treated as (in Chapter 9.2) 
As the walkers were competing in a race for which prizes were being awarded, 
it was felt that it would be unfair to the volunteers to ask them to collect 
every urine sample which they produced during the race, as it would have 
meant them carrying extra bottles and other equipment. Therefore, only pre- 
and post-race samples were collected from the walkers. 
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Table 1 
: dean level of creatinine expressed as uD per 100 cm3 and urine 
levels of H4NA, HVA, NMA and NA expressed as uD per r creatinira 
from 14 walkers before and after a 54-mile race 
Crea tinin 
Before Race After Race 't' SPI 
e 
}g100 102 35 163 146 -3.8 <0.001 
Kr1 2.5 ± 0.9 5.5 2.5 -4.2 <0.001 
HVA 3.5 ± 0.9 5.2 ± 2.4 -2.6 o. 02>P)o. o1 
KMA 0.27 ± 0.06 0.49 0.14 -5.4 (0.001 
ILk 0.25 ± 0.08 0.39 0.10 -3.9 <0.001 
Ratio K 1.23 ± 0.65 1.31 0.50 -0.37 N/S 
Ratio ! VA 
I 13.2 3.2 11.3 
5.1 1.21 N/S IS MA 
Ratio Ä 0.72 0.23 1.2 ± 0.6 -2.7 0.02>P) 0 01 . 
Table 14 
Mean levels of HMMA, HVA, NMA and MA expressed as ug per cm3 
urine volume from 14 walkers before and after a 54-mile race 
Before Race After Race 't' 'P' 
ENA 2.6 ± 1.3 9.5 ± 5.0 -4.8 <0.001 
HVA 3.6 1.6 8.8 ± 6.9 -2.6 0.02)P>0.01 
NNA 0.28 ± 0.12 0.87 ± 0.38 -5.4 40.001 
HA 0.25 10.11 0.65 ± 0.23 -5.7 40.001 
Patio 'A 1.2 - 0.7 1.4 - 0.6 -0.5 N/S 
HVA Ratio 
j 13.3 
± 3.1 10.8 5.4 1.4 N/S 
Ratio Ä 0.7 ± 0.24 1.3 ± 0.6 -2.9 0.01>P)0.002 
Scheme 4 Outline of catecholamine metabolism showing mean values for 
catecholaziine metabolite outputs based on crestinine and 
expressed as the Percentage increase of pre- to post-walk 
DA ý-'---> 3MT HVA (49%) 
NA . MIA (86%) 
11 IMA (12c) 
A -ý MA (56%) 
5.2 Results 
The mean output of creatinine expressed as per 100 cm3 urine 
(Table 13) was found to be significantly increased between the pre- and 
post-walk specimens. 
Tables 13 and 14 show the mean level of HNMA, HVA, IM and MA, 
pre- and post-walk, expressed as pg metabolite per mg creatinine and 
also as pg metabolite per cm3 urine volume for the fourteen volunteers 
who successfully completed the race; also included is a comparison of the 
pre- and post-walk ratios, NMA/MA, HVA/NMA and HMAA/HVA. These results 
suggest that a statistically significant difference exists between the 
pre- and post-walk values for I1}iNA, HVA, NIIA and MA and similarly between 
the pre- and post-walk HNI HVA ratios, in both sets of data, but no 
significant difference is apparent between the NMA/X4A and HVA/NMA pre- 
and post-walk ratios. 
Scheme 4 illustrates the mean percentage increase, based on 
creatinine output, for each of the four metabolites found after the race. 
This indicates that the mean output of HVA increased by 49'% compared to 
the 120% for MwiMA. Similarly NMA and MA increased by 86 and 56% respectively. 
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5.3 Discussion 
The possibility that our results might be influenced by the effect 
of dehydration was considered. The competitors were all physically fit 
and experienced long distance runners over this type of terrain and were 
familiar with the problems of dehydration. The mid-day start to the race 
meant that the walkers were subjected to the hot afternoon sunshine and 
had urine samples been collected throughout the race, instead of just prior 
to the race and at the completion, it may have been possible to detect 
changes due to dehydration which may have occurred over this period. 
Unfortunately, it was not possible to collect urine specimens throughout 
the entire race. Most competitors completed the race in 16 - 20 h. 
As a result the latter part of the race was completed during the night and 
early morning. The weather during this period was very wet, misty and cold 
and the competitors made ample use of the hot soup and drinks available at 
the check points situated at 8-mile intervals along the route. The final 
urine specimens, taken on completion of the race, were probably produced 
with the individuals in a reasonable state of water balance. 
When the amount of each metabolite per cm3 of urine before and after 
the race were calculated and compared, the results indicated a significant 
increase had occurred for HL"INA, HVA, NNýA and NA output. However, the 
relative amounts as measured by the ratios Ni. IA/MA and HVA/NMA remained 
relatively constant, only the HMNiA/HVA ratio showing a significant change. 
These results are very similar to those obtained by Sarviharjul83 who found 
the ratio of NA/A levels before and after exercise to be similar. 
The increase in urinary creatinine levels found between the pre- and 
post-walk samples is almost certainly due to the breakdown in muscle 
creatine189 as a result of the hard physical exercise involved in racing 
54 miles. The increase in the urinary levels of the catecholamine metabolites 
expressed as pg metabolite per mg creatinine found after the race, suggests 
that the rates of secretion of the catecholamines, dopamine, NA and 
adrenaline, have all increased dueto the hard physical work involved and its 
accompanying stress factors. 
-so - 
It is now generally accepted190 that the adrenal gland plays a key 
role in regulating the response of an animal to 'stressors'. Taggert and 
co-workers191 measured plasma levels of NA and adrenaline in eleven subjects 
before and after a seven minute period of vigorous exercise on a bicycle 
ergonometer, and found both NA and adrenaline levels to be increased, 
results which are consistent with the finding of the increased urinary 
output of NNA and MA in the present study. The increase in NA secretion 
during muscular exercise is due to the increased sympathetic nerve activity. 
However, why there is a concomitant increase in adrenaline output during 
exercise is not clear. ' It has been suggested1y2 that there is a consistent 
relationship between the amount of adrenaline released on the one hand and 
the degree of mental stress or unpleasantness on the other and that the 
increase in adrenaline found after hard physical exercise is associated 
partly with the quality of the emotional193,194 response to the physical 
stress. However, it is well known195 that adrenaline released from the 
adrenal medulla has the effect of increasing the conversion of glycogen to 
glucose in liver and muscle cells, thus enabling the body to cope with 
strenuous physical exercise by providing the necessary fuel (glucose) from 
the glycogen store. Similarly, in times of stress, the release of adrenaline 
is an important means whereby fatty acids are made available for metabolism. 
196 
The increased urinary outputs of the catecholaaine metabolites found 
after the race could be due to an increase in sympathetic activity as a 
result of increased muscle activity coupled with an increased adrenal medullary 
output of adrenaline, whose effect would be to increase the overall metabolic 
rate of the body tissues thus enabling the body to cope with the increased 
physical and mental stresses. Unfortunately no blood sugar samples were 
obtained from our volunteers. However, what proportion of the adrenaline 
secretion is due to physical stress and how much is produced by mental stress 
factors is unknown. Conrad et al 
197 
showed that the plasma levels of 
catecholamines increased after physical work in a group of subjects even 
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"though they were maintained in a hyperglycemic state by means of a glucose 
infusion. Sarviharjul83 also found that plasya glucose levels fell 
significantly after quite vigorous exercise, possibly due to glucose uptake 
into the muscle cells, whilst the urine NA and adrenaline levels over the 
same period rose significantly. 
It would appear from our urinary levels of 2; 4A and MA that the 
secretion of both NA and adrenaline increased during the race in proportion 
to their pre-race levels. Other workers198 who studied a group of racing 
car drivers, found that the drivers' plasma level of NA and adrenaline were 
very high 3 min after the race had finished compared to the values obtained 
3 min before the start. However, if one expresses their data as the ratio 
NA/A, values of 6.6 and 6.4 are found for pre- and post-race levels 
respectively, findings which are'comparable with the observations in this 
study of'the ratios of NNA/MA levels when expressed either as )g per cm3 or 
pg metabolite per mg creatinine. The reason for the significant difference 
between the HN HVA ratio pre- and post-race appears to be that the output 
, 
pg per mg creatinine does not show the same relative increase as the of HVA/ 
output of I? 1MA/)g per mg creatinine, possibly due to a rapid increase in 
the synthesis of NA from its precursor dopamine, as a result of the 
increasing physical stress. The secretion of dopamine, as well as NA and 
adrenaline, does not appear to have'been studied under conditions of 
physical stress. In the normal state the sympathetic nerves liberate amounts 
of dopamine and NA in the same proportion as that in which they are stored 
in the nerves. 
199 This suggests that an increase in the output of NA 
after sympathetic nerve stimulation, should be accompanied by a similar 
proportionate increase in dopamine output. Provided that the increase in 
NA observed after physical exercise is due only to increased sympathetic 
nerve activity, then the urine output of NMA and HPA, the products of NA 
and dopamine metabolism respectively, might be expected to show some degree 
of correlation and reflect overall sympathetic nerve activity. In the 
- S11- 
present study the lack of any statistical difference between the mean 
before and after walk HVA/iiM ratios could suggest that the excess NA 
produced as a result of hard physical exercise, is in fact derived from an 
increase in sympathetic nerve activity rather than from the adrenal medulla. 
It would appear therefore that after any hard, strenuous physical 
activity the secretion of the catecholamines, NA and adrenaline, increases 
probably in proportion to the severity of the stress, which is reflected 
ISSIQS 
by the finding of a relatively constant relationship between the urine and plasma 
ratios of NA to adrenaline as well as the urine levels of NMA/11A before and 
after physical exercise. The increase in plasma adrenaline and urine MA 
levels found after physical exercise is probably due in the main to an 
increase in body metabolism, but a small percentage may also be produced due 
to mental stress factors. Our findings also suggest that the urine levels 
of the catecholamine metabolites are a fair reflection of the plasma 
catecholamine values, as was hypothesised at the outset of this research. 
,. 
- 53 - 
CHAPTER 6 
A STUDY OF THE OVERNIGHT URINE CATECHOLAMINE METABOLITE 
LEVELS FOUND IN NORMAL AND HYPERTENSIVE SUBJECTS 
6.1 Introduction 
It has been shown200 that a consistently raised blood pressure is 
potentially dangerous because of the attendant risks of subsequently 
developing cerebrovascular, coronary or renal disease. 
Hypertensive subjects, in the main, can be divided into two major 
groups, (i) those whose raised blood pressure is due to a variety of patho- 
logical conditions and'is therefore a secondary condition, and (ii) those 
who have a consistently high blood pressure, even when resting, and for 
which no pathological cause can be found. The latter are said to have 
'essential hypertension'. 
It is knor+n201,202 that the sympathetic nervous system plays an 
I 
important part in controlling blood pressure and that certain drugs which 
interfere with the normal sympathetic control of blood vessels, induce a 
much larger fall in blood pressure in hypertensive subjects than in normo- 
tensives. It is possible that the elevated blood pressure of patients suffer- 
ing from essential hypertension is associated with excessive sympathetic 
activity and that these patients will have a corresponding increase in the 
plasm and urine levels of the sympathetic hormone, N. A.. Studies with hyper- 
tensive patients have produced conflicting results. Holtz et al 
203 in 1947, 
were the first to observe an increase in pressor amines in the urine of a 
hypertensive subject, but no data were given. Later von Euler204 studied a 
group of 500 hypertensive subjects and observed that the majority of these 
patients excreted normal amounts of urinary NA when compared to a control 
group, but 16% had levels which were significantly above normal. Some 
research 
205-208 
has confirmed von Euler's findings, whilst other work209,210 
has found no apparent differences in urinary NA levels between normal and 
hypertensive subjects. 
Strong evidence for an abnormality in the function of the sympathetic 
nervous system in hypertension was obtained with sophisticated plasma assay 
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Table 15 
A comparison between the mean overnight and daytime outputs for Hi'IMA 
HVA, NMA and MA expressed as uff' Der minute for a P'rouo of seventeen 
normotensive subjects 
Mean 't' 'P' 
HN? iA overnight 1.6±0.5 
-3.03 0.01)P)0.001 
MO U daytime 2.4+0.8 
HVA overnight 2.2±U. 8 
-4.2 (0.001 
HVA daytime 3.4±0.8 
NMA overnight 0.23±0.06 
-1.8 0.1)P)0.05 
Mk daytime 0.26±0.06 
MA overnight 0.18±0.06 
-2.2 0.05)P)0.02 
MA daytime 0.22±0.06 
Table 16 
Overnight output of catecholamine metabolites (Yg per minute) from 
twenty hypertensive patients comp ared with 17 normal subjects 
! can fps 
. 
Hypertensives HKIIA 2.4+0.7 
3.7 P(0.001 
Normaals HIIIA 1.610.5 
Hypertensives EVA 2.210.5 
0.1 N/S 
Normals HVA 2.2 0.8 
Hypertensives NVA 0.2210.06 
-0.41 V/S 
Vormals WILA 
Hypertensives 14A 
Normals NA 
0.23±0.06 
0.19+0.07 
0.75 N/s 
0.18+0.06 
tecniuques involving gas-chromatography211 and double-isotope labelling 
studies. 
212-214 These studies showed the presence of increased circu- 
lator; º NA levels in patients with essential hypertension and that the levels 
were positively correlated with the diastolic blood pressure. 
212,213 
Nevertheless, it would be premature to suggest that a direct causal 
relationship exists between the circulating NA level and the increased 
blood pressure. It might be expected, however, that both hypertensive and 
normotensive subjects would, during a state of rest such as occurs during 
sleep, have lower plasma levels of NA than during the daytime active period. 
Recently, Brezinovä and Carruthers215 found for four sleeping hypertensive 
patients raised plasma levels of NA which were higher than the 
daytime plasma 
NA levels determined in a group of resting normotensive individuals, 
96 
showing that hypertensive subjects, even when asleep, have increased amounts 
of NA in their blood. 
Using our simple techniques for the estimation of urinary HMMA, HVA, MA 
and mA, we have compared the output of these catecholamine metabolites in 
timed overnight urine collections obtained from a group of seventeen normal 
subjects, ten males and seven females, whose ages ranged from 32 - 55 years 
and who'were neither taking medicants nor were suffering from any disease 
which could have interfered with the tests, with those obtained from a group 
of twenty hypertensive patients. This group was comprised of fourteen males 
andsia females, all completely untreated and previously undiagnosed, whose 
ages ranged between 45 - 65 years and whose blood pressure ranged from 
175/110 to 250/160. 
6.2 Results 
Table 15 gives the mean outputs per minute obtained from the 
overnight and daytime urine collections in the normal subjects, for each of 
the catecholamine metabolites, HMNA, HVA, NAA and IRMA. These results indicate 
that significant statistical differences exist between the mean night-time 
and day-time values, particularly with regard to the output of HVIRA and INA. 
A comparison between the overnight results for the hypertensive group 
and the normals (Table 16) expressed as )ig per minute output, shows that 
there is a very significant difference between the mean output of HM A in 
the hypertensive group compared to the normal group, but no significant 
differences are apparent between the two groups regarding the overnight 
- 5,5 - 
mean outputs of HVA, M4A and ILk, which in the hypertensive patients tend 
to be lower than those obtained in the normal subjects. 
6.3 Discussion 
There are three probable reasons for the conflicting results regarding 
the association of raised blood pressure with raised blood and/or urine 
levels of NA in hypertensive subjects. 
206-215 
First, the estimations have either been carried out on random urine 
samples146 or 24 h urine collections142 or have been related to output per 
- hour216 and consequently the values from different research groups cannot 
easily be compared. 
Secondly, the patients and the normal controls have varied. Thus some 
hypertensives have been compared against hospital in-patients216 whilst 
146 
others have been compared against hospital personnel. Often the patients 
are resting or lying down during the collection period, whilst the control 
subjects are active and being subjected to everyday stresses. Thirdly, 
many of the hypertensive subjects have been treated with anti-hypertensive 
drugs prior to the urine collection, this treatment being stopped for varying 
periods of time before the start of the test period. As a result the 
patients are no longer 'untreated' hypertensives. 
Prior to this study, no-one has used overnight urine outputs of cate- 
cholamine metabolites to compare untreated hypertensive patients with normo- 
tensive subjects. Further, in this study, both the control subjects and 
the patients were under the same conditions of posture, lying resting or 
asleep, and during the urine collection period both groups were in their 
own familiar surroundings, thereby eliminating any mental stress factors 
which could arise from the subjects being placed in unfamiliar surroundings, 
such as a hospital. 
The results obtained from the normotensive subjects clearly illustrate 
the marked increase in catecholamine metabolite outputs, when expressed as 
jig per minute, during the daytime compared with the night-time. This day- 
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time increase is expected due to the increase in physical and rental 
activity which occurs during the daytime compared to the night-time 
sleeping period. 
Evidence which suggests a possible abnormality in the functioning 
of the'sympathetic nervous system in hypertension has recently been inferred 
from assays of the plasma levels of catecholamines2ll-214 which have shown 
an increase in circulating levels of NA in hypertensive patients. From- 
our study of normal and hypertensive overnight urine samples we found a 
significantly higher mean overnight output of HMMA, expressed as ig per 
minute, in our hypertensive group when compared with the normal group. 
(Interestingly, the overnight output of MLk by hypertensives is very similar 
to the normal daytime output for normotensives, a finding which closely 
parallels the work of others. 
96,215j The increase in the overnight output 
per minute of MOM found in our hypertensive patients implies that even 
when sleeping, untreated hypertensive patients have a higher plasma level 
of catecholamines or a more active sympathetic nervous system than normal 
sleeping subjects. These catecholamines in turn are metabolised 
(see 
Chapter 1, Scheme 2) to give increased urine levels of I MA. However, our 
finding of similar overnight outputs for HVA, N14A and MA, expressed as yg 
per minute, for the two groups, is at first sight, puzzling. 
One reason for the finding of an increased plasma level of NA in 
hypertensive patients could conceivably be due to an increased secretion 
of NA from the ends of the sympathetic nerves. It has been shown, 
217,218 
that discharge of NA, by exocytosis, is closely linked with a corresponding 
discharge of the enzyme dopamine- ß-hydroxylase from the nerve vesicles. 
Louis and co-workers219 found a proportionate increase in both NA and 
dopamine- ß -hydroxylase levels in hypertensive subjects which appeared to 
correlate well with their elevations in resting diastolic blood pressure. 
Other workers2110220 have also found increased plasma levels of dopamine- - 
hydroxylase in hypertensive patients. In contrast, 
Rberg 
et x1221 found no 
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Scheme General outline of catechola ine metabolism 
NA P ºi'ýiA 
DOMA. H?! MA 
AM 
Scheme 6 An alternative method whereby the excess plasma noradrenaline 
levels found in hypertensive subjects might be metabolised 
Nerve Circulation Muscle 
Release 
NA NMA 
Formation Excess 
of Deactivated ID24A 
NA 
Uptake, Uptake2 
I 
by NA --) DOMA 
significant difference in dopamine-f3 -hydroxylase levels between 
his hypertensive and normal groups. If the finding of an increased 
plasma level of NA and dopamine -/ -hydroxylase in hypertensive patients 
is valid, then under normal conditions one would expect that the 
increased secretion of NA would be rapidly deactivated by a corresponding 
increase in the CONT and hAO enzyme systems, to produce increased 
metabolite levels in the urine (Scheme 5). On the other hand, if the 
normal metabolic mechanisms were impaired this could account for enhanced 
plasma levels of NA and a distorted urinary metabolite pattern, as we 
observe. Support for the suggestion that the enzymes responsible for 
0 
metabolism of NA are perturbed in hypertension comes from recent work222 
which has shown that untreated hypertensive patients have significantly 
higher blood cadmium levels than normal subjects. It might be that 
replacement of the natural divalent Mg 
++ 
co-factor 
60,61 for the 
COMT enzyme system by cadmium, itself a divalent metal, leads to a 
less active or inactive enzyme system. 
Alternative mechanisms which could account for the increased plasma 
level of NA found in hypertensives, are failure of the normal re-uptake 
process223 due either to nerve degeneration or to an abnormality in the 
binding mechanism. It has been shown224, in cats, that. severence of sympa- 
thetic nerves leads to a marked inability of the degenerating nerves to bind 
and store active catecholamines. However, there is no evidence to suggest 
that hypertensive patients have any degeneration of their sympathetic nervous 
system, unlike people who suffer from an inherited disease, known as familial 
dysautonomia, in which degeneration of part of their autonomic system is a 
clinical feature. Furthermore, the finding225 of low urinary levels of HNMA 
in this condition is contrary to our findings in hypertensive patients of a 
normal urinary output of NMA with raised levels of IDIMA and suggests that 
actual degeneration of nerve fibres leads to a reduced rather than an 
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increased output of catecholamines. Ir the second mechanism inability of 
the nerves to re-bind secreted NA, results in an increased plasma level, 
then given the normal mechanisms of metabolism we would again expect to 
observe a general increase in urinary metabolite levels. 
Our finding of a normal urinary level of YRA in hypertensives lends 
support to the idea (Scheme 6) of a partial metabolic block occurring in the 
normal breakdown of NA in hypertensive patients. The effect would be a 
decrease in the rate of inactivation of released NA, some of which could 
perhaps be re-bound by the sympathetic nerves. However, it is known 
226 
that if neuronal uptake is interfered with then extra-neuronal uptake 
(uptake2) increases and that any excess NA is removed from the circulation 
by being loosely bound to vascular smooth muscle and also cardiac muscle. 
227 
The uptake of catecholamines by this method is rapidly followed by their 
intracellular catabolism by IRO and COMT enzymes, and constitutes a 
mechanism whereby extra-cellular catecholamines are destroyed. However, 
if the extra neuronal COIJ, T enzyme system is partially defective in 
hypertensive subjects, then any excess NA would tend to be deactivated 
by the usually minor pathway via the NAO system, to produce 3,4- 
dihydroxymandelic acid (DOI4ýA). 
Thus one might postulate that the increased plasma NA levels 
which have been found in hypertensive patients could, in part, be caused 
by a defect in the extra neuronal COPIT enzyme, due either to the 
presence of an abnormal metal (Cd++) which may compete with the normal 
metal co-factor, or the binding of cadmium to an abnormal iso-enzyme, 
the presence of which has recently been suggested by Glauser et a1.222 
If the latter idea is accepted then the excess DOMA resulting from the 
presence of an abnormal COXiT iso-enzyme in the extra neuronal uptake 
processes will be converted by the normal liver COXT enzyme, to produce 
ultimately increased urine levels of HMMA without any significant 
elevation of NI', A output, results which are consistent with our findings. 
The excess NA attached to the vascular smooth muscle could perhaps be 
responsible for the increased vascular constriction which would produce 
the increase in blood pressure which is symptomatic of essential 
hypertension. 
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To confirm the above proposal, it would be of value to measure urine 
levels of DOMA and compare the specific rates of reaction for the MAO and 
CONT enzyme systems using radioisotope labelled substrates in normal and 
hypertensive subjects, as well as a study of 'trace metals' in this 
disease. 
I 
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C17 
URINARY CAT1 CHOLAI'IINE 1Yi'1'ABOLITS LEVELS POUND IN PATIENTS 
AF'TEtt SU1 ARACRNOID HAEAORR AGS 
7.1 Introduction 
It is now well established228 that the cerebrovascular tree is 
innervated by sympathetic nerve fibres. Histochemical studies229 have 
demonstrated noradrenergic nerve endings in the walls of the intracerebral 
vessels and electron microscopy230 has confirmed the presence of typical 
autonomic nerves with dense localised swellings which are thought to 
contain NA. 
The precise physiological role of these nerves, however, is unknown. 
Recent work229' 
231 has suggested that the autoregulatory mechänism of 
cerebral blood flow is controlled by the sympathetic nervous system. 
Harper et a12i2 studied the effects of stimulating the cervical sympathetic 
nerve trunk and the intracarotid infusion of noradrenaline on anaesthetized 
baboons maintained at varying levels of arterial carbon dioxide pressure. 
They concluded that the extraparenchymal vessels are influenced by the 
sympathetic nervous system, whilst the intrapärenchymal vessels are under 
local intrinsic metabolic regulation, the pial vessels being influenced by 
both systems. However, although sympathetic discharge may constrict the extra 
parenchymal: and pial vessels, normal autoregulatory processes affecting the 
intraparenchymal vessels will tend to maintain a normal flow. Following a 
subarachnoid haemorrhage (SAH) radiological evidence233 often indicates 
the presence of spasm in the cerebral vessels. Similarly, the observations 
234 - 22 
of high urine catecholamine levels in patients who have suffered a SAH and what 
role, if any, catecholamines might play in the production and maintenance of 
cerebral spasm is uncertain. 
The aim of this investigation was to study the variation in the 
excretion of catecholavine metabolites of patients who had suffered a SAH 
and to relate these levels to the clinical state of the subject, in order 
to assess the usefulness of serial measurement of catecholamines as a 
possible aid to prognosis in the SAH patient. 
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Table 17 
Overall mean urinary outputs of the catecholarnine metabolites 
obtained from twelve relatively fit patients (Group I) after SAH, 
compared with results from ten patients (Group II) who were drowsy or 
disorientated after SAH 
Group I 
Group II 
't' 
P 
HI-1%IA HVA NMA 14A 
mg per 24 h mg per 24 h g per 24 h jig per 24 h 
3.4 ± 1.3 3.5 1.5 459 225 355 171 
4.54 ± 1.8 3.8 1.2 692 347 511 172 
-3.2 -0.8 -3.4 - 3.8 
0.011P)0.001 , N/S 0.01>p>0.001 <0.001 
Table 18 
Comparison between the overall mean urinary outputs of the catecholamine 
metabolites pre- and post-operation obtained from the ten SAH patients in 
Group III 
HMMA HVA MA MA 
mg per 24 h mg per 24 h pg per 24 h jig per 24 h 
Group III 
a) - before operation 3.8 2.0 3.5 1.5 51¢ 243 542 201 
b) - after operation 4.1 1.6 3.6 1.2 507 291 412 180 
't' 0.6 -0.4 -0.1 -2.5 
P N/S N/S N/S 0.02>P>0.01 
Comparison between 
Table 19 
the overall mean Urinary outputs of the catecholamine 
metabolites pre- and post-operation (Group III) with those of the relatively 
fit patients (Group I) 
1 
u NNA JWi. Ni+SA 
' 
A"u4 
mg. per 24 h mg per 24 h pg per 24 h pg per 24 h 
Group I 3.4 1.3 3.5 1.5 459 225 355 171 
Group III (a) 
Before operation 
+ 3.8 2.0 t 3.5 1.5 + 51¢ 243 542 201 
't' -1.1 -0.02 -0.9 4.1 
P N/S N/S N/S <0.001 
Group III (b) 
After operation 
4.1 + 1.6 3.6 ± 1.2 507 ± 291 412 ± 180 
't' -2.1 0.3 -0.8 -1.3 
P 0.05>P) 0.02 N/S N/S N/S 
Thirty-eight patients admitted consecutively to a neurological centre 
were studied. Their ages ranged from 11 - 65 years. The patients were 
studied over the period of their stay in hospital, an average of two weeks. 
On day 1,2 and 3, after admission and then every 2-3 days afterwards, a 
24 h urine sample was collected for the estimation of HMMA, HVA, NTMA and 14A. 
On the basis of their clinical condition, the patients were classified into 
four groups, by the neurosurgeon in charge of the unit, as follows: 
Group I- consisted of 12 patients who were classed on examination 
as being relatively fit and alert after a SAH (No. of observations - 39) 
Group II - consisted of 10 patients who were drowsy, disorientated 
with or without neurological signs (No. of observations - 34) after a SAH. 
Group III - consisted of 10 patients who had an operation within 2-3 
days to relieve their symptoms (No. of observations - 55, one of whom 
subsequently died after operation) - defined as pre-and post-operation SAH 
patients. 
Group IV - consisted of 7 patients (one post-operation) who 
subsequently died within 3-7 days after their SAH (No. of observations - 24) 
7.2 Results 
" Comparison of the catecholamine levels between the different clinical 
groups revealed several interesting points. For example, comparing Group II 
with Group I patients (Table 17) showed significantly higher urinary mean 
outputs of HH1MA, Ni1A and MA, but not of UVA in the Group II patients. 
There was apparently therefore some degree of correlation between an impaired 
level of consciousness and high urinary catecholamine metabolite levels. 
A study of the Group III patients (Table 18) before and . ter operation, 
indicated that no significant increase or decrease after the operation took 
place in the urinary levels of HvN4A, HVA and NNA, but a decrease in the mean 
output of MA was observed after the operation, a finding which might suggest 
that the operation relieved some 'stress' factor which was present before 
the operation. 
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Table 20 
Comparison between the overall mean urinary outputs of the catecholamine 
metabolites found in Group I, with seven patients, Group IV, who died 
after a SAH 
WIMA 
mg per 24 h 
Group I 3.4 1.3 
Group IV 5.2 1.6 
HVA 
mg per 24 h 
3.5 1.5 
4.6 1.3 
NNA 
ýg per 24 h 
459 225 
866 ± 531 
MA 
)g per 24 h 
355 171 
606 266 
't' 4.4 2.6 
P /0.001 0.02)P)O. 01 
4.1 
<O. 001 
4.2 
<0.001 
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When a comparison was made of the alert Group I patients, with the 
Group III pre- and post-operation patients (Table 19), no significant increase 
between the Group IIIa (pre-operation) and the Group I values for MMA, 
HVA and NYA was apparent, but there was however, a significant difference 
between the Group I and Group IIIa patients with regard to the high MA 
values in the pre-operative patients. A comparison between Group I and 
Group IIIb (after operation) indicated a slight increase in HJNA, but no 
significant differences between the HVA, NIM1A and PA - the operation 
apparently reducing the output of NSA closer to the Group I, value. 
A comparison between Group I and Group IV - the patients who subsequently 
died after a SAH (Table 20) showed that all four urinary mean levels of 
catecholamine metabolites were significantly increased in the Group IV patients, 
some of the values for NMA output reaching levels comparable with those 
encountered in phaeochromocytoma. 
A study of the daily mean values for HKI A (Fig 12) shows that the 
Group I patients who recovered spontaneously from a SAH showed no apparent 
increase in HMMA output. The Group II subjects have elevated HMMA values 
for the first four days after a SAH, but the level then falls. The patients, 
Group III, who underwent operation, have HYDMA levels well within the range 
established in Chapter 2. The patients who died, Group IV, had the widest 
fluctuations in HMMA output with a peak level much greater than those found 
in the other three groups by the sixth day. 
Similarly, a study of the HVA output in each Group (Fig 13) appeared 
to suggest that for Groups I, II and III the mean values were similar and 
tended to lie nearer the lower end of the observed normal range (Chapter 2.5). 
Only in Group IV did the HVA show a peak, which tended to parallel the H1'iM1A 
peak, but even this level was still well within the observed range for HVA. 
A study of the N11A output between the four groups (Fig 14) produced some 
interesting results. The mean level of NNA in the Group I subjects is 
higher on day 1 than Ihubsequent 
days, but the results would be considered 
normal. The Group III patients show a rise in Nii: A the day after their 
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operation, but their NINA mean levels tend to remain within the observed range. 
However, when we consider the mean NMA output in Groups II and IV 
the results, apart from those found in Group IV (day 3/4), would tend to 
fall above the mean 12S. D. limits of the method. We have shown (see 
Appendix e) that the distribution of the catecholamine metabolites from 
our normal group have a positive skew distribution. As a result empirical 
top normal limits have been imposed on our data (see Addendum). As a rough 
guide the upper level (UL) for NMMMA has been set at 650 pg/24 h. Using this 
empirical figure we find that the mean daily output for the Group II patients 
is much higher than those of Groups I and III and fluctuates either side of 
this arbitary upper limit, but the mean level does not fall with time over 
the study period. The mean values for NNA in the patients who died, 
Group IV, tend to lie above the arbitary level of 650 pd24 h and in general 
would be classed as abnormal. 
Similarly, setting our upper limit for MA at 600 ug/24h (Fig 15) would 
result in all the mean daily values for Groups I, II, III and IV being 
classed as normal. A closer look at the data shows that the MA mean levels 
from Group I tend to rise as *2A falls. In Group III the mean level of 
NA falls steadily with time. The patients in Group II tend to have higher 
mean KA levels which tend to remain high and do not fall until 8 or 9 days 
after the SAH. The Group IV patients show wide fluctuations in mean MA output. 
7.3 Discussion 
High urinary levels of catecholamines have been found in the majority 
of patients with acute cerebral'lesions. 
234,235 
The highest levels have 
been reported in SAH patients. However, these workers expressed their 
results not as output per 24 h but as ug catecholamine per mg creatinine 
for NA, adrenaline and total catecholamines. Some of their urine samples 
were collected days after admission, and in only eleven patients were more 
than three measurements carried out. Nine patients had total metadrenalines 
estimated at least once, but elevated levels were found only in one unconscious 
patient. 
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In the present study, the daily mean outputs of NMA and M suggest 
that certain SAH patients in Group I and Group III appear to exhibit a 
normal stress reaction, which after an initial rise, was followed by a fall 
in urinary NNA and VIA output. Groups II and IV however, had continuing 
high urine levels of NNA and PiA which did not fall with time, suggesting 
that these patients have a high production or rapid turnover of NA and 
adrenaline. The mechanism which produces this prolonged effect is unknown. 
Sesenbach et a1237 in 1951, demonstrated in man that NA when 
administered parentally, produced a greater increase in cerebral vascular 
resistance (58) than the increase in arterial blood pressure of 31% 
resulting in a reduced cerebral blood flow. Other workers 
238 
reported in 
man that adrenaline produced an increase in mean cerebral arterial blood 
pressure and cerebral blood flow without a significant change in cerebro- 
vascular resistance, while NA increased cerebrovascular resistance, producing 
a decrease in cerebral blood flow despite a substantial increase in mean 
cerebral arterial pressure. The effect of a high circulating level of 
catecholamines on the cerebral blood vessels has been reported239 in a 
patient who was found to be suffering from a catecholamine secreting tumour, 
who was shown angiographically to have diffuse vasoconstriction of the 
cerebral vessels. It has also been demonstrated 
240 
that spastic vessels aan 
themselves release NA. These findings could suggest that at a critical level 
of circulating catecholamines the cerebral vessels will start to constrict. 
These spasms may then cause NA to be released from the spastic vessels which 
may initiate further cerebral artery spasms which would have the effect of 
prolonging and maintaining the spasms due to the high level of NA. A suggestion 
which our finding of continued high levels of urinary NI'IA in many of our 
badly affected patients might lend support. 
The part played by this increase in NA in maintaining cerebral artery 
spasm is not clear. It could be a natural attempt by the body to prevent 
blood flow from the ruptured vessels. Boulay233 who studied spasm in 
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cerebral arteries after SAH showed that spasm is more common on the same 
side as the aneurysm, but spasm can also be seen in arteries distant from 
the initial bleed, which have normal lengths of arteries separating them. 
Death occurred in half his cases who were shown to have spasm on angiography, 
most were in coma and all had a severe degree of arterial spasm. He also 
showed after a SAH that spasm of the arteries took between 1-4 weeks to 
relax. Why these spasms are produced in some patients and not in others is 
difficult to explain. One suggestion might be that the degree of constriction 
of the arteries depends on the severity of the initial bleed. This would 
result in a variable degree of physical stress occurring within the body with 
the concomitant production from the adrenal medulla of NA and adrenaline in 
amounts which would be directly related to the severity of the stress. 
It is known 191 that NA and adrenaline production may vary with the type of 
stimulus. The increase in urine output of N! VIA and MA found in our four groups 
of patients might perhaps lend support to the suggestion of an increasing stress 
factor which could be related to the severity of the haemorrhage. 
It would certainly appear that the appearance of spasm in the cerebral 
arteries can be related to high levels of circulating NA in a non-SAH patient? 
39 
Comparable urine levels of NI4A to those produced by patients with 
catecholamine-secreting tumours were found in the patients who died and many 
of the more severely affected patients in Group II. 
The mechanism whereby spasm in the cerebral arteries after the initial 
bleed is maintained over long periods is difficult to explain. A possible 
suggestion could be that the hypothalamus has a 'direct effect' on the 
sympathetic nervous system. An increased hypothalmic response could perhaps 
be induced by spasm of the small arteries supplying the hypothalamus. 
The effect of this would be to increase sympathetic activity and lead to 
an increased production of catecholamines. Ischaemic lesions, due to anoxia, 
have been found at autopsy, in the hypothalamus of patients who died following 
a SAH. 
241 The increased sympathetic drive, resulting in increased plasma 
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levels of catecholamines, would in turn potentiate the spasms, thereby 
increasing the hypothalmic ischaemia, thus creating a vicious circle of 
events which contribute to the high morbidity and mortality found in this 
condition. 
A clinical pointer which emerged from this study is the finding 
of mean urine levels of NI4A which lie within the empirical normal limit 
in SAH patients who recover either spontaneously 
(Group I), or after 
operation (Group III), compared to the mean values for NiiA found in the 
SAH patients who subsequently died (Group Iv) or who had a marked degree 
of paralysis or were disorientated (Group II), whose mean NNA values 
tended to lie above the empirical range and in many cases were still above 
the empirical normal limits days after the SAH had occurred. It would appear 
that daily 1iA estimations in SAH patients may be useful in predicting the 
possible outcome. A falling NPiA or a value within the normal limits would 
be good, an increasing NMA or a value lying above the upper limit would be 
bad. 
A further interesting point from this study is the quite low mean 
daily values for HVA found in the first-three SAH groups compared to the 
calculated normal mean level for HVA (Chapter 2,5), which might suggest 
that the production of dopamine may be reduced after a SAH. Even the 
patients who subsequently died did not increase their mean output of HVA 
more than one standard deviation higher than the calculated normal mean value. 
Recent work242 - 
244 in relation to the condition known as hyperprolactinaemia 
has indicated that the secretion of prolactin by the pituitary is under 
direct tonic inhibition by the hypothalamus and that dopamine-is thought 
to be the major prolactin inhibiting factor operating between the 
hypothalamus and the pituitary. It would be pure speculation to suggest 
that the prolonged excess of NA found in some cases of SAH could be due to 
failure of their hypothalmamic-pituitary feed-back mechanism, due to a 
reduced dopamine level. It would be interesting to measure and compare 
blood levels of dopamine and noradrenaline in a group of SAH patients. 
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CHAPTER 8 
STUDIES ON THE URINARY LEVEL OF CATrCHOLArüNE 
XETAbOLITES FOUiD IN PATIENTS WITH EITHER A 
PHiUOCHNOi'iOCYPOi to OR A NEU1OBLASTO'r TUMOUR 
AND TM UTILITY OF THE METABOLITE ANALYSES 
IN ACCURATE DIAGNOSIS 
PART I_ PHAEOCHROMOCYTOMA 
PART II - NEUItOBLASTOMA 
PitRT I- PNAEOCHRO, OCYTTOi'A 
8.1 Introduction 
Phaeochromocytona, although closely related histo- 
genetically to the highly malignant neuroblastoma, is usually benign. Like f 
the adrenal medulla, itself a major derivative of neural crest ectoderm, 
these tumours are examples of sympathetic tissue functioning as an endocrine 
gland; this results in the overproduction of a variety of catecholamines 
with their subsequent adverse effect on the host. One of the major clinical 
effects on the patient is either paroxysmal or, more frequently, persistent 
hypertension, due to the sudden or constant secretion of excess catechol- 
amines from these tumours. The output of catecholamines, however, is 
variable and appears to be closely related, according to Crout and 
Sjoerdsma, 245 to the size of the tumour. Small tumours (less than 50g) tend 
to have a rapid rate of output and secrete pure amine into the host producing 
severe symptoms, whilst larger tumours have a slower output of the physio- 
logically active catecholamines and tend instead to put out a higher pro- 
portion of metabolites. This apparent relationship between tumour size and 
catecholamine excretion probably relates to the type of tumour rather than 
its actual size since a low secretion rate may not be detected at an early 
stage unless the individual is subjected to external stress either as a 
result of surgical procedures or perhaps after parturition. A phaeochromo- 
cytoma can therefore be considered as a" potential danger. 
Engel and von Euler 
? 46 
in 1950 were the first to demonstrate that 
urine obtained from a patient with a phaeochromocytoma contained an excess 
of catecholamines and they suggested that estimation of the urinary free 
catecholamines-might be used as a diagnostic test for phaeochromocytoma. 
However, the measurement of free catecholamines is unlikely to be a 
sure indication of the relative rates of secretion of catecholamines by the 
tumour. The actual amount of free catecholamines found in the urine is 
only a very small fraction of the total catecholamines secreted. Various 
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Table 21 
Output of H1h1MA, HVA, NMA and MA mp, per 24 h urine volume 
found in 19 cases of phaeochromocytoma compared with outputs 
determined for a group of 123 normal adults 
Case 
No. Sex FT', 1i 4A HVA NRA 14A 
1 J. D. M 18.6 * 6.3 2.46 * 0.33 
3.6 2.8 2.20 * 0.36 
6.4 5.8 1.16 * 0.27 
5.1 4.3 1.02 * 0.25 
6.1 4.2 0.81 * 0.49 
2 K. M. M 29.2 * 3.8 9.74 * 1.49 
26.7 * 5.2 8.03 * 1.97 * 
3 P. W. M 6.2 12.3 * 1.68 * 1.28 
7.3 13.7 * 1.80 * 1.55 * 
4 D. M. M 3.1 10.3 * 0.79 * 5.92 * 
5 V. T. F 21.6 * 17.5 * 4.77 * 0.40 
6 B. S. F 11.8 * 10.3 * 1.66 * 0.40 
7 B. L. F 12.2 * 17.9 * 1.69 * 3.59 * 
8 O. B. F 1.4 6.5 2.91 * 0.32 
3.7 2.9- 3.61 * 0.94 * 
9 W. H. N 8.9 * 3.8 2.95 * 5.48 * 
10 A. J. F 27.6 * 7.1 9.18 * 0.93 * 
11 J. R. F 4.2 2.8 1.11 * 1.10 * 
4.5 4.7 1.57 * 1.83 * 
12 I. M. M 7.3 4.3 5.69 * 3.85 * 
13 R. F. ri 5.6 2.6 1.95 * 8.57 * 
3.2 1.4 2.73 * 3.86 * 
4.6 4.1 0.85 * 2.88 * 
6.1 5.5 1.32 * 4.54 * 
14 I. C. F 7.8 * 3.2 1.33 * 1.75 * 
15 E. M. M 7.0 4.7 1.49 * 0.91 * 
45.8 * 5.2 1.62 * 0.96 * 
10.7 * 3.6 4.21 * 0.37 
16.6 * 7.9 6.29 * 0.40 
15.8 * 7.4 3.78 * 0.49 
17.6 * 7.2 6.36 * 1.08 * 
46.6 * 6.0 6.84 * 0.54 
tont/ 
Table 21 (cont) 
Case 
No. Sex ILMMA HVA h'MA MA 
16 P. B. F 19.5 * 7.6 5.26 * 3.88 * 
10.7 * 6.2 3.37 * 2.63 * 
10.9 * 5.7 4.54 * 3.23 * 
7.9 * 4.8 2.57 * 2.45 * 
13.6 * 6.5 4.21 * 3.33 * 
10.9 * 7.1 3.97 * 3.74 * 
7.2 8.2 3.30 * 3.19 * 
17 B. C. F 8.8 * 5.1 2.62 * 0.88 * 
7.5 5.0 2.98 * 1.10 * 
18 H. P. F 28.3 24.7 * 2.29 * 2.86 * 
19 J. H. F 10.6 * 5.9 2.62 * 2.96 * 
Normal adults 
Mean 3.3 4.9 0.39 0.35 
Ranges. (1.6-7.5) (2.4-8.8) (0.25-0.65) (0.25-0.55) 
;* Values falling above the observed normal ranges 
Table 22 
The distribution of catecholamine metabolite levels within 
and above the normal range in 43 24 h urine samples taken 
from 19 subjects known to have a rhaeochromocytoma 
Above Within 
Normal Range Normal Range % Normal 
HMMA/mg per 24 h 24 19 44 
HVA/mg per 24 h7 36 84 
NI4A/mg per 24 h 43 0, 0 
MA/mg per 24 h 33 10 23 
0 
Table 23 
Nineteen cases of yhaeochromocytoma classified as having 'elevated' 
or 'normal' metabolite levels according to the metabolite analysis used 
HMMA/mg per 24 h, as sole test 
RVA/mg per 24 h, as sole test 
NNA/mg' per 24 h, as sole test 
NA/mg per 24 h, as sole test 
Combined }INMA+HVA/mg per 24 h 
Elevated Normal Missed 
13 6 32 
7 12 63 
19 00 
16 3 16 
15 4 21 
!I 
workers, 
120,247 in this field have measured the urinary levels of }INI4A 
but as we saw from (Chapter 1) Scheme 2, in Haan the catecholamines are 
first metabolised to IRMA and I MA before their conversion to MV-1A. Because 
of this, measurement of MMA alone gives no indication of the relative 
amounts of NA and adrenaline which have been secreted. The output of dopamine 
in connection with phaeochrooocytoma was not considered important until 1956 
when ?. acNillan163 analysed tissue from an atypical phaeochromocytoma and 
found that it contained a high concentration of dopamine which she 
suggested might be characteristic of a malignant phaeochromocytoma. 
Robinson248 et al also found in a study of 48 phaeochronocytonas, that one 
was malignant and that both the primary and secondary growths produced 
dopamine which resulted in high urine levels of HVA. 
The urinary catecholamine metabolites, &IMA, HVA, NMA and NA were measured 
in 19 proven cases of phaeochromocytoma and compared with the normal adult 
range for each metabolite which 
had been determined using the previously 
described methodology, to evaluate which, if any, of the four catecholamine 
metabolites might serve as a reliable index for the detection of an active 
phaeochromocytoma. 
8.2 Results 
Table 21 shows the extreme variability in the outputs of the four 
metabolites, EMMA, HVA, NVIA and MA found in different patients and even in 
the same patient on different days. 
Table 22 shows the distribution of the metabolite analyses for the 
known pathological urines within and above the normal range for each 
metabolite. The results indicate that using the measurement of HP"SNIA and 
HVA (mg per 24 h), to detect a phaeochromocytozra would have produced false 
negative results in 44% and 84%, respectively, of the cases. The output of 
KA (mg per 24 h) would have been negative in 23% of the results. However, 
the output of P2IA (mg per 24 h) would have been diagnostic for all 43 urine 
samples. 
Table 23 expresses the same analytical results in a rather different 
way; it groups the 19 actual cases-of phaeochromocytoma as having an 'elevated' 
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Fit, 16 Relationshin between NMA end Hf , 1A nP per 24 h in urine 
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Fig 17 Relationship between HVA and HNMA mg per 24 h urine 
from patients with phaeochromocytora 
d 
x 
ENNNA 
from patients with phaeochromocvtora 
Table 24 
Output of ITI-TA, HVA, NMA and MA/ug per mg, creatinine found 
in 17 cases of phaeochromocytoma compared with normal ranges 
Case 
No. Sex HifýIA HVA N-rr1A 14A 
1 J. D. M 6.7 * 2.3 0.9 * 0.12 
2.6 2.0 1.6 * 0.26 
3.5 3.2 0.6 * 0.15 
2.6 2.2 0.5 * 0.13 
3.4 2.4 0.5 * 0.28 
2 K. M. M 19.7 * 2.6 6.6 * 1.0 * 
23.4 * 4.6 7.0 * 1.7 * 
3 P. W. M 20.0 * 39.6 * 5.4 * 2.9 * 
34.8 * 65.2 * 8.6 * 7.4 * 
4 D. M. M 2.6 8.7 * 0.7 * 5.0 * 
5 V. T. F 15.9 * 12.9 * 3.5 * 0.3 
6 B. S. F 15.9 * 13.9 * 2.2 * 0.5 * 
7 B. L. F 8.2 * 12.1 * 1.1 * 2.4 * 
8 O. B. F 2.2 10.0 * 4.5 * 0.5 * 
11 J. K. F 3.0 2.0 1.7 * 1.7 * 
3.9 4.1 1.4 * 1.6 * 
12 5.6 * 3.3 4.4* 3.0 * 
13 R. F. H 4.2 2.0 1.5 * 6.4 * 
4.3 1.9 3.7 * 5.2 * 
3.8 3.4 0.7 * 2.4 * 
4.1 3.7 0.9 * 3.0 * 
14 I. C. F 11.5 * 4.7 2.0 * 2.6 * 
15 E. N. N 10.4 * 7.0 * 2.2 * 1.4 * 
42.4 * 4.8 1.5 * 0.9, * 
14.3 * 4.8 5.8 * 0.5 * 
12.6 * 6.0 * 4.8 * 0.3 
16.1 * 7.6 * 3.9 * 0.5 * 
11.9 * 4.9 4.3 * 0.7 * 
56.8 * 7.3 * 8.3 * 0.7 * 
/cont. 
Table 24 (cont) 
Case 
Ido. Sex E L& HVA 1: MA MA 
16 P. B. F 19.9 * 7.6 * 5.4 * 4.0 * 
16.0 * 9.3 * 5.0 * 3.9 * 
10.4 * 6.3 3.9 * 3.2 * 
18.1 * 8.7 * 5.6 * 4.4 * 
17.3 * 11.3 * 6.3 * 5.9 * 
13.8 * 15.2 * 6.1 * 5.9 * 
17 B. C. F 11.9 * 6.9 * 3.5 * 1.2 * 
10.0 * 6.7 * 4.0 * 1.5 * 
18 H. P. F 24.9 * 10.6 * 2.5 * 10.2 * 
20 J. R. F 13.6 * 3.0 4.8 * 11.2 * 
(Died) 
Normal ranges 
Ilean 2.2 3.3 " 0.26 0.23 
Range (1.1-5.0) (1.6-5.9) (0.16-0.4) (0.16-0.37) 
* Results above the observed ranges. 
Table 25 
The distribution of catecholamine metabolite levels, compared with 
creatinine L above and outside 
the normal range in 39 urine samples 
taken from 17 subjects known to have Dhaeochsomocytoma 
Above Within 
Normal Range Normal Range Normal 
HN,:;. A/ug per mg creatinine 27 12 31 
HYA/pg per mg creatinine 20 19 49 
NMA/jg per mg creatinine 39 00 
NA/p. g per mg creatinine 34 7 18 
Table 26 
Seventeen cases of phaeochromocytoma classified as having 'elevated' 
or 'normal' metabolite levels according to the metabolite analysis used 
ENMA/}ig per mg creatinine 
HVA/jig per mg creatinine 
N1 yg per mg creatinine 
NNA/pg per mg creatinine 
HNMA+HVA/ug per mg creatinine, 
combined test 
Elevated INormal Missed 
13 4 24 
10 7 41 
17 00 
15 2 12 
16 16 
or 'normal' level for each metabolite analysis of their urine samples 
The data suggests that the best single test to use in detecting 
a suspected phaeochromocytoma would be to measure the output of N'1A 
expressed as mg per 24 h urine volume. The output of MA would have. produced 
3 normal testa, whilst the outputs of Hi"NA and ItVA (mg per 24 h), if 
measured individually, would have given normal " tests for 6 (322) and 12 
(63; '6) patients respectively. The concurrent estimation of HMMA and HVA, 
however, would have produced better figures with only 4 normal findings 
out of the 19 cases. 
When we examine the relative amounts of I'4MA and IDMA expressed in mg 
per 24 h (Fig 16) in relation to the line defined by normal subjects 
(cf Chapter 2 Table 1) there is no doubt that the output of 2JMA relative 
to HI411A is in general, proportionally greater in the pathological urines. 
The figure clearly illustrates that although one can find normal levels of 
HI4MA in these phaeochromocytoma patients, their NTIA levels were all 
elevated above the normal range. Fig 17 shows the relationship between 
HMIA and HVA. This suggests that in phaeochromocytomas, unlike neuro- 
blastoras (see later) the output of HMMA relative to HVA, in general is 
proportionally much greater in the pathological urines than in normal urine. 
When the results are expressed as ug metabolite per mg of creatinine 
instead of, as a 24 h output rather similar conclusions may be drawn. For 
17 cases of phaeochromocytoma, (Table 24) indicates, as before, marked 
variability in the outputs of the individual catecholamine metabolites 
from patient to patient. Similarly, when pathological urines are classi- 
fied, on the basis of 39 results for each metabolite we find (Table 25) that 
whilst the output of NMA expressed now as jig per mg creatinine, was outside 
the normal range in all cases, the output of MA was normal in l of cases, 
and the output of E14A and HVA were within the normal ranges in 31% and 495, 
of tests respectively. 
The findings presented in Table 26 suggest that the best single 
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Fig 18 Relationshin between NYLk and MwMA/ug ner mg creatinine 
in urine from tatients with nhaeochromocytoma 
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Fig 19 Relationship between HVA and I i1"IA/uo, per mg creatinine 
in urine from patients with phaeochromocvtoma 
a 
x 
H"L"IA 
test of the metabolites for detecting a phaeochromocytoma, if a random sample 
of urine is used, would be the output of NMA expressed as )ag N14A per mg creatinine 
whilst the output of MA would have produced two false normal results, out of 
Interpretation of the outputs of RMMA and HVA separately would 
i 
have produced 4 (24%) and 7 (41%) false normal findings out of the 17 cases; 
the combined test, however, produced only one normal result. 
'W'hen we compare the relative amounts of I*IA and H*tA, expressed as pg 
per mg of creatinine in relation to normal behaviour (Fig 18), the results 
are similar to those of (Fig 16) in that in the pathological urines the 
output of IMA is much greater in proportion to that of IMA and, as before, 
the results for MIA lie above the normal range. More of the Ht4MA values 
tend to fall above the normal range when expressed as jg E1111A per mg 
creatinine rather than mg per 24 h. 
Similarly, Fig 19 compares the relative outputs of Hi'fl'MA and EVA in 
relation to the normal outputs and shows that in phaeochromocytoma H! HA 
levels tend to be increased more than HVA levels, relative to normal 
behaviour, although expressing the output of HVA as pg per mg creatinine 
tends to produce more abnormal results than when the output of HVA is 
expressed in mg per 24 h. 
8.3 Discussion 
In many hospital laboratories the standard procedure used to screen 
for the presence of a phaeochromocytoma is to measure the urinary output of 
IMMA per 24 h. This is done either chroinatographically108 or using a 
spectrophotometric technique. 
120 
One of the problems encountered in screening in this manner is the 
fact, as can be observed from our results, that the outputs of the individual 
metabolites can vary with time. Richards et x1249 described two patients, 
one of whoa had a urinary M-MA value of 7 mg per 24 h one day and thirteen 
days later the value was 46 mg per 24 h. The other patient on six separate 
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occasions had urine MIA levels of 72 - 420 mg per 24 h, findings similar 
to those found in three of our patients (Nos. 1 J. D, 15 E'- and 16 PB). 
Normal levels of HI-d"IA have been found250'251 in urine from patients 
with known I+ haeochromocytomas. In a careful study of 39 phaeochromocytoma 
patients Kelleher et a1251 found only one normal iaUiA urine level in 70 
tests. The finding of normal values for 443 of the hi"ü". A analyses in the 
present study is a little disturbing; in part explanation perhaps is the 
fact that the 43 samples used came from a smaller number Il9) of phaeo- 
chromocytoma patients, and additionally, were not distributed evenly over 
the donors. The finding by Crout et x1250 of 3 out of 23 cases of phaeo- 
chromocytoma which had normmal levels of ID14A (13) is closer to our findings 
of 6 normals out of 19 cases (32%). 
The finding of an increased urinary output of HVA in six of our cases 
might indicate that these phaeochromocytomas have malignant characteristics 
if MacMillan's postulate is correct. 
163 Robinson et al 
248 
studied a patient 
who had a malignant tumour. This patient prior to the removal of his tumour 
was excreting large amounts of HMMA, HVA, NMA and MA in his urine. The 
tumour was removed and histologically appeared to be benign. The patient's 
excretion of catecholamines and catecholainine metabolites returned to normal 
for eleven months, after which his HMMA and NMA output started to increase 
until at the time of his death his secondary growths were producing excess 
catecholamines, the metabolites of which were being excreted in amounts 
similar to those obtained in the case of his primary tumour. This indicated 
that both primary and secondary growths secreted large amounts of DOPA and 
dopamine. 
I 
Louise et a1252 in a study of 11 phaeochromocytoma patients found two whosE 
urine contained large amounts of DOPA and dopamine, as well as raised levels of 
NA and adrenaline; both patients curiously were normotensive. Histological 
examination of their tumours confirmed that they were phaeochromocytomas, but 
no information was given regarding follow up studies in these two 
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patients in order to detect the development of possible malignant 
secondary tumours. Hypersecretion of DOPA is a characteristic of non- 
chrom. affin sympathetic tumours such as neuroblastomas, 
2yjr255 tumours which 
are normally highly malignant. Patients with phaeochromocytoma tumours 
who are found to have excess levels of HVA in their urine should be carefully 
followed up routinely, after the tumour has been removed in order to detect 
any signs of secondary growths-becoming functionally active. 
The concurrent measurement of HMI-LA and HVA expressed in mg per 24 h 
would have proved more successful in diagnosing phaeochromocytoma than 
separate analyses. Apparently the distortion of the catecholamine metabolism 
pattern caused by the tumour has variation from individual to individual 
for these two metabolites and thus the distortion is best discerned when 
the two parameters are measured. The metabolite whose analysis alone, 
expressed as output in 24 h, was found to be the best indication of phaeo- 
chromocytoma was MA. All cases showed abnormal levels. This finding 
extends and confirms the work of others251 who measured total metadrenalines 
using the Pisano technique143 and also two-dimensional chromatography with 
quantitation by visual comparison of the spots obtained. They found 
abnormally high metadrenaline levels in all urine samples obtained from 
phaeochromocytoma patients. Crout et al 
250 
considered that the levels of 
urinary NA. and adrenaline were the most reliable diagnostic indices of a 
phaeochromocytoma, but there is much evidence 
251,255,256 to suggest that the 
total output of metadrenalines, or indeed the individual levels of NMA and 
MA are equally useful as guides in detecting phaeochromocytoma. Our results 
certainly support this contention. Furthermore, using the present method 
for analysis of NMA and NSA, neither the specialised equipment nor the 
specialised techniques 
148-152 
previously required are necessary. 
When we compare outputs in 24 h of Fir, 24A and NNA we find our results 
closely parallel those of Kelleher et al251 in that there is a much greater 
proportional increase in normetadrenaline than HMMA. A comparison between 
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: I-JA and HVA suggests that in phaeochromocytom.. as, unlike neuroblastcmas 
(see later) there is a relatively greater increase in M- A. An increase 
in HVA compared to 104A, might suggest the presence of a DOPA or dopamine 
secreting atypical or malignant phaeochromocytora, or in a child a neuro- 
blastoma (see later). 
Because of the relative ease in collecting accurate 24 h urine 
specimens from adults most catecholamine metabolite analyses are quoted as 
output per 24 h. Very few figures have been produced which relate output 
of catecholamines to that of creatinine, the usual reference when random 
urine samples are analysed. Kelleher et al251 quote results for the output 
of INIA in two of their cases. One of them, when converted to Vg EII1A per 
mg creatinine, would have been within the present method's normal range, 
the other would have been abnormal. However,, both had N14A outputs eight 
times the normal level we have found for this metabolite when it is 
expressed in terms of pg per mg of creatinine: 
Gupta et a1257 produced normal urinary ranges for total metadrenalines 
based on a modified Pisanö 
43 
technique for random urine specimens and 
expressed their results as mg total metadrenalines per g creatinine. Using 
their method they found no false positives in 150 hypertensive patients but 
five cases of neural crest tumours gave very high figures. These workers 
suggested using their modified technique as a supplement to urinary HMMA 
estimation. 
The outputs of HIiMA and HVA when expressed in terms of creatinine 
appeared to give fewer negative findings than when the results were 
expressed as mg per 24 h, a finding which is difficult to explain, although 
work carried out by Sunderman247 who studied the urinary output of MMA 
per 24h suggested that with urine volumes from 400 - 800 cm3 per 24 h 
the excretion of HVIMA was significantly lower than when the urine volume lay 
between 800 - 3,000 cm3 per 24 h. He did not give any reason for 
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this variation apart from suggesting that the urine volume of adults should 
exceed 800 en3 if rceasurement of 1ß"1A is to be carried out. In the present 
study, only 4 out of the 43 24 h urine collections had urine volumes within 
the 4CC - 800 cm3 range, and one of these was obtained from a young child. 
It is apparent from the relationships between IDAA and NMA in which- 
ever mode they are plotted, that the estimation of MIA is the best of the 
metabolites for the detection of a phaeochromocytoma. It was the only 
test which would have indicated the presence of an active phaeochromocytoma 
for all our test samples. 
An advantage in the separate assay of 2+2"1A and MA over the estimation 
of total metadrenalines is that the outputs of NMA and MA when measured 
individually reflects to a certain degree the secretion of NA and adrenaline 
from the tumour. From a surgical point of view the need to know whether a 
tumour is secreting a lot of adrenaline is important because of the pos- 
sibility of cardiac dysrhythmias occurring during operation. This 
infornation cannot be derived from a total metadrenaline estimation. 
Tumours which are found to be extra-adrenal, particularly malignant second- 
aries, usually produce NA only, whilst the commoner adrenal tumours often 
secrete a mixture of NA and adrenaline. In these cases the differential 
assay of N-14A and PLk would be superior as a diagnostic tool. 
On the basis of the results of this work it is suggested that the 
routine screening of hypertensives who may be suspected of harbouring a 
phaeochromocytoma58 should consist of a quantitative estimation of total 
urinary metadrenalines produced in 24 h. Any urines found to have raised 
levels could then be analysed for MIA and MA individually. Further, it is 
suggested that the practice of initial quick screening for excess M-MA 
should be re-considered in view of our findings, but that if it is performed 
the results may be more reliably expressed as pg per mg creatinine rather 
than as mg per 24 h. 
Additionally, all cases of phaeochromocytomas, where high levels of 
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NA secretion are indicated, should have HVA estimations carried out as an 
indication of whether they are malignant164 especially in the cases where 
a tumour has previously been detected and removed. 
PART II - ! l'EURObL. AS`N, lA 
8.4 Introduction 
A neuroblastoma is a highly malignant tumour which develops from 
the neural crest tissue of children. It is one of the cou. monest types 
of infantile tumour, yet it is frequently misdiagnosed in spite of the 
fact that neural crest tumours are unique in producing easily detectable 
amounts of catecholamines in up to 90ö of patients. 
259 
The reason is 
probably because the primary tumour may never become clinically obvious. 
The first report260 of an increase in'the excretion of pressor amines 
from a patient with a neuroblastoma occurred in 1957. This was followed by 
a further report261 in which the excess catecholamines were measured using 
166,262,263 
biological techniques. Later workers also found elevated levels 
of urinary NA in these patients. 
The finding 
117 
of an increased output of HMMA, led other groups 
264,265 
to measure this compound as an aid to the detection of neuroblastoras. 
165,166 However; the most noteworthy discovery was the finding of high levels 
of dopamine in urine obtained from patients with neuroblastoma. This led 
to the demonstration that HVA, a metabolite of dopamine, was also present 
in large amounts. 
166 
Studies 
117,139,264 
on the output of the 0-methylated 
catecholamines are fewer in number. Sandler162 commented in 1964 that 
the metabolites which probably undergo the largest proportional increase in 
excretion are these amines, but little work has been done in measuring the 
individual levels of NMA and MA. 
In this work a study was made, using the methods which have been 
developed, to evaluate which, if any, analyses of urinary metabolites might 
prove useful for the early detection of neuroblastoma. 
8.5 Results 
Table 27 gives the results for the output of WIMA, HVA, I1A and NA 
expressed as weight per 24 h urine volume found in nine children with proven 
neuroblastoma; normal ranges for children aged 2- 11 years are given for 
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Table 2 
Output of Hif. MA. HVA. NMA and MA mg per 24-h urine volume found in 9 cases, 
aged 3-8 years, of neuroblastoma compared with normal ranges 
for 
children aged 2- 11 years 
Case 
No. Sex HI4NA HVA NMA MA 
1 N. S. F 2.9 - 8.1 * 0.95 * 0.32 
2 J. H. F 15.0 * 12.2 * 2.05 * 0.45 * 
3 C. S. F 5.0 * 14.4 * 0.95 * 0.41 * 
6.3 * 12.8 * 1.08 * 0.51 * 
4 R. H. F7 2.4 4.8 0.60 * 0.33 
1.2 3.2 0.46 * 0.29 
5 C. C. F 2.6 3.7 0.45 * 0.64 * 
6 A. H. M 10.1 * 33.9 * 2.2 * 0.23 
7 R. C. M 14.1 * 34.5 * - 1.23 * 0.29 
8 B. M. M 21.6 * 24.3 * 3.22 * 0.37 * 
29.8 * 28.9 * 7.32 * 0.58 * 
32.6 * 32.7 * 8.00 * 0.71 * 
17.7 * 23.2 * 1.38 * 0.50 * 
" 14.2 * 17.1 * 1.16 * 0.34 
8.0 * 20.1 * 0.72 * 0.30 
9 C. L. N 4.5 it 9.4 * 2.28 * 1.27 * 
2.9 9.4 * 0.66 * 0.27 
Normal children (age 2- 11 years) 
Mean 2.6 3.6 0.26 0.24 
Range (0.6-4. 0) (0.6-5.5) (0.07-0.37) (0.09-0.36) 
* Results above i the range defined by two standard deviations on either side 
of the normal mean 
Table 28 
The distribution of catecholanine_metabolite levels within and 
above the normal ran-go in 17 24 h urine sarnoles 
from 9 subjects known to have neuroblastoma 
Above Within 
Normal Range Normal Range °4 Norma 
HN mg per 24 h 12 5 29 
HVA/mg per 24 h 14 3 18 
NIIA/mg per 24 h 17 00 
liA/mg per 24 h98 47 
Table 29 
Nine cases of neuroblastoma classified as having 'elevated' or 'normal' 
metabolite levels according to the metabolite analysis used 
}fl to/mg per 24 h, as sole test 
HVA/mg per 24 h, as sole test 
NMA/mg per 24 h, as sole test 
MA/mg per 24 h, as sole test 
Combined 1-fl *A+HVA/mg per 24 h 
Elevated Normal % Missed 
6 3 33 
7 2 22 
9 0 0 
5 4 44 
7 2 22 
Fig 20 Relationshin between I M. A and h '4A/mg per 24 h in urine 
from children with reuroblastona 
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Fig 21 Relationship between HVA and E"ü1A/nP per 24 h urine 
from children with neuroblastoma 
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Table 30 
Output of HIMA, HVA, NM; A and 11A p- per mg of creatinine found in 10 cases 
of neuroblastoma, aped 3-8 years (original nine plus one) compared with 
normal ranges for children aped 2- 11 years 
Case 
NO. Sex EN IA HVA PIA MA 
1 N. S. F 35.0 * 98.0 * 3.7 * 0.15 
2 J. H. F 63.3 * 51.5 * 8.6 * 1.9 
3 C. S. F 14.2 * 41.0 * 3.0 * 1.3 
22.8 * 46.4 * 3.9 * 1.8 
4 R. H. M 29.2 *, 78.0 * 11.2 * 7.1 
13.0 * 25.9 * 3.3 * 1.8 
5 C. C. F 5.5 7.9 0.9 1.4 
6 A. H. M 41.0 * 138.0 * 9.0 * 0.9 
7 R. C. M 31.0 * 98.0 * 2.7 * 0.6 
8 B. M. M 126.0 * 142.0 * 18.8 * 2.2 
113.0 * 110.0"* 27.8 * 2.2 
166.0 * 160.0 * 43.4 * 3.6 * 
60.0 * 78.0 * 4.6 * 1.7 
60.0 * 73.0 * 4.9 * 1.4 
19.0 * 48.0 * 1.7 0.7 
9 C. L. M 12.7 * 26.6 * 6.4 * 3.6 * 
9.0 29.0 * 2.0 0.8 
10 J. M. F 31.4 * 22.0 * 12.8 * 0.8 
Normal children (age 2- 11 years) 
Mean 7.1 9.7 0.8 0.8 
Range (3.3-12.5) (3.7-17.1) (0.5-2.1) (0.3-2.9) 
*Results above the range defined by two standard deviations on either 
side of the normal mean 
Table 31 
The distribution of catecholanine metabolites. comrared with 
creatinine. within and above the normal range 
in 18 urine samples taken from 10 subjects 
known to have neuroblastoma 
Above Within 
Noreal Ran, -e Normal Range % Normal 
IýMLýiA/pg per mg creatinine 16 2 11 
HVA/}lg per mg creatinine 
417 
1 5.5 
rMA/pg per mg creatinine. 15 3 16 
NIA/pg per mg creatinine 3 15 83 
Table 32 
Ten cases of neuroblastoma classified as having 'elevated' or 'normal' 
metabolite levels according to the metabolite analysis used 
Elevated Normal % Missed 
HNNA/jg per mg creatinine, 
as sole test 9 1 10 
HVA/jg per mg creatinine, 
as sole test 9 1 10 
NMA/}Zg per mg creatinine, 
as sole test 7 3 30 
MA/vg per mg creatinine, 
as sole test 3 7 70 
Combined Hi'- +}WA/ug per 
mg creatinine 9 1 10 
z der mz creatinine Fip, 22 Relationshin between N %k and TQAl u, 
in urine from children with neuroblastoma 
d 
x z 
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Fig 23 Relationship between HVA and IUOL4/uP ter mg creatinine 
in urine from children with neuroblastoma 
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comparison. Values marked with an asterisk denote results which fall 
outside a range which covers two standard deviations on either side 
of the normal mean. Table 28 shows the distritution of the 17 analyses for 
the four metabolites from the 9 subjects within and above the normal range. 
The analyses for NAiA alone were above the normal range in all cases. 
For, the other metabolites varying proportions of the analyses were 
above the normal range. 
When the results for each individual neuroblastoma patient are 
studied (Table 29) to decide which single analysis, if any, would have 
been 100% positive in detecting all 9 cases, we find that the best is 
that for KA which was elevated in all cases. This is followed by HYA 
(78%) and HMMA (67%) respectively. 
Fig 20 shows the relationship between the 24 h outputs of MINA and 
ItiNA in relation to the normal proportions and illustrates the finding 
of a relatively greater increase in MA compared to MIA. Similarly, 
Fig 21 shows the relationship between output of MMA and HVA. This indicates 
that neuroblastoma patients appear to have a greater output of HVA relative 
to WU by comparison with normal (contrast the phaeochromocytoma patients 
Fig 17). Again we may alternatively express the levels of urinary 
metabolites in terms of creatinine output instead of on a time basis. 
Table 30 shows the total results (18) obtained in ten neuroblastomas 
(the original nine plus one extra) expressed as pg metabolite per mg of 
creatinine. As before the asterisks signify results falling outside 
two standard deviations from the accepted normal mean value for each 
metabolite measured. 
A study of the 18 results obtained from the ten cases (Table 31) 
suggests that when metabolite levels are expressed in terms of 
creatinine output, HVA is the metabolite most likely to exhibit an 
abnormal level followed by E NIA and NNA, with MA as expected, a very 
poor index. 
In Table 32 the results are analysed in terms of how successful each 
? g_ 
N 
ýýrýýý 
k. 
measured metabolite level, expressed as pg per mg creatinine, would 
be when 
used as a diagnostic index. H1ýiMA and HVA appear equally suitable but their 
combination would have missed the individual' that each failed to detect 
separately. ? AMA is markedly less useful as a diagnostic index when its 
level is expressed in terms of creatinine rather than in terms of time. 
Figures 22 and 23 show the variation of MA and H'IA respectively, with 
E"iNA, (all levels being expressed in terms of creatinine), in the urine 
samples from neuroblastoma cases in relation to normal behaviour. 
8.6 Discussion 
Most medical workers would agree that neuroblasto a in a young child 
is often initially misdiagnosed, despite the fact that this tumour produces 
large amounts of catecholam4nes, Perhaps this is because it is rare for a 
neuroblastoma patient to be hypertensive. It has been suggested266 that 
'true' neuroblastomas possess virtually no storage granules for catechol- 
amines, thus the amines which are produced are rapidly broken down intra- 
cellularly and secreted as inactive metabolites into the circulation. 
267 
This should. produce high urinary levels of INA, RITA and MA which should 
make the condition simple to detect. It is also possible that the secretion 
of DOPA may be responsible for the relative absence of sympathetic over- 
activity in neuroblastoma. The amino acid DOPA has been shown to have 
268 
hypotensive action in man. 
Hitherto, a choice has had to be made as to which urine test, or tests, 
to use for detecting neuroblastoma and monitoring any subsequent treatment. 
In recent years, the trend has been to 'screen' for excess I11101A in urine 
from suspected neuroblastoma patients using simple techniques, rather than 
55,269 to use the two-dimensional chromatographic methods previously developed, 
27' 
in 1956-57, which are capable of detecting raised levels of both UNNA and 
HVA. Labrosse271 developed a 'spot test' which consists of applying a drop 
of urine to a filter paper disc, followed by the addition of a drop of 
diazotised solution of 4-nitroaniline. An excess of purple colour 
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development by comparison with a normal suggests a positive result. The 
test uses random samples of urine and the colours produced are, to an 
untrained eye, extremely variable. 
Bond272 in 1975, after initial screening, using the Labrosse spot-test, 
measured Ht* A quantitatively in 50 children with neuroblastoma and found 
seven who had normal levels of IDF . Presumably these had been detected 
on clinical grounds rather than positive spot-tests. Her better diagnostic 
figure of 86% compared to our 67% for-excess F3-:. MA per 24 h could be due to 
the fact that some neuroblastomas can produce quite a large amount of 
1-(4-hydrory-3-methoxyphenyl) ethane-l-2-diol (EMPG) which would, using 
the method employed by her 
120 be oxidised to vanillin, thus producing higher 
HiMDU values. 
Be11273 had observed in 1962 that the output of urinary NA in neuro- 
blastora patients, even when higher than normal, was not high enough to 
be easily detected except by the most sensitive fluorimeters, and he recom- 
mended as a screening test for neuroblastomas, the method of Gitlow e± x1111 
for detecting excess HNI1A. Using this method four out of his sixteen cases 
would have been normal when expressed as the ratio of the absorptions of the 
ethyl acetate extract at 450 and 550 nm. In eight cases where HNMA was 
measured, as output per 24 h using the Pisano120 technique, normal results 
were obtained in five patients. However, when his results were expressed 
as jig HMMA per mg creatinine all sixteen cases would have proved positive. 
Our results of a 90% detection rate using ENNA level, expressed as lug 
metabolite per mg creatinine, as a diagnostic index, but only 67% when 
expressed in terms of output in 24 h supports his findings. 
Other workers274 who measured H NIA levels in seven consecutive 24 h 
urine collections obtained from a four year old child with neuroblastoma 
found all seven values to be within the normal range for HMi4A expressed as 
mg per 24 h yet the levels of NA, and especially dopamine were high. ' No 
values for HVA or metadrenalines were reported. 
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Gitlow et a1259 developed a further screening test for E41 A which 
consists of adding diazotised 4-nitroaniline reagent to four drops of 
urine at alkaline p: i. The colour produced is extracted with iso-amyl 
alcohol and compared visually against a standard amount 
(5 )g) of HX 4A, 
added to a normal urine and taken through the test procedure. Using this 
method, for 35 proven cases of neuroblastoma, a true diagnosis was obtained 
in 32. Two out of the three negative cases where shown quantitatively to 
have normal levels of HMMA expressed as jig per mg creatinine; however, 
all three had increased levels of HVA expressed as yg metabolite per mg 
creatinine. The quantitative results for H}114A and HVA together produced a 
diagnosis rate of 100° which agrees well with our present findings. These 
workers also found that 89% of their cases were indicated by analysis for 
total metadrenalines. This result is not directly comparable with the 
present study where individual 14I"Lk and MA measurements were carried out. 
Recently, Bray eta1275 have also found two neuroblastoma 
patients who had normal levels of urinary EMMA, when measured using 
the Pisano technique but both had increased levels of EVA when 
120 
evaluated following two-dimensional chromatogrpphy. This result 
led to the conclusion that evidence for neuroblastoma is best 
sought by the two-dimensional chromatographic technique. However, 
the finding of a consistently elevated 24 h output of urinary NMA 
in our 9 cases of neuroblastoma might suggest that a good single 
test for detecting a neuroblastoma would be the measurement of 
this metabolite expressed as mg per 24 h. Unfortunately, in many 
instances only random samples of urine can be obtained from young 
children and our results here suggest that concurrent estimation of 
HIOLk and HVA after two-dimensional paper chromatography and 
expressing the results in yg metabolite per mg creatinine would 
give the best chance of detecting a neuroblastoma. For correct 
__ 
interpretation and evaluation any result obtained must be compared 
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against the corresponding normal metabolite values which have been 
determined using the identical procedures. 
Based on our limited study of a small group of neuroblastoma 
patients our findings could imply that screening for the presence 
of a neuroblastoma, using as a single test, either Hii'1iA, HVA or NMA 
might present diagnostic problems depending on whether the results 
are expressed as jig per mg creatinine or mg per 24 h. As the urinary 
.j 
excretion patterns of catecholamine metabolites are often very variable 
in children with neuroblastoma, our tactics should be to measure all four 
urinary metabolites, H. LAA, UVA, NMA and MA, in order to construct as 
complete a picture as possible of their urinary catecholamine metabolite 
levels, rather than to rely solely on any one individual metabolic assay 
to detect the presence of a neuroblastoma tumour. 
r 
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9.1 Materials 
a) Materials for extraction and chromatography 
Ethyl acetate, propan-2-ol, methanol, ethanol, 2-methylbutan- 
2-01, pyridine, glacial acetic acid and 0.88 ammonia were 
AnalaR reagents (B. D. H. Ltd. ) Anisole (B. D. H. Ltd. ) was technical 
grade. Chromatography was carried out with Whatman Grade 
1 25 x 25 cm paper and Whatman Grade 2 Chroma 20 x 40 cm paper. 
Dowex cation exchange resin AG-50-X8 (H+ form) 200 - 400 mesh 
(Cal-Biochem) was converted to the Na+ form by stirring it over- 
night with 3M sodium hydroxide. The sodium hydroxide was 
removed by decantation and the resin was washed with distilled 
water until the washings were neutral (pH 7.0). The resin was 
then stored, prior to use, under distilled water in a dark 
coloured glass bottle. 
b) Standard solutions 
i) HMIA and HVA (Sigma Chemical Co. London) lg dm 
3 
of each acid 
was dissolved in ethanol to form a combined solution. 
ii) NNA and MA (Sigma Chemical Co. London) were dissolved in 
q-0.01 M HC1 (ig dm 
3 
of each)-to form a combined solution. 
c) Working Reagents 
2M Aqueous ammonia, 4M alcoholic ammonia, aqueous ethanol 
(50% v/v), aqueous ethanol (85% v/v), aqueous sodium hydroxide 
(20% v/v), aqueous sodium periodate (2% w/v) and aqueous sodium 
metabisulphite (10% w/v) were all made up using AnalaR reagents. 
d) Diazotisation 
Fresh solutions of 4-nitrobenzenediazonium chloride were prepared 
as needed by mixing aqueous sodium nitrite (0.5% w/v), 
4-nitroaniline (2.5 g dm 
3) dissolved in 1M hydrochloric acid, 
and distilled water in the proportions 1: 1: 2 respectively; both 
reagents were kept at room temperature. 
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e) Equipment 
Mixing and stirring was carried out using a Fisons Whirlymixer. 
High Voltage Electrophoresis was carried out using CAN-AAG HVE 
equipment. Shandon glass tanks (30 x 30 x 30 cm) were used for 
chromatography. 
The chromatography papers were accommodated on Shandon all-metal 
chromatography frames (5 papers per frame). The papers were 
scanned with a Joyce-Loebl Chromoscar using a 625 nm filter. 
A Pye Unicam SP. 600 Series II instrument was used with silica 
cells (matched) to estimate solutions of vanillin at 350 nm. 
Preliminary scanning for vanillin was carried out using a Pye- 
Unicam SP. 800A recording spectrophotometer. All pH measurements 
were done using an E. I. L. Model 38B pH meter. A Technicon 
Autoanalyser was used to measure the creatinine levels of the 
urine samples using the method of Chasson et al276 Statistical 
I 
analysis of the results was performed using an Olivetti 101 
Programmable Desk-top Calculator, and a pdp 11/34 Computer. 
Statistical Tables277 were used to calculate body surface area. 
9.2 Technique for Accurate Urine Collections 
Twenty four hour urine collections were obtained based on the 
following general instructions which were given to all participants. 
The volume secreted by the kidneys over the collection period is the crucial 
one: urine already in the bladder at the start of the test and secreted 
some time before should not be included; that in the bladder at the end 
of the test and secreted between the relevant times should be included. 
The procedure is as follows: - 
8 a. m. Day 1. 
8 a. m. Day 2. 
Empty bladder completely. Discard 
specimen. Collect all urine passed until 
Empty bladder completely. Add this urine 
to the total collection. 
Timed overnight collections were obtained from normotensive adults, 
University students and hypertensive patients using the same tecrnique. 
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The 24 h urine samples obtained from babies were collected by attaching 
plastic collecting bags to them; timing was started after the passing of 
the first urine sample, which was discarded; all urine passed over the 
next 24 h was collected. The walkers emptied their bladders before and 
at the completion of the race and these samples were collected. All urines 
were acidified to pH 3.0 with concentrated hydrochloric acid as soon as 
possible after collection and if analysis was not done next day were stored 
deep frozen at -200 C. 
9.3 Extraction Procedure for Estimation of ID. MA and HVA in Urine 
After mixing the urine, its volume was measured and a portion was 
removed and adjusted to pH 3. An aliquot (3 cm3) was then placed in a 
C19 test-tube with 15 cm3 ethyl acetate. The tube was stoppered and the 
contents mixed vigorously with a Whirlymixer for exactly 2 min before 
centrifuging at 2000 r. p. m. for 15 min. 
An aliquot of the organic supernatant liquid equivalent to a 'one 
minute volume' was removed and placed in a small conical tube. This 
aliquot was carefully reduced under vacuum at room temperature and the 
residue dissolved by adding three drops of methanol down the sides of the 
tube to ensure maximum recovery. The methanol solution was applied as a 
small spot at a distance of 2.5 cm from two adjacent sides of a sheet of 
chromatography paper. 
9.4 Chromatography of H11NA and HVA 
The chromatography papers, consisting of four tests and one standard, 
were placed in a Shandon metal frame prior to chromatography. The standard 
chromatogram comprised 3 spots (3 eil of a standard solution containing 
3 pg each of HILMA and HVA) applied at 4 cm intervals on a diagonal line 
drawn from the lower left-hand corner to the upper right-hand corner of 
the paper. The chromatography papers were developed overnight by 
ascending chromatography (16 h) using as first solvent (propan-2-ol/ammonia/ 
water, 80: 10: 10). The chromatograms were removed from the first solvent 
tank and allowed to dry, before being re-chromatographed at right angles 
to the first solvent run, in the solvent system (anisole/acetic acid ('10: 30) 
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for 7 hours. The chromatograms were removed from the frame and allowed 
to dry before being dipped in a lCr,, ö solution of sodium carbonate, blotted 
and hung up to dry completely. Finally they were dipped in a solution 
of freshly prepared diazotised 4-nitroaniline to develop the phenolic 
acids. The surplus solution was removed by a clean sheet of blotting paper. 
9.5 Estimation of IDNA and HVA on Chromatograms by Scanning 
The well separated purple and grey spots of H AA and HVA, respectively, 
were delineated by means of a blue wax pencil mark (which served as a 
useful guide in the correct alignment of the spots on the slide holder 
of the Chromoscan) drawn 0.25 cm above and below the spots, at right 
angles to the direction of the first solvent front. The spots were 
then carefully cut out as (2.5 x 1.0 cm) oblong sections with the long 
side at right angles to the direction of the second solvent system 
and placed whilst still damp on the slide holder of the Joyce-Loebl 
Chromoscan. The oblong sections containing the }LNi1A and }WA spots were 
then covered with a strip of clear sellotape (2.5 cm wide) to hold them in 
position and the slide holder placed in the Chromoscan. The recording 
pen was zeroed using a blank section of the chromatogram and the spots 
were scanned using a red filter (625 nm). The integrated numbers for each 
peak were recorded. 
* An aliquot of supernatant equivalent to a 'one-minute volume' was 
calculated from the formula: 
Total volume of urine (cm3) 
x5= 'one-minute volume' 
Total period of collection (min) 
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9.6 Eznression of Results and Standard Curve for HMMA and HVA 
The chromoscan estimation was standardised using 1,2,3,4 and 5 pg 
quantities in methanol of IL-1, A and HVA. Each amount was chromatographed 
in triplicate and scanned. It was found that the mean values of the records 
peaks for each triplicate determination were linearly related to the amount 
of material in the standard. Therefore, the HMMA and HVA present on the 
chromatograms of urine extracts were estimated by comparison with the mean 
of three (3 µg) standard amounts of IUQ4A and HVA chromatographed with the 
test samples. 
The results are expressed as follows: - 
As z 
cvz d 
A. 1000 = mg/24 h 
Where At = Integrated value recorded for test 
As =" mean value of 3 (3 )ig) replicate 
standards 
c= Concentration of standard (3 jg) 
d= 1440 min/day 
v=1 min urine volume used. 
Any test which gave a reading higher than the 5K standard value was 
re-chromatographed using half quantities, as the linearity of the standard 
graph tended to decrease at higher concentrations. 
9.7 Evaluation of Experimental Technique 
a) Recovery of HMMA and HVA from distilled water 
Triplicate estimations of HMMA and HVA were carried out using 
1,3 and 5 yg amounts in distilled water (3 cm3). The pH was adjusted 
to 3.0 with HC1 and the solutions were mixed with ethyl acetate (15 cm3), 
centrifuged, chromatographed and scanned as described above (9.3 - 9.6). 
b) Recovery of HMMA and HVA from urine 
To samples of urine (3 cm3) at pH 3.0 were added three drops 
of sodium metaperiodate solution and the solutions were allowed to 
stand for 30 rains at room temperature. The urine samples were extracted 
and chromatographed in the normal way (9.3 - 9.4). Treatment with 
diazotised 4-nitroaniline showed that HINiYiA and HVA had been removed. 
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The above procedure was repeated, but with the addition, after the 
30 minute oxidation period, -of five drops of 10Y sodium metabisulphate 
solution to neutralise any excess periodate remaining, followed by the 
addition of 10 can amounts containing 10 )ig of 104MA and EVA standards. 
The urines were then taken through the complete extraction, chromatography 
and scanning procedure ( Chapter 9,3 - 5) 
9.8. Preliminary Attempts at Extracting NMA and 11. A from distilled Water 
a) Solvent extraction (modified Yoshinara et x1142 technique) 
MA (10 Pg) and 1QA (10 pg) were added to distilled water (20 cm3), 
the pH was adjusted exactly to pH 0.9 with the aid of a pH meter and the 
mixture boiled for 20 mins, cooled and adjusted carefully with sodium 
hydroxide (20%) to pHlO. Sodium chloride (log) was dissolved in the 
mixture, which was then extracted by shaking with two successive amounts 
(2 x 20 cm3) of ethyl acetate. The ethyl acetate layer was removed and the 
pooled extracts evaporated to dryness. The residue remaining was re-dissolve 
in methanol (3 cm3), transferred to a small conical test-tube and carefully 
concentrated under reduced pressure to approximately (0.5 cm3) before being 
spotted onto a 25 x 25 cm Whatman No. 1 chromatography paper. The paper 
was subjected to two-dimensional chromatography using 2-methylbutan-2-ol/ 
0.88 ammonia (4: 1) as the first overnight solvent system, followed by 
butan-2-ol/pyridine acetate buffer (4: 1): (the buffer of pH4 comprised 
water/pyridine/acetic acid in the proportions (100: 10: 41) as the second 
overnight solvent. The 1MA and kA spots were visualised using diazotised 
4-nitroaniline and the purple spots were eluted with 4 cm3 of a 2% sodium 
carbonate/methanol (2: 1) mixture and measured colorimetrically at a 
Wavelength of 520 nm. 
b) Extraction using ion-exchange resin Dowex AG-50W-X8. Na 
4. form 
i) Percentage recovery of the metadrenalines from the resin 
after different extraction times 
Six samples (20 cm3) of distilled water were placed in glass beakers 
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(50 cm3) and adjusted to pH 0.9; to the first three beakers 20 yg of 
NtA, to the second three beakers 20 pg of PIA were added. The solutions 
were transferred to boiling tubes and boiled for 20 rains, cooled and 
adjusted to pH 7.0 before 10 cm3 of Dowex resin was pipetted into each 
sample. The mixtures were then stirred continuously for 15 mins. 
After the resin had settled the supernatant was decanted and the resin 
washed successively with water (lO cmd), 5Cý ethanol (5 cmi) and 85% 
ethanol (10 cm3) followea by decantation. The resin was finally stirred 
with 4M alcoholic ammonia (10 cm3) for 1 min. The resin mixture was 
filtered through a sintered glass filter funnel and the eluate divided into 
two portions - blank and test. The test portion was oxidised to vanillin 
with sodium periodate and estimated spectrophotometrically (as in Chapter 9, 
9c). The whole process was repeated four times with different elution 
times for the }MA and JJ, A from the resin with 4M alcoholic ammonia, namely 
3,5,10 and 15 mies. 
ii) Percentage recovery of the metadrenalines from the resin 
after varying the concentration of alcoholic ammonia 
Duplicate samples of distilled water (10 cm3) containing NAA (10 P g) 
and hA (10 pg) were treated as in (Chapter 9.8 b above). The resin 
samples were mixed (3 mins) with 1,2,4 and 8M alcoholic ammonia solutions 
(10 cm3) and the supernatants were filtered and worked up for vanillin 
(as in Chapter 9,9 c). 
9.9 Procedure Used for Extraction and Estimation of NMA and 1': A in Urine 
a) Extraction 
24 h urine collections, acidified with 10 cm3 of concentrated acid 
were measured. An aliquot equal to the amount passed in 30 mins was removed 
and acidified with conc. Hcl to pH 0.9 using a pH meter. The urine was 
transferred to a Pyrex boiling tube, capped with aluminium foil to prevent 
evaporation and heated in a boiling water bath for 20 min to hydrolyse the 
sulphate conjugates of the metadrenalines. The tubes were then cooled to 
room temperature by immersing them in cold water and the pH of the urine 
was carefully adjusted to 7.0 using 20 % sodium hydroxide. The bottle of 
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prepared cation exchange resin was shaken and 10 cm3 of the resin slurry 
pipetted into the neutral urine and the mixture stirred rapidly for exactly 
15 min before the resin was allowed to settle and the supernatant decanted. 
The resin plus adsorbed amines was stirred for 2 min with a solvent and then 
decanted. The following solvents were used successively: water (10 cm3), 
50ý ethanol (5 cm3) and 85iß ethanol (10 cm3). The resin was then stirred 
vigorously for exactly 5 min with aqueous 2Ir. ammonia (10 cm3) to elute the 
amines. The mixture was filtered through a sintered glass filter funnel 
and the eluate shaken and divided into two equal portions which were placed 
in glass Kober tubes (20 cm3) capacity, labelled 'test' and 'control'. 
Each aliquot represented a 15 min volume of urine. These extracts were 
carefully reduced under vacuum to about 0.5 cm3, keeping the temperature 
below 60°C, before two drops of glacial acetic acid were added and the 
samples taken to dryness. 
b) Chromatopraphv 
Chromatography was carried out on 25 cm square Whatman No. 1 paper 
specially cut for this purpose (Fig. l). Three slots were cut out of the 
paper to produce two strips 2.5 cm wide. These two strips were labelled 
'test' and 'control'. The metadrenaline extracts, test 1, control 1; 
test 2, control 2; etc. were dissolved in a small amount of methanol (1 cm3) 
added a few drops at a time, and the methanol extract was applied evenly 
over the rectangles, marked in pencil at the bottom of the strip corresponding 
to the tube number. Care was taken to ensure that all the extract was 
applied to the strip. The papers were dried and NMA and )A (1 jil of 
standard solution) was applied to the right of the rectangle on the control 
strip. This helped to locate the urine NIA and )A bands on the control strip. 
The chromatogram was suspended with the edge AB just under the surface 
of methanol contained in a narrow plastic trough, the ascending methanol 
concentrated the amines spread over the rectangles into a narrow and 
compact band. The chromatogram was removed from the trough when the 
solvent front reached the line (X-X) after approx 5- 10 min. 
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The chromatograms were removed and allowed to dry before being placed 
on a Shandon metal chromatography frame. A standard chromatogram was 
developed with each frame of tests. This consisted of known amounts of 
Nri, A and 14A (10 µl of standard solution) applied to 'control' and 'test' strips. 
The chromatograms were allowed to develop overnight (16 h) in the 
solvent system 2-methylbutan-2-ol/0.88 ammonia (4: 1). Neat morning, 
the chromatograms were removed from the solvent tank and dried in a fume 
cupboard. The control strip (Fig. l Chap. 2) was then carefully dipped in 
10Z sodium carbonate solution, blotted dry and re-dipped in freshly 
prepared diazotised 4-nitroaniline solution to develop the purple marker 
spots of NMA and )A which were cleanly separated using this technique. 
c) Elution of ketadrenalines and Quantitation Spectrophotometrically 
The areas of the test strip which corresponded in Rf with the control 
MA and i"A bands were then delineated and cut out of the test strip. 
Each portion was placed in a glass stoppered tube (10 cm3) containing 
4M alcoholic ammonia (8 cm3). The tubes were capped for 1h to allow 
elution of the NDIA and MA to take place. The chromatography paper pieces 
were then carefully removed from each tube and the residual solution 
accurately divided into two halves; one portion (4 cm3) was placed in 
a test tube labelled 'blank'; the remaining portion into a tube labelled 
'test'. Distilled water (2.1 cm3) and (2.0 cm3) were added respectively 
to blank and test followed by 2% sodium periodate (0.1 cm3) to the test 
Solution alone. This converted the NMA and MA in the test solutions to 
vanillin. Each test was then measured spectrophotometrically against its 
own unozidised blank at 350 nm. 
Standard amounts of NNMA and ri1 (6,10,20 and 30 }. ig) were added to 
4 cm3 of 4M alcoholic ammonia and converted to vanillin as above. 
Graphs of absorbence versus amounts added were found to be linear 
(Fig. 2 Chapter 2). Test results could be calculated directly from the 
calibration graph or the standard amounts chromatographed alongside the 
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test chromatograms could be eluted, oxidised and quantitated. 
In practice the amount extracted from the standard chromatogram was 
found to be extremely reproducible over the whole of the research 
period. The outputs of the NrIA and IA per 24 h were calculated as 
follows: 
As zcaö=N 
Where At = Absorbance of test KMA or MA at 350 nm 
As = Absorbance of Standard NMA or FA at 350 nm 
c= Concentration of Standard (5 yg) 
d= 1440 min/day 
v=7.5 min urine volume used 
M= output of NASA or KA yg per 24 h 
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ADDEN DUi", 
a) Empirical Normal Ranges 
Due to the degree of skewness found in our normal adult sample 
interpretation of our data as to what might be considered normal and 
what abnormal presents difficulties. If our data had been normally 
distributed then values falling outside 2 S. D. from the mean would be 
considered as suspicious and values greater than 3 S. D. would be 
treated as abnormal. 
Empirical limits, however, could be placed on our skew data by 
considering the frequency distribution plots for HMMA, EVA, NMA and MA 
where certain values are found to lie at the higher end of the distribution 
curves. " These high values in the light of clinical experience could be 
viewed with suspicion. If we consider each distribution curve in turn then 
we find in the case of HIiMk output per 24 h that a result of 7.5 mg/24 h 
would be classed as suspicious, as would two results lying between 6-6.5 
mg/24 h. Values similar to these levels can be found in patients who are 
known to be producing excess amounts of catecholamines (e. g. phaeochromocytoma) 
If we eliminate these three values from'our 123 'normal' results, we could 
then define an arbitary upper limit of normal at 6.0 mg/24 h for EMMA. 
Similarly, there are two values of 8.8 and 8.6 mg/24 h in the 123 normal 
IiVA results which clinically would be considered as suspicious. By removing 
these two values we could now set our upper limit of normal at a value 
of 8.2 mg/24 h. 
A study of the output of NNA suggests that two results falling 
between 700 - 750 p&124 h would be classed as suspicious. Eliminating 
these two values would allow the upper limit to be fixed at 650 ßg/24 h. 
Similarly setting the upper limit at yg/24 h for 1'1A wouldinclude all 
123 results. 
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Results obtained from our abnormal groups could be judged against 
our empirical normal levels, in the light of previous clinical experience 
gained in the application of the tests to various groups of patients. 
Measuring increases which take place within the same group of individuals 
should not be affected as in this case each subject would act as his or her 
base-line control. 
b) Urine metabolites vs are 
A visual inspection of the data found for the metabolite output 
of He%A, INA, 14A and YA in babies and young children 
(Chapter 3, Fig 3) 
suggests that the urinary output of each metabolite increases with increasing 
147)149)170 
age, a view which has been put forward by other workersHowever, 
when the outputs of EMMA, EVA, KM and 1iA obtained from the 123 
adults (aged 18 - 78) were plotted against age, there was no obvious increase 
or decrease in the catecholamine metabolite output with increasing age. 
This was confirmed by deriving the correlation coefficients for each 
metabolite against age. The correlation coefficients were as follows: - 
rp 
HY A 0.01 0.5 
HVA 0.05 0.5 
FkA 0.07 0.5) P>O. l 
hA 0.09 0.5 >P>0.1 
It would appear from our results that the output of the catecholamine 
metabolites increase with age from birth to puberty, a finding which 
presumably reflects the increase in size and activity of the growing 
organism, but no further increase takes place with increasing age 
after puberty. 
c) Student Group 
The results of the data in Chapter 4 (Table 12) suggest that the 
mean overall output of MA shows a significant increase in Groups 2,3 and 4 
when compared to the Control (Group I) mean value. In order to try and 
improve the specificity of the test results, each student's values were 
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Table 33 
Indicates the significance of the results when the differences 
between paired samples for the overnight outputs of HXMA, HVA, 
NMA and MA in various groups from the 20 University students 
are compared 
Group I- 
compared to 
Group 2 
ru 
Group 
Group 2 
compared to 
Group 3 
Group 3 
compared to 
Group 4 
Significance 
min 
Significance 
UVA 
g min 
Significance 
EMA 
min 
Significance 
FA 
pimin 
0.1) p) 0.05 0.51 pý0.1 N/S N/S 
0.1) p) 0.05 0.5 N/S N/S 
N/S N/S N/S N/S 
N/S N/S N/S N/S 
N/S N/S N/S N/S 
a 
compared against his or herown control value using a paired It test in 
order to measure the difference between the means of the paired samples. 
Using this test we calculate the mean of the difference between the 
observations d and then the standard error of the mean. To find 't', the 
mean of the differences d is divided by the S. E. M. 
t=ä 
SD 
Nn 
The table of distribution is entered at n-1 degrees of freedom in the 
case of the student group (n = 20) 
From the results (Table 33 ) we can see that a comparison of Group I 
(Control) with Groups 2,3 and 4, Group 2 compared with Group 3, and 
Group 3 compared with Group 4, indicates that there is apparently no 
significant statistical differences between the outputs of HP'ikA, HVA, NM. A 
and kA for any of the Groups studied over the selected time periods. 
This finding could in part be due to the small sample sizes and the 
imprecision of the methodology. Further work using larger samples and 
matched controls would be useful. 
d) System' International Units (S. I. ) 
This system is based on expressing 'actual biological activity' in 
a sample and is defined by two parameters. The first of these is the 'mole'. 
All substances whose Atomic or Molecular weights are known can be expressed 
in terms of 'numbers of molecular units', that is an 'amount of substance' 
per unit volume. The 'accepted' unit of volume, the litre (1000 cm3) has 
been adopted for laboratory work. 
Thus moles per litre gives Molar concentration, unlike the 
conventional system, mg per 100 cm3, which is Mass concentration. 
To convert the conventional units for HIIIA, HVA, } 'iA and MA 
expressed as mg/24 h top moles per 24 h, we can multiply the conventional 
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unit by a factor, derived by dividing the molecular weight of the 
compound into 1000. 
Observed Normal Range 
Conventional Unit 
m, -/24 h 
ay'A 1.5 - 7.5 
UVA 2.4 - 8.8 
NM. A 0.20 - 0.71 
MA 0.20 - 0.60 
Empirical Norma l Range 
Conventional Unit 
mp/24 h 
HM A 1.5 - 6.0 
ILVA 2.4 - 8.2 
IA 0.2 - 0.65 
MA 0.2 - 0.60 
Factor 
X 5.06 
X 5.50 
X 5.35 
X 4.90 
Factor 
X 5.06 
X 5.50 
X 5.35 
X 4.90 
Observed Normal Range 
S. I. Units 
u mol/24 h 
7.6 - 38 
13.2 - 48 
1.1 - 3.8 
1.0 - 2.9 
Empirical Normal Range 
S. I. Unit 
u mol/24 h 
7.6 -30 
13.2 - 45 
1.1 - 3.5 
1.0 - 2.9 
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APPENDIX 
Statistics 
a) Mean and Standard Deviation 
dean 
To calculate the mean we add up the observed values and divide 
by the number of there. 
Ix 
z=n 
In addition to knowing the mean value of a series of measurements it is 
informative to have some idea of their range about the mean as this gives 
the figures at the top and bottom of the range which are furthest away from 
the generality. However, these figures do not give any indication as to the 
spread of the deviations about the mean. This problem is solved by the 
standard deviation. 
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A point to note is that whether the calculation is 
done on the whole 'population' of data or on a sample drawn from it. 
The population itself should approximate to a so called 'normal' (or Gaussian) 
distribution. 
The standard deviation therefore is a measure of the dispersion of a 
set of observations from their mean. If the distribution is Gaussian, 1,2 and 
3 standard deviations above and below the mean include 68%, 96% and 99.7% of 
the observations respectively, for a large sample size. 
The formula for calculating S. D. is derived from: - 
i) 
Variance =z-ä2 
n-1 
where z= mean 
n= number of observations. 
ii) The square root of the variance provides the standard deviation. 
S. D. =f a2 
n-1 
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The coefficient of variation from the mean is given by : 
coeff. of variation _ 100 x S. D. 
x 
However, if we are dealing with sample sizes below 30, then we must 
apply Student's 't' test to determine the probability that a certain range 
round the sample mean includes the population mean. Thus having calculated 
the mean and S. D. of our sample we then determine the standard error of the 
mean. 
S. E. M. = S. D. 
j -n 
To find the 95% confidence limits above and below the mean we now have to 
find a multiple of the S. E. K. (for large sample sizes this is 1.96) but for 
small sample sizes we resort to the use of tables for 't'. 
To find the number by which we must multiply the standard error to give 
95% confidence limits, we enter the 't' table at (n - 1) degrees of freedom 
and read across to the column headed 0.05. The S. E. M. value is then multiplied 
by this figure and the resultant value is added or subtracted from the sample 
mean. We can now state with a 95% chance of being correct, that the range 
we have determined includes the population mean. 
i 
b) Reproducibility 
The standard deviation of the day to day reproducibility for the 
method was calculated using the formulae: - 
D.. 
_. _ R= 2n -1 
Where D is difference between duplicates 
n is number of pairs of duplicates 
c) Students' 't' Test 
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This test is used to determine the significance of the difference 
between the means of two samples whose means and S. D. are known or can be 
calculated. We assume a 'null hypothesis' that there is no difference 
between the means of our two samples in that they are derived from the 
same large population. We calculate first the standard error of the 
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difference between the means for each sample 
S. D. Diff. = SD2 + SD2 
nl n2 
Where SD2 is the square of the standard deviation for the two samples, 
n1, n2 are the number of observations in Groups 1 and 2. 
'Allen the difference between the means (31 - z2) is divided by the standard 
error the result is 't' 
Thus 't' = zl - z2 
SD2 + SD2 
nl n2 
d) Probability 
To find the probability level of a calculated 't' value a table 
of 't' distribution is used280 which is entered at (n1 - 1) + 
(n2 
- 1) 
degrees of freedom. If the 't' value for a given degree of freedom is larger 
than the 't' value given in the 0.05 Probability (5yß) column then this would 
suggest that the 'null hypothesis' (no difference between the means of our 
two samples) is probably unlikely and that the samples do not come from the 
same population. 
e) Skew distribution 
An assumption was made in this Thesis that the output of the 
catecholamine metabolites HMMA, EVA, Ni-! A and NSA in the general population 
conformed to a normal Gaussian distribution pattern and therefore our normal 
sample of 123 adults would also be normally distributed so that mean, S. D. 
and 't' tests could be applied to the data. 
However, inspection of the data (Chapter 2) obtained from our normal 
sample, when the frequency distribution curves of the outputs for each 
metabolite are drawn, suggests that a moderate degree of positive skewness 
occurs in our normal sample, which may also be expected in the general 
population. If this is correct then application of Gaussian curve attributes, 
mean, S. D. and Students' 't' test would be invalid. To overcome a degree of 
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skewness our data would have to be'transformed' in order to try and normalise 
this degree of skewness. 
The common measure of skewness is defined by 
Kean - Mode Skewness = Standard Deviation 
or for distributions which are not, too skew we can say 
Coefficient of skewness =3 
(Nean - 
deviation Standard deiation 
The range lying between +3 and -3. 
The W test for normality 
To confirm mathematically the earlier suggestion (Chapter 2,5 ) 
that our data was positively skewed, the raw data from the 123 normal adults 
for each of the specific catecholamine metabolites was subjected to computer 
(pdp 11/34) analysis using the W test of Shapiro and Wilk. 
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Basically this test is designed to produce a variance figure (W) which by use 
of special tables can be used to test the data for 'degree of skewness' or 
normal distribution. 
The W figures obtained from our 123 normal adults-for H1 A, HVA, NMA 
and NA were as follows: - 
W nterpretation from W Tables 
IDDIL 0.911 Value indicates skew distribution 
HIA 0.942 4 
liMA 0.937 .. to 
MA 0.912 "" it 
These results confirm that our chosen sample has in fact a positive skew 
distribution. The imput data was then 'transformed' by conversion to log 
base10 values to try to correct the 'skewness' and W tests were recalculated 
on the transformed data, with the following results: - 
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W W-Tables - Interpretation 
Hr'J A 0.933 Improved figure but data still skew 
HVA 0.940 Data still skew 
NYI. A 0.821 Greater degree of skewness 
M 0.944 Improved figure but data still skew 
These results confirm that our normal sample of 123 adults show a positively 
skew distribution concerning the output of HM . A, INA, NNA and r, A and that 
log base10 transformation of the data, whilst improving in some cases the 
degree of skewness would not produce a 'normal distribution' curve. Thus, 
in order to define rigid statistical limits for our data, non-parametric statistical 
tests would have to be employed. 
The finding of a skew distribution for the output of the catecholamine 
metabolites has not, to my knowledge, been reported before. Normal results 
quoted previously in the literature have all been measured on smaller sample 
sizes and the means and S. D. values have been determined assuming a normal 
Gaussian distribution. 
One possible explanation of our skew distribution could be that our 
sample of 123 'normal' adult results does in fact contain a proportion of 
'abnormal' results, from people who, Whilst apparently well, have a biochemical 
abnormality and that our so called 'normal group' is in fact a combination 
of two distinct populations. 
In a large sample we might therefore expect to find more 'abnormal' 
normal values, and hence a larger degree of skewness. A small sample size 
perhaps would not exhibit as marked a degree of skewness and in fact when 
our first thirty results were tested for skewness, the W-test indicated a 
normal distribution, however, increasing the sample size above fifty results 
in marked skewness. 
It would appear that selecting small sample sizes below 30, tends 
to produce a more normal distribution and as most of the work on catecholamine 
metabolites in the past has been done on small sample sizes, the skew 
distribution found in the present work might not have been as apparent. 
-101 - 
When our data from the twelve babies and fourteen young children were 
subjected to the V'-skew test, the results were as follows: - 
Raw data 
Babies Y Distribution 
& AA 0.777 Skew 
h -VA 0.846 Skew 
NKA 0.951 Normal 
). A 0.779 Skew 
Children Y w data 
Distribution 
EMMA 1.0 Normal 
EVA 1.0 Normal 
NMA 1.0 Normal 
Log base10 
W Distribuiion 
0.893 Normal 
0.907 Normal 
0.983 Normal 
0.876 Normal 
IA 1.0 Normal 
Results for our babies and children's group indicate a more 
normal distribution but are based on small sample sizes. 
f) Correlation coefficient 'r' 
The correlation coefficient282 is measured on a scale that varies 
from +1 through 0 to -1 . Perfect correlation between two variable is 
expressed by a correlation coefficient of 1. When one variable increases 
as the other increases the correlation coefficient is positive; when bne 
decreases as the other increases the correlation coefficient is negative. 
Complete absence of correlation is represented by a correlation coefficient of 0. 
A coefficient of correlation is a single number that tells us to what 
extent two characteristics are related. It tells us to what extent 
variations in the incidence of one characteristic of a population go with 
variations in another characteristic of the same population. However, in 
interpreting correlation it is important to remember that correlation is 
not causation. There may or may not be a causative correlation between the 
two correlated variablesand if there is a connection it may be indirect. 
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However, the nearer the calculated correlation coefficient approaches 1, 
then we can say that the hypothesis that our two variables are linearly 
related is better than the hypothesis that the results are randomly distributed. 
Calculation of correlation coefficient x= one variable 
y= second variable 
Formulae 
r= (z-T) (Y - Y) 
1 (z - i)2 (Y - Y)2 
To test the deviation of a correlation coefficient, r, from 0 or nil 
correlation, it is better to use the 't' test in the following calculation. 
t=r fn 
--2 'I 1 
The 't' tables are entered at n-2 degrees of freedom. This value for 't' 
will give the probability level at which our correlation coefficient might 
or. might not be regarded as significant. If the children and babies in 
Chapter 3 are viewed as comprising one group then the correlation coefficients 
and calculated 't' values are large, thus giving in many cases, degrees of 
significance greater than 0.001 in a population whose ages range from 
1 month to 11 years. 
However, based on the significant differences between the sample 
means for the babies (Group A) and the children (Group B) and allowing for 
the fact that the babies' outputs show a slight skew distribution, the 
groups might be considered as arising from different populations. In order 
to test this we can calculate the standard effor of the difference between 
the two means from the formulae. 
S. E. diff =I SD2 SD2 
nl n2 
If we now divide the difference between the two means by the S. E. 
difference we can now find out how many multiples of its standard error this 
difference represents. Applying this test to our Group A babies and Group B 
young children groups results in standard error differences ranging from 8- 10. 
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The probability of these differences arising by chance is exceedingly 
low and the hypothesis that these samples came from the same population 
is very unlikely. It would appear therefore from (Figs 3,5,8,9 - Chapter 
3) that although good correlation between the different parameters is 
apparent when the two groups are combined as one, correlations should be 
calculated separately for each group. However, because of the small 
sample sizes involved, one would expect to find a lower degree of 
correlation. For a better correlation of output with age in babies and 
young children, larger sample sizes with smaller age intervals between the 
selected groups should be studied in order to obtain meaningful results. 
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